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Abstract: 
Background: Cluster randomized trials (CRTs) are a widely used research design in 
healthcare, health services, public health and education research. CRTs randomly assign 
groups of individuals to different experimental arms. Because CRTs randomize groups 
rather than individual subjects, they pose ethical challenges that do not arise in 
individually-randomized clinical trials. 
Research Questions: This dissertation sought to examine how ethical challenges in 
CRTs, particularly challenges relating to obtaining informed consent, are addressed in 
practice. This dissertation also sought to provide principled guidance as to who must be 
considered a research subject in a CRT, and when consent must be sought from research 
subjects in CRTs. 
Methods: The association between consent practices in healthcare CRTs and particular 
trial features were examined using a multivariable logistic regression model. 
Information on ethical challenges encountered by CRT researchers in practice was 
obtained using descriptive qualitative analysis of semi-structured interviews with 
experienced CRT investigators. Two normative questions, “Who is the research subject 
in CRTs?” and “When is consent required in CRTs?” were addressed by appealing to a 
conceptual framework derived from the basic principles of research ethics. 
Results: Consent in CRTs is associated with publication after 2004, publication in 
higher-impact journals, smaller cluster sizes, and the use of individual-level 
experimental and data collection interventions. CRT researchers are most concerned 
with issues around informed consent, and less concerned with issues related to the 
analysis of harms and benefits in CRTs.  
iv 
 
Research subjects are individuals who are intervened upon by investigators, 
either directly or via manipulation of their environment; who interact with investigators; 
or who contribute identifiable private information. Consent must be sought for CRT 
participation from research subjects. Seeking consent after randomization of clusters is 
permissible if methodologically necessary. Some CRTs may meet criteria for a waiver 
of informed consent. Consent is not required from cluster members who are not research 
subjects.  
Conclusions: This dissertation describes the state of the art of ethics practices in CRTs, 
and presents guidance around consent issues in CRTs that will inform the development 
of international ethics guidelines for CRTs. 
 
Keywords: 
Research ethics; Cluster randomized trials; Informed consent; Public health research; 
Health services research. 
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Chapter 1 
 
Introduction
 2 
 
This dissertation will address ethical challenges associated with cluster randomized 
trials (CRTs). It asks two related questions: 1) what is currently being done in CRTs to 
address some of the unique ethical challenges that stem from the CRT design?  2) How 
ought two key ethical challenges—the identification of research subjects in CRTs and 
adherence to proper informed consent practices—be addressed? 
The cluster randomized trial is an experimental design that has become increasingly 
commonplace in health services research, quality improvement, education, public health 
and a variety of other fields1-4. It differs from individually-randomized controlled trials 
(RCTs) in fundamental ways1. In an RCT, subjects are recruited individually and then 
randomly assigned to different intervention arms. Subjects are subjected to different 
experimental interventions in each study arm. Outcome data is collected from the 
individual subjects and analyzed. Based on the data collected, inferences are then made 
about the comparative effectiveness of the experimental interventions. 
In a CRT, groups of individuals are randomly assigned to different intervention 
arms. Depending on the kind of interventions under study, the experimental interventions 
may be applied either to the entire group, or to the members individually. Data may be 
collected from all group members, from a sample of group members, or from other sources 
that may reflect the group members’ response to the intervention such as hospital 
administrative data. After the data analysis, inferences may be made about the effects of the 
experimental interventions on the group-level outcomes, on individual-level outcomes or 
both.   
 3 
Thus, in typical RCTs, the individual research subject is the unit of randomization, 
intervention, and analysis. In CRTs, the cluster is the unit of randomization. The unit of 
intervention may be the cluster, individual cluster members, or another entity closely 
associated with the cluster (such as a health professional) such that the intervention on that 
entity produces a cluster-level effect. The unit of analysis may be the cluster, the 
individual, or both1,5.  
The randomization of groups leads to a host of ethical challenges that are unique to 
the CRT design. It is not always obvious who is the research subject in CRTs4,6-8. This is 
especially true in CRTs with interventions that are administered broadly at the cluster level, 
such as in large scale CRTs of public health interventions. Are all residents of a community 
participating in a CRT research subjects? What if they are not affected by the study 
intervention? Identifying the research subject is also complicated in CRTs in such fields as 
healthcare or education, in which the study interventions are administered to an individual 
such as a health professional or teacher, and the effect evaluated by collecting data on 
group members such as patients or students4,6-8. Are the research subjects the cluster 
members, individuals who receive interventions in order to produce cluster-level effects 
(such as health professionals or teachers), or both? 
In some large CRTs, it may not be feasible to obtain informed consent from all 
cluster members2,4,9. It may also not be possible for some cluster members to avoid 
experimental interventions that are designed to affect the entire cluster2,4,9. There are also 
concerns that obtaining informed consent from subjects in some CRTs may threaten the 
validity of trial findings2,4,9. Because of these challenges, investigators’ obligations with 
respect to obtaining informed consent in CRTs are not well-established.  
 4 
It is not clear whether the typical criteria that are used to evaluate the harms and 
benefits of interventions performed on individual subjects in traditional RCTs can be easily 
applied to CRTs of group-level interventions5,6.  
The moral status of groups is unclear. Some clusters may be groups of individuals 
with legitimate structure and representation, such as communities10. Other kinds of clusters 
are less well defined with no clear leadership, such as customers in a shopping mall that is 
participating in a CRT11. There is little principled guidance as to who has the authority to 
decide on behalf of clusters whether or not to participate in a trial12, nor is there any 
normative work outlining the scope of authority of these “gatekeepers”. Furthermore, there 
is no normative work addressing the question whether groups of individuals may have 
collective interests that are in need of protection as that group participates in a CRT. 
Communities may have collective interests that require regulatory protection10, but the 
status of groups that are not communities (e.g. sports teams, schools, medical practices) is 
not clear. 
Recent research ethics guidelines recognize some of the difficult ethical challenges 
that arise in CRTs. The United Kingdom Medical Research Council included 
recommendations for ethical CRT conduct within its methodological guidelines for 
CRTs12. The Council of International Organizations of Medical Science’s 2009 ethical 
guidelines for epidemiological research also take note of the logistical challenges in 
obtaining informed consent in some CRTs13. However a systematic examination of the 
ethical challenges related to CRTs has yet to be undertaken. As a result, there is no 
authoritative, comprehensive guidance on the ethical conduct of CRTs to aid investigators 
in performing research with high ethical standards.  
 5 
Similarly, research ethics committees have no standard to guide their review of 
CRT protocols6,14. The lack of comprehensive, authoritative guidance on the ethical 
conduct of CRTs has lead to substantial variability in the findings of research ethics 
committees who have evaluated CRT protocols14. This variability in research ethics review 
has become an impediment to the conduct of multicenter CRTs6,14. One group of authors 
highlighted this problem, writing that “…the moral hazard of this uncertainty is that few 
formal patient safety studies may be undertaken, resulting in a slowdown in progress…”15. 
This dissertation is undertaken in the context of a larger project, funded by the 
Canadian Institutes of Health Research16. This project, which includes both empirical 
methods and philosophical reflection by a group of experienced CRT investigators and 
ethicists, is designed to comprehensively evaluate the key ethical challenges related to 
CRTs, and to spearhead the development of international consensus guidelines for the 
ethical conduct of CRTs16. The conclusions of each of the papers that comprise this 
dissertation will contribute to the body of scholarly work that addresses the ethical 
challenges of CRTs. This work will be invaluable in informing the guideline development 
process, and will also provide useful guidance to investigators and research ethics boards 
who deal with the ethical challenges of CRTs on a daily basis. 
In order to address the two questions posed at the beginning of this chapter, the 
dissertation will proceed as follows: 
Chapter two will review the basic methodological features of CRTs and the ethical 
challenges that stem from this design. Chapter two will also outline the basic principles of 
research ethics that form the conceptual basis for research ethics guidelines and 
 6 
regulations. The basic principles of research ethics will be used as the framework for 
evaluating the empirical findings in chapters three and four, and as the basis for normative 
work in chapters five and six.  
Chapter three provides a quantitative description of current informed consent 
practices in healthcare CRTs. It examines consent practices in a sample of 161 CRTs in 
primary and hospital care settings. The chapter includes descriptive statistics on the 
proportion of CRTs that obtained informed consent from patients. The chapter also 
describes a logistic regression analysis that identifies methodological features of CRTs that 
are independently associated with the practice of obtaining informed consent from patients 
in healthcare CRTs. 
Chapter four describes an empirical study in which 20 CRT investigators were 
interviewed about the ethical challenges associated with CRTs and their experiences in 
addressing these challenges. Qualitative analysis methods were used to provide a rich 
descriptive summary of researchers’ experiences addressing the ethical challenges that are 
unique to CRT design and conduct. 
Chapter five addresses a key ethical question: “Who is a research subject in 
healthcare CRTs?” In this chapter I argue for a principled, comprehensive definition of 
“research subject” and I apply it to the CRT context. This work allows the formulation of 
guidelines that adequately protect subjects in CRTs while avoiding excessive regulatory 
burdens on CRT investigators, and enables research ethics boards to consider protections 
for research subjects on a more pragmatic level.  
 7 
Chapter six reviews the challenges associated with obtaining informed consent in 
CRTs, including the feasibility of seeking informed consent in large-scale CRTs, the 
potential for bias introduced by the consent process, and the timing and content of consent 
discussions. This chapter then draws on one moral theory that underpins the requirement 
for informed consent for research participation to argue when, and from whom, informed 
consent is required in CRTs, and what information must be disclosed to potential subjects 
during consent discussions. 
Chapter seven summarizes the preceding chapters, and reflects on the findings of 
the empirical work in the light of the conclusions of the two normative chapters. This 
chapter includes a reflection on the relationship between empirical work and normative 
work in the scholarly enterprise of research ethics. It considers the implications of the 
findings in this dissertation for the development of ethical guidelines for CRTs. It also 
considers the implications of this work for other study designs that are used in the quality 
improvement, health services and public health fields. Finally, chapter seven lays out plans 
for future work that stems from both the content and the methodology used in this 
dissertation. 
 8 
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Literature Review and Glossary of Terms 
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This chapter introduces the CRT design and the ethical questions that arise from its 
methodological features. First, the features of the CRT design will be explained. Basic 
statistical issues, the uses of the CRT design, and CRT typology will be reviewed. Second, 
a conceptual framework for the evaluation of ethics challenges in human subjects research 
will be described. Third, this conceptual framework will be used to guide a comprehensive 
review of the literature outlining the ethical problems relating to CRTs 
Introduction: Cluster Randomized Trials 
What is a Cluster Randomized Trial? 
A cluster randomized trial (CRT) is an experiment in which groups of individuals 
(clusters) are randomly assigned to different intervention arms, so that the same 
intervention is delivered to the entire cluster1. The efficacy of the experimental intervention 
may be evaluated using data from several sources. Data may be obtained from all cluster 
members or from a sample of the cluster membership. Cluster-level data may also be 
obtained from other sources, such as administrative databases.  
CRTs are becoming an increasingly important methodological tool in a variety of 
fields, including public health, education, health services research, and for the evaluation of 
quality improvement and knowledge translation interventions in healthcare. 
 
 
 
 
 
  
 
12 
What are the methodological differences between CRTs and RCTs? 
 
Randomization of Groups Instead of Individuals 
In an individual randomized, controlled trial (RCT), individual subjects are randomly 
assigned to one trial arm or another. The hallmark feature of the CRT is that, rather than 
randomly assigning individual research subjects to study arms, groups of individuals are 
randomly assigned to different study arms.  
It is important at this point to distinguish between the cluster—the actual group of 
individuals under study --andthe unit of randomization—the entity that is actually 
randomly assigned. In many CRTs, the cluster and the unit of randomization are the same. 
This happens most often when the cluster is an intact social unit, such as a community, 
family or sports team. Alternatively, the unit of randomization can be an entity that is 
distinct from the cluster, but whose association with the cluster results in randomization of 
the entire cluster. For example, in a primary care CRT, a clinic may be the the unit of 
randomization, creating clusters comprised of that clinic’s patients.  
 
Correlation of outcomes between cluster members 
Cluster members’ responses to the experimental intervention are often correlated 
with one another. In other words, the effect of the intervention may vary between clusters 
for reasons unrelated to the efficacy of the intervention, but related instead to common 
characteristics of cluster members. Depending on the type of cluster and the type of 
intervention under study, responses between cluster members may be correlated for several 
reasons: 
  
 
13 
• Cluster members may share similar environments, such as in CRTs of public 
health interventions in which all members of the same community receive a 
cluster-level intervention;  
• Cluster members may have genetic similarities, such as when families or 
isolated communities are used as clusters in a CRT. 
• Individuals with particular traits that are relevant to treatment response may 
self-select cluster membership because of a particular cluster characteristic. For 
example, older patients may choose a physician with a reputation for being 
skilled in geriatric medicine.  
• Personal interactions between cluster members that result in sharing of 
information about experimental interventions may create a clustering effect. 
Similarly, personal interactions between cluster members may lead to rapid 
spread of communicable diseases1. 
 
Increased sample size, decreased precision 
The correlation in responses between cluster members violates an assumption of 
standard statistical tests that observations on different subjects are independent. 
Accordingly, sample size calculations and hypothesis tests must be adjusted to account for 
the correlation between cluster members. The degree of within-cluster correlation may be 
quantified using the intra-cluster correlation coefficient (ICC, ρ). One interpretation of the 
ICC is simply the pairwise Pearson correlation between any two members of the same 
group or cluster1. An ICC of 0 indicates that there is no within-cluster correlation of 
subjects’ responses to an experimental intervention, while an ICC of 1 indicates perfect 
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correlation. In practice, the ICC may be estimated based on existing literature, or measured 
empirically in a pilot sample.  
Formulae for sample size and hypothesis tests must be adjusted to account for the 
within-cluster correlation. To account for clustering effects, the estimate of the required 
number of individuals in each trial arm should be multiplied by a variance inflation factor, 
[1+(m-1)ρ], where m is the number of individuals in each cluster, and ρ is the ICC. This 
gives a sample size that accounts for within-cluster correlation1. Because of these 
adjustments, CRTs generally require larger sample sizes than do individually-randomized 
trials to achieve the same degree of precision. 
Hypothesis testing involving procedures such as the t-test or chi-squared test, as well 
as formulae for confidence interval estimation, must be similarly adjusted. These 
adjustments result in larger p-values for hypothesis tests, and wider confidence intervals 
around the estimated effect sizes1. A common approach to adjusting for within-cluster 
correlation in the analysis of CRT data is to add a random effect term to a multivariable 
regression model so that standard errors are adjusted for within-cluster variation. It is also 
possible to conduct analyses of summary measures of outcomes at the cluster-level, thereby 
avoiding the need to adjust for within-cluster correlation. 
As a result of the need for larger sample sizes, CRTs often impose greater 
administrative and financial burdens on study investigators and sponsors. For this reason, 
the selection of the CRT design for a study must have a very good rationale. 
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Why is a CRT used?  
Given the statistical and logistical disadvantages of the CRT design, the use of the 
CRT must be justified by some other methodological advantage. There are several reasons 
for choosing the CRT design. For some studies, there may be multiple reasons for choosing 
the CRT design. 
 
The CRT Evaluates Group-level Interventions 
CRTs are often used to evaluate interventions that are designed to affect the entire 
group. For example the COMMIT study compared the efficacy of different public 
education and media strategies aimed at increasing smoking cessation in participating 
communities2. These interventions are administered to the entire community, and therefore 
the community was used as the unit of randomization. 
This same justification for cluster randomization may apply to some CRTs in 
healthcare, particularly to CRTs evaluating knowledge translation (KT) or health service 
interventions. KT CRTs evaluate training or educational interventions for health 
professionals that are intended to improve patient care. Outcomes of interest may include 
health professional behaviours as well as patient-level outcomes. For example, one CRT 
evaluated the efficacy of different educational strategies for physicians designed to 
improve evidence-based prescribing for patients with diabetes and cardiovascular disease3. 
The outcomes evaluated included physicians’ perceptions of the efficacy of the 
intervention, as well as objective changes in prescribing practices as ascertained from 
patients’ prescription data accessed from a national pharmacy database. CRTs are used to 
evaluate changes in health service provision or changes to healthcare systems, as these 
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interventions are conducted only at the cluster level. For example, a CRT evaluating a 
modification to patients’ electronic medical record to issue prescribing reminders for 
patients with diabetes4 is most easily implemented at the practice level. For this reason, a 
CRT design was chosen with the medical practice being the unit of randomization. 
 
Avoidance of Treatment Contamination and Maximizing Adherence 
The CRT design may be chosen in order to avoid treatment contamination. Treatment 
contamination refers to a phenomenon observed in individually randomized trials in which 
subjects assigned to one arm may share elements of their intervention with subjects in 
another trial arm who are in close proximity1. For example, contamination might be 
observed if individuals in the same family are participating in a trial of a dietary 
intervention, and are randomly assigned to different arms. It is possible that subjects would 
share elements of the different interventions with each other. Treatment contamination 
tends to bias the outcome of a trial toward a null result. CRTs are therefore used to evaluate 
individual-level interventions that are easily shared by individuals who may be 
participating in the same trial1.  
CRTs are also used to evaluate interventions directed at healthcare professionals or 
organizations in which it would be difficult to apply the intervention to some patients and 
not to others1. One example of such a trial evaluated the efficacy of early breastfeeding in 
reducing the frequency of postpartum hemorrhage5. The unit of randomization for this trial 
was the birth attendant rather than the individual patients, as the birth attendants may have 
found it difficult to only advise early breastfeeding to half of their patients.  
  
 
17 
Random assignment in clusters may also improve intervention adherence within the 
cluster. A CRT evaluating the effect of treated nasal tissues on incidence of respiratory 
illness randomized families rather than individuals6. Investigators believed that adherence 
to use of the assigned tissue type would be enhanced if entire families were the unit of 
randomization rather than individuals within families. 
 
Evaluation of Individual- and Group-level outcomes 
The CRT design permits the evaluation of both individual-level outcomes and group-
level outcomes within the same study1. This is particularly advantageous in CRTs 
evaluating vaccine efficacy7. A CRT randomly assigning communities to two different 
vaccine programs allows for comparison between the relative efficacy of vaccine programs 
for vaccinated persons (an individual-level outcome) as well relative vaccine efficacy at the 
community level (a group-level outcome that includes both vaccinated and unvaccinated 
individuals)7. 
 
Political, Logistical and Administrative Reasons 
The CRT design has sometimes been employed for political reasons, often in 
developing countries in which communities were the unit of randomization. Investigators 
have encountered situations in which community leaders have refused to allow random 
assignment of individuals within communities, and have insisted that all community 
members be offered the same intervention. One example is a CRT evaluating the effect of 
vitamin A supplementation on child mortality. 450 villages in Indonesia were randomly 
assigned to either participate in mass vitamin A supplementation or to serve as control 
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communities. Investigators reported that it was “not politically feasible” to randomly assign 
individuals within communities to either intervention or control arms8. 
The statistical inefficiency of the CRT design may be outweighed by administrative 
or logistical factors9. Randomization in clusters may decrease the number of research 
personnel required to collect data, and decrease the logistical challenges required for data 
collection such as time and travel requirements9. Some subjects, such as patients, may only 
be accessible through health professionals or health care organizations, so the use of these 
professionals or health care organizations as the unit of randomization may be necessary9. 
It may also be easier to access administrative data or private health information in some 
circumstances if a health professional or health care organization is used as the unit of 
randomization9. 
In some CRTs, medical practices were randomized rather than individual patients in 
order to assuage the fears of health professionals who were uncomfortable having their 
patients randomly assigned to either the intervention or control arms1.  
 
Typologies of CRTs 
Two typologies have emerged to describe the variety of interventions that may be 
evaluated in the multiple fields that employ the CRT design. The aim of developing a 
typology is to be able to easily refer to CRTs or to CRT interventions that share common 
features. These two typologies group CRTs and CRT interventions based on the ability of 
individual cluster members to either consent or opt out of study interventions. 
Edwards and colleagues created a dichotomous typology to describe CRTs10. Cluster-
cluster CRTs are trialsin which experimental interventionsare administered at the cluster 
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level and designed to affect all individuals in the cluster. Examples include public health 
interventions such as mass media campaigns or water treatments, curricular innovations in 
education, or healthcare quality improvement innovations that are implemented at the level 
of a hospital or health system. Individual-cluster interventions are CRTs in which 
experimental interventions are administered to individual cluster members, primarilyto 
avoid experimental contamination, with the intent of producing an individual-level effect. 
Examples include individual health interventions evaluated in CRTs that randomize 
medical practices in order to avoid contamination.  
Eldridge and colleagues expanded Edwards’ classification to four categories: cluster-
cluster, individual-cluster, professional-cluster and external-cluster11. Importantly, Eldridge 
et al recognize that a CRT may include both interventions administered at the cluster level 
as well as interventions administered to individual cluster members. Therefore, the 
Eldridge typology classifies CRT interventions, rather than classifying CRTs as a whole. 
Cluster-cluster interventions have a similar meaning for Eldridge et al. as for 
Edwards et al. The key feature of a cluster-cluster intervention is that the intervention is 
applied at the cluster level, and affects all cluster members. Cluster members cannot avoid 
or opt out of a cluster-cluster intervention.  
Individual-cluster interventions are also similarly classified in the Eldridge and 
Edwards typologies. These interventions are applied to individuals, who have the 
opportunity to choose whether or not to participate in the CRT. The CRT is chosen to avoid 
experimental contamination in the administration of the experimental intervention. 
Professional-cluster interventions are used in CRTs in which the cluster is defined by 
its relationship to a professional, such as a teacher or healthcare professional. These are 
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typically educational or quality improvement interventions directed at professionals, and 
are designed to influence how those professionals serve those for whom they are 
responsible. An example is the use of automated reminders of optimal prescribing practices 
of antiplatelet medications for diabetic patients in primary care4. Patients do not have the 
opportunity to avoid the effects that the experimental intervention may have on their care, 
although there may be an opportunity for patients to decline to have their data used11.  
External-cluster interventions are primarily used in healthcare CRTs, and refer to 
interventions that re-organize health systems by using additional  or different  healthcare 
providers11. Randomization of clusters is done to avoid contamination, or for logistical or 
financial reasons. An example of an external-cluster intervention is the use of a nurse 
specialist to administer asthma care instead of or in addition to a primary care physician12. 
Patients can opt out of studies using external-cluster interventions simply by refusing to 
utilize the additional staff11.  
These categories may be useful in categorizing interventions that have different 
ethical implications, particularly respect to subjects’ ability to choose whether or not to 
undergo a particular type of intervention. However, this typology hasa number of problems 
that limit its widespread use without further clarification and validation.  
First, these categories only refer to the experimental interventions under study in a 
CRT. Trials also include interventions used solely to collect data13. In CRTs, these may be 
interactions with, or interventions on individual subjects; they may consist of collection of 
subjects’ identifiable private information; or they may use administrative data that allows 
the evaluation of group-level outcomes. The categories in the Eldridge typology do not take 
account of data-collection procedures.  
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Second, while it makes sense to categorize the experimental interventions in a CRT, 
rather than categorizing the trials themselves (which may contain different kinds of 
interventions), it is easy for users to conflate a typology describing the interventionsas 
describing the trials themselves. Therefore, it is important to be clear on the distinction 
between a subject’s ability to avoid or opt out of an intervention, and a subject’s ability to 
avoid or opt out of a trial.Subjects can only opt out of a trial if they are able to avoid or opt 
out of all experimental and data-collection interventions.  
Third, Eldridge concedes that users may disagree on the categorization of a particular 
intervention, and that there may be overlap between categories11.  
Fourth, the typology does not capture all of the interventions in CRTs in which the 
cluster is defined by its relationship to a professional such as a healthcare professional or 
teacher. These CRTs may have interventions that are directed at those professionals, and 
are designed to produce a specific effect on those professionals, such as in increase in 
knowledge. These interventions do not necessarily have a measurable cluster-level effect, 
and so describing them using the professional-cluster typology seems inappropriate. 
Finally, the four-category Eldridge typology for CRT interventions may be reducible 
to two categories that resemble Edwards’ classification. Professional-cluster interventions 
closely resemble cluster-cluster interventions, in that they are administered at the cluster 
level that cannot be avoided by individual cluster members. The fact that a cluster member 
may opt out of data collection is a feature of the trial, not of the intervention in question, so 
professional-cluster interventions are probably best thought of as a subspecies of cluster-
cluster interventions. External-cluster interventions resemble individual-cluster 
interventions, in that individual cluster members can choose not to participate in the trial or 
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see the additional staff members. For CRTs of external-cluster interventions, cluster 
randomization is undertaken for practical reasons, not because of the nature of the 
interventions. It may be reasonable to think of external-cluster interventions as a subspecies 
of individual-cluster interventions. 
In this dissertation, the preferred terminology will refer to cluster-level interventions 
and individual-level interventions. Cluster-level interventions are those that are directed at 
the entire cluster, and intended to produce an effect on all cluster members, independent of 
their ability to avoid the intervention. These include Eldridge’s cluster-cluster and 
professional-cluster interventions. Individual-level interventions are those that are directed 
at individual subjects and are intended to produce an effect on that particular subject. These 
include Eldridge’s individual-cluster and external-cluster interventions. Interventions 
directed at professionals that are designed to produce an effect on those professionals, 
without necessarily producing a cluster-level effect, will be considered separately. 
 
A Conceptual Framework for Addressing Ethics Questions in 
CRTs 
There is a small but growing literature that discusses the ethical issues of the CRT 
design. Specifically, commentators have been concerned with the logistical feasibility of 
obtaining consent from subjects in large trials9-11,14-16, the potential biasing effect of the 
consent negotiations in CRTs of behavioural interventions9,10,15,17, the lack of benefit to 
subjects in control groups14,15, and questions about who has the authority to speak on behalf 
of a cluster 9,10,18.  
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CRTs share many of the characteristics of individually-randomized clinical trials. It 
therefore makes sense to appeal to the robust literature on the ethics of clinical trials as a 
starting point for a discussion of the ethical questions of CRTs. In some instances, 
however, there will be a lack of fit between research ethics guidelines for individually-
randomized clinical trials and CRTs that randomize groups of individuals. Current research 
ethics guidelines and regulations were developed to address ethical challenges in which 
subjects are recruited individually, as in a typical RCT. The ethics of CRTs in which a 
cluster is the unit of randomization and/or the unit of intervention are less clear. 
In instances in which widely-accepted solutions for ethical challenges in individually 
randomized trials do not address problems in CRTs, it is helpful to turn to a broadly-
accepted framework for the discussion of ethical issues in human subjects research. This 
conceptual framework has been developed over more than forty years of scholarly work. 
By using this approach, solutions to ethical problems posed by CRTs can be defended by 
appealing to widely accepted ethical principles, and to the moral theories on which these 
principles are based.  
 
The Ethics and Regulation of Human Subjects Research 
The study of the ethics of research involving human subjects evolved largely in the 
second half of the twentieth century19,20. Scholarly work in research ethics occurred in 
parallel with the development of regulations governing human research that have been 
promulgated by various international bodies and federal governments. Both normative 
reflections on human subjects research and regulatory documents generally refer to 
research in which subjects are identified and recruited individually, prior to the application 
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of research interventions. With a few notable exceptions, CRTs are not specifically 
mentioned in most scholarly work and regulatory documents, meaning that the application 
of research ethics principles and guidance to CRTs is left to the interpretation of ethicists, 
researchers and research ethics boards. Below, we review first the evolution of scholarly 
work that lays out the basic principles of the ethics of human subjects research, then review 
in detail the key regulatory documents that researchers and research ethics boards may 
draw upon while reflecting on the ethical questions posed by CRTs. 
 
Basic Ethical Principles for Human Subjects Research 
The most broadly accepted articulation of the basic ethical principles for human 
subjects research comes from the Belmont Report, the 1979 Report of the US National 
Commission for the Protection of Human Subjects in Biomedical and Behavioral Research 
(referred to hereafter as the “National Commission”)21. The Belmont Report outlines three 
basic ethical principles that guide the conduct of human subjects research: respect for 
persons, beneficence, and justice. The Belmont report also specifies moral rules that stem 
from each of these principles21. 
The principle of respect for persons is derived from a philosophical heritage that 
emphasizes the unconditional worth of all autonomous individuals21-23. Therefore, the 
principle of respect for persons requires that the choices of autonomous individuals be 
respected, and that individuals with diminished autonomy be protected. The Belmont 
Report states that to respect an autonomous individual is to respect that individual’s wishes 
with regard to research participation, and to maintain the confidentiality of private 
information. Thus, the principle of respect for persons entails moral rules requiring the 
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informed consent for research participation from research subjects, as well as requirements 
for safeguarding subjects’ private information. The Belmont Report also recognizes that 
individuals with diminished autonomy are vulnerable to exploitation. To respect these 
individuals requires extending additional protections. These include requirements for 
consent from an authorized substitute decision-maker, the requirement for the potential 
subjects’ assent for research participation, and limits on the kinds of risks to which an 
individual with diminished autonomy may be exposed as a result of research 
participation21. 
The principle of beneficence encompasses two moral obligations: to refrain from 
doing harm, and to maximize possible benefits while minimizing harms. The principle of 
beneficence entails moral rules with respect to the analysis of harms and benefits that 
particular studies pose to their subjects. Investigators and ethics committees are responsible 
for ensuring that the risks and benefits to research subjects stand in reasonable relation21.  
The principle of beneficence also applies more broadly to societal benefits that 
accrue from scientific research. It is an issue of beneficence as to whether the knowledge 
benefits of a scientific research program justify the risks that research poses both to 
individual subjects and to our social fabric21. 
The principle of justice refers to the fair distribution of the burdens and benefits of 
research, and entails moral rules about selection of study populations and subjects. Justice 
requires that no individuals or groups of individuals be systematically excluded from 
research, thus depriving them of the benefits of research participation, unless that exclusion 
can be justified on scientific grounds. This requirement is particularly relevant to groups 
such as women and children, who might stand to benefit from research participation, but 
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who have historically been unjustifiably excluded from research studies. Justice also 
requires that a group not be unfairly burdened with the risks of research participation. This 
means that a group should not be used as a population of convenience, as has occurred in 
the past with hospitalized individuals, visible minorities, underprivileged persons, and 
prisoners21. 
More recently, a fourth principle, respect for communities, has been proposed and is 
gaining increasing acceptance24. This principle recognizes the value of communities as a 
source of personal values and self-understanding, and their importance for the well-being 
of community members. Some types of communities legitimately exercise power to make 
decisions that are binding on their members. The principle of respect for communities 
demands that investigators respect communal values and social structures, and abide by 
decisions of legitimate community authorities24. 
These basic principles are intended to entail prima facie obligationsthat must be 
fulfilled25. Ethical challenges arise when obligations stemming from one principle conflict 
with obligations stemming from another. There is no implicit hierarchy of principles:  
“Although we begin our discussion of principles of biomedical ethics with respect 
for autonomy, our order of presentation does not imply that this principle has 
priority over all other principles. A misguided criticism of our account is that the 
principle of respect for autonomy overrides all other moral considerations. This we 
firmly deny.25”.   
It is the task of the research ethics committee to resolve ethical dilemmas resulting from a 
conflict between principles. This can be done by a weighing of the competing moral 
demands20,22,26, which requires a thoughtful appeal to the moral theories that underpin each 
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of the basic principles22. In subsequent chapters, we will apply this approach to a critical 
examination of the ethical questions posed by CRTs. 
 
Ethical Guidelines for Human Subjects Research 
Guidelines for the ethical conduct of research involving human subjects were 
promulgated prior to the systematic articulation of basic ethical principles in the Belmont 
Report 27,28. Although early guidelines are not obviously based on the Belmont Report 
principles, these guidelines and the Belmont Principles reflect common moral norms25.  
The promulgation of the Nuremberg Code marks the effective start of international 
efforts to regulate the conduct of human subjects research. The Code comprises a set of 
recommendations for the conduct of ethical research that emerged from the trial of Nazi 
physicians who conducted medical experiments on non-consenting prisoners during the 
Second World War. The experiments in question often caused terrible suffering to subjects, 
and frequently had little scientific importance or methodological validity. These 
experiments took place in spite of research regulations in German and Russian law that 
required the informed consent of research subjects29. The Nuremberg Code’s first 
requirement isabsolute: researchers must obtain informed consent from subjects. The 
Nuremberg Code also requires that the research be scientifically valid, that unnecessary 
suffering should be avoided, that risks be justified by the humanitarian importance of the 
research, and that research be stopped if there is risk of death or injury to the subject29.  
The Nuremberg Code does not specifically address the broad range of areas of 
inquiry and variety of research methodologies in human subjects research. It does not 
contemplate such challenges as research on individuals with limited decision-making 
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capacity such as children or incapable adults, nor does it recognize that some human 
research necessarily involves interventions that may pose serious risks to research subjects. 
Taken literally, the Nuremberg requirements would curtail the biomedical research 
enterprise.  
The World Medical Association has promulgated its own ethical guidelines, which 
have become known as the Declaration of Helsinki. Initially published in 1964, and revised 
on eight occasions, most recently in 2008, the Declaration of Helsinki has become the most 
widely utilized international guideline for the conduct of human subjects research. The 
Declaration of Helsinki differs from the Nuremberg Code in that it explicitly allows for 
research on subjects with diminished autonomy, even though it pays more attention to the 
use of vulnerable or disadvantaged populations in research. 
Revisions of the Declaration of Helsinki27, Guidelines from the Council of 
International Organizations of Medical Science30,31, and guidelines from the Canadian 
Institutes of Health Research, National Science and Engineering Research Council and 
Social Sciences and Humanities Research Council32, along with the Australian National 
Health and Medical Research Council33 include their own statements of basic principles. 
Although each agency’s guidelines articulate basic principles differently, all are clearly 
indebted to the authors of the Belmont Report27,30-33. Numerous research ethics guidelines 
therefore outline specific moral rules that stem from the basic principles of respect for 
persons, beneficence and justice outlined in the Belmont Report. 
In 1981, US Department of Health and Human Services issued new human subjects 
research regulations in 1981 based on the recommendations of the National Commission. A 
subpart of these regulations that includes informed consent requirements and rules for 
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Institutional Review Board review are known as the Common Rule because, as of 1991, 
they apply to all human subjects research conducted or funded by US Federal 
departments34. The Common Rule offers specific guidance as to the procedural 
requirements for research ethics review. It also outlines, in great detail, requirements for 
informed consent, including a provision for a waiver of consent for certain kinds of 
research34. Human subjects research in Canada is governed by the guidelines adopted by 
the country’s three major research funding agencies, namely the Tri-Council Policy 
Statement: Ethical Conduct of Research Involving Humans32. The Tri-Council Policy lays 
out eight basic ethical principles that are largely reducible to the three Belmont Principles. 
This framework of ethical principles gives rise to detailed guidance for consent processes, 
the assessment of the harms and benefits of research, and the just recruitment and treatment 
of research subjects32.  
 
Guidelines for CRTs 
Two guidelines address specific ethical problems in CRTs, but neither 
comprehensively addresses the breadth of ethical questions that have been encountered in 
CRTs.  
The 2009 revision of the Council of International Organization of Medical Science 
(CIOMS) International Ethical Guidelines for Epidemiological Studies30 clearly derives 
from three Belmont Report principles of respect for persons, beneficence, and justice. 
CRTs are one of five types of studies for which the CIOMS guidelines state that a waiver 
of consent may be permissible: If a CRT is evaluating cluster-level interventions that are 
difficult to avoid, then a waiver of consent may be permissible.  
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The CIOMS guidelines suggest that even if consent is not possible, that community 
residents should still be notified that a CRT is being conducted30. If consent from 
individual cluster members is not possible, the CIOMS guidelines require that investigators 
identify an entity that has the authority to give permission for the cluster to be enrolled in 
the CRT. According to CIOMS, the decision-maker should have the authority to make 
decisions to undertake interventions similar to those being evaluated by the CRT. The 
decision-maker may also choose to consult the community more broadly prior to agreeing 
to CRT participation. The CIOMS guidelines give research ethics committees the latitude 
to require that investigators consult with community members prior to commencing a 
study, in order to seek the community’s input into the study protocol. The CIOMS 
guidelines also contain sections pertaining to research performed on underprivileged 
populations that may be applicable to CRTs conducted in developing countries30.  
The 2002 UK Medical Research Council’s statement Cluster Randomized Trials: 
Methodological and Ethical Concerns18 contains guidance with respect to consent 
procedures and the role of cluster decision makers. The MRC guidelines require 
investigators to seek consent from individual cluster members whenever possible (i.e. for 
CRTs involving individual-level experimental interventions or interventions on individual 
cluster members for the purpose of data collection)18. The MRC guidelines also set out 
detailed guidelines for the function of individuals who make decisions on behalf of 
clusters, referred to in the guidelines as Cluster Representation Mechanisms (CRMs)18. 
CRMs must act in the interests of both the cluster and the individual cluster members, 
which may be difficult if these interests conflict. The CRM has rights similar to those of an 
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individual subject in an individually randomized trial, including the right to withdraw the 
cluster from the CRT. 
Neither set of guidelines clearly identifies when seeking informed consent is 
necessary and when using a waiver of consent is acceptable. They only specify 
circumstances in which consent may not be required. Nor do these guidelines detail the 
essential elements of disclosure in consent negotiations. Neither the CIOMS nor MRC 
guidelines lay out clear rules for the analysis of harms and benefits in CRTs. 
 
Using a conceptual framework for research ethics to address ethics questions in CRTs 
This dissertation will employ a conceptual framework rooted in the basic ethical 
principles of respect for persons, beneficence, and justice. Ethical questions arising from 
the CRT design will be framed in terms of conflicts between obligations that stem from 
conflicting principles. Ethical challenges in CRTs will then be addressed by evaluating the 
competing moral demands of each conflicting principle. By appealing to the moral theories 
on which each principle is founded, and to associated moral concepts articulated in the 
research ethics literature, one can hope to identify a justifiable solution to the ethical 
problems associated with the CRT design. This work will, in turn, inform the development 
of comprehensive research ethics guidance that adequately addresses the breadth of ethical 
questions arising in CRTs35. 
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Ethical Questions in CRTs 
Many of the ethical problems relating to CRT conduct have been identified in the 
literature by CRT investigators who have encountered these challenges in practice. This 
dissertation contributes to the activities of a working group of experienced CRT 
investigators and ethicists, funded by the Canadian Institutes of Health Research. This 
working group systematically reviewed the literature on the ethics of CRTs and identified 
key ethical questions raised in the literature. Using the conceptual framework outlined 
above, the working group identified important ethical issues that had not surfaced in the 
CRT literature35,36 as well as questions arising from the conceptual framework for research 
ethics. It identified six broad questions that, once addressed, will provide comprehensive 
guidance to investigators and research ethics committees: 
1) Who is the research subject in CRTs? 
2) When, from whom, and how must consent be obtained? 
3) Does clinical equipoise apply to CRTs? 
4) How should the risks and potential benefits of CRTs be evaluated? 
5) How ought vulnerable groups be protected in CRTs? 
6) Who are cluster gatekeepers, and what are their responsibilities? 
Each of these questions will now be briefly considered. 
 
1) Who is the research subject in CRTs? 
A key ethical problem in CRTs is the identification of research subjects36. In typical 
RCTs it is generally obvious who the research subjectis. The subject is any individual who 
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is recruited, enrolled, and intervened upon. In CRTs it may be unclear who the research 
subjectsare. CRTs often target groups of individuals, but it is not obvious that all group 
members who may be affected by CRT interventions are, in fact, research subjects. For 
example, a CRT may randomly assign communities to different mass media campaigns 
aimed at increasing residents’ participation in physical activity37. Although there are no 
direct interventions on the community residents, they may still be research subjects. What 
if a resident is not exposed to the campaign? What about individuals who may be visiting 
that community? What about residents of control communities that do not receive any 
intervention? 
Some CRTs may intervene upon professionals (e.g., physicians or teachers) and 
evaluate the effect of the intervention using data from the individuals that the professionals 
serve (e.g. patients or students). It is unclear whether the research subjects arethe 
professionals who are intervened upon, the individuals that they serve, or both9,38-40. In one 
example, a trial randomized primary care clinics to different continuing education 
strategies, and evaluated the effect of the education strategies on prescription patterns by 
abstracting data from patients’ prescriptions41. Are the patients research subjects? How 
about the health professionals who are the recipients of the study interventions?  
There are two important reasons to examine the question of who the research subject 
is in CRTs. First, failure to correctly identify who is and who is not a research subject in 
CRTs may result in the failure to adequately protect some research subjects or may, 
conversely, lead to overzealous protection of individuals who are not research subjects, 
leading to the hindrance of important research. Second, research subjects in CRTs must be 
identified before other ethical challenges, such as consent issues or the analysis of harms 
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and benefits, may be considered either as a normative question or as a pragmatic issue for 
investigators and research ethics boards. 
Both the MRC ethics guidelines for CRTs18 and the CIOMS guidelines for 
epidemiologicresearch 30 assume that cluster members will necessarily be subjects, without 
providing any justification. The issue of whether or not professionals who are the recipients 
of educational or quality improvement interventions in CRTs are research subjects has been 
addressed in two papers in the research ethics literature; both concluded that health 
professionals are research subjects39,40. Several other papers offer diverging views on 
whether consent is required from health professionals, without explicitly considering 
whether or not the professional is, in fact, a research subject. Some authors argue that 
consent should be sought from health professionals9,38, while others argue that consent 
requirements should be waived42. 
Only one paper has explicitly considered whether the patients of health professionals 
participating in a CRT need to be considered research subjects39. The paper concluded that 
patients of a health care provider whose care may be indirectly affected as a result of 
interventions on the provider are research subjects. However, no argument is offered in 
support of this conclusion39. Further normative work is required to examine arguments that 
may support or refute these conclusions. The question of who is a research subject will be 
addressed in detail in Chapter Five of this dissertation. 
 
2) When must consent be obtained in CRTs? 
The bulk of the literature on the ethical challenges of CRTs focuses on issues around 
obtaining informed consent from research subjects1,9-11,14-16,42. Ethical problems relating to 
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informed consent in CRTs can be grouped into four broad categories. Each of the issues 
described below will be addressed in more detail in Chapter Six of this dissertation. 
 
2.1) Feasibility of obtaining informed consent in CRTs 
CRTs have become the gold standard methodological technique for evaluating the 
efficacy of public health interventions applied to groups such as neighborhoods, 
communities or larger social-political entities. Assuming that citizens of communities 
participating in public health CRTs are research subjects (something that is not a foregone 
conclusion), the logistical effort and expense that would be required to obtain consent for 
research participation from all subjects would make many large community-based CRTs 
unfeasible1,9,10,14,15,18,39,40. Some research ethics guidelines include rules for waiving the 
requirement for obtaining informed consent if this is not feasible18,27,30,32,34. However, there 
has been no principled examination of the moral justification for the use of a waiver of 
consent. Identifying a justification for the use of a waiver of consent will be helpful in 
developing clear guidelines that specify when the use of a waiver of consent is permissible 
for CRTs. 
 
2.2) Threats to internal validity due to consent requirements 
CRTs are often used to evaluate interventions designed to modify the behaviour of 
the research subjects. Several commentators have suggested when information is disclosed 
to subjects during consent negotiations about the study’s purpose and interventions, this 
may be sufficient to prompt a behavioural change among subjects10,15,17,42. This unintended 
behavioural change effect may be sufficient to threaten the validity of effect estimates. 
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Some have argued that the potential for bias in CRTs of behavioural interventions is 
sufficient to justify either a waiver of consent for some CRTs, or an alteration of the 
information that is disclosed to potential subjects during consent negotiations10,15. A 
principled moral justification for waiving consent requirements because of potential threats 
to validity from disclosure in consent negotiations has yet to be articulated in the CRT 
literature.  
One strategy for minimizing bias and for increasing sample sizes has been to use a 
passive consent, or “opt-out” model for subject enrollment. This has been used frequently 
in education43 and health services research44-46. Subjects are assumed to be agreeable to 
CRT participation unless they (or their substitute decision-maker) explicitly opt out. 
Although national and international ethics guidelines allow for waivers or alterations of 
consent requirements in specific circumstances, none discuss the use of an opt-out consent 
model18,27,30-34. Furthermore, there has been no substantive normative work that examines 
whether or not an opt-out consent model is sufficiently respectful of subjects’ autonomy so 
as to be a reasonable substitute for seeking informed consent. 
 
2.3) Timing and Meaning of informed consent in CRTs  
In typical RCTs, subjects give consent for trial participation at the time of enrolment. 
This consent includes consent to random assignment, to receive the study intervention, and 
to undergo any interventions necessary to gather data. In many CRTs, investigators may 
not be able to seek subjects’ consent for random assignment or for the experimental 
interventions11,42. Whether obtaining consent for CRT participation is possible prior to 
randomization depends, in large part, on the type of cluster and unit of randomization47. It 
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may be possible to enroll a cluster and obtain consent prior to randomization if the cluster 
is small and all members are easily accessible, such as in a family. If clusters are large, or if 
cluster members are not identifiable at the outset of a trial, obtaining consent after 
randomization is the only option47. 
If random assignment of clusters is done before subjects are enrolled, then consent 
for random assignment is not possible. It is also unclear what information must be 
disclosed to subjects who are enrolled in a CRT after random assignment of clusters. Some 
commentators have expressed concern that obtaining consent after randomization of 
clusters violates subjects’ autonomy rights14,15,42.  
The experimental intervention may be a cluster-level intervention that individual 
subjects may not be able to avoid. In these cases, refusal would be meaningless11,42. Some 
cluster-level interventions which are unavoidable may be eligible for a waiver of consent, 
but consent for some data-collection interventions may still be required. Some of the 
conceptual work in this dissertation will examine whether the pragmatic challenges relating 
to obtaining informed consent in CRTs can be reconciled with investigators’ obligations to 
respect subjects’ autonomy. 
 
2.4) Can professional obligations mandate CRT participation? 
Many professionals must engage in continuing education in order to maintain their 
licensure. Similarly, organizations such as hospitals or school boards may undertake 
quality improvement initiatives. Continuing education and quality improvement programs 
may be evaluated using CRTs. Can a professional obligation to partake in continuing 
education entail an obligation to participate in a CRT evaluating a continuing education 
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program? Can organizations that choose to participate in a quality improvement CRT 
mandate participation by their employees? Commentators42 have offered several arguments 
as to why professional obligations should necessarily entail CRT participation by 
professionals. These arguments will be examined in Chapter Six. 
 
3) Does clinical equipoise apply to CRTs? 
In individually-randomized medical clinical trials, the random assignment of patient-
subjects to trial arms is justified by the concept of clinical equipoise. Clincal equipoise 
refers to a state of honest professional disagreement in a community of experts as to the 
preferred treatment. If such a state exists, then subjects are not disadvantaged by random 
assignment to one arm or another. The RCT must be designed to disturb this state of 
clinical equipoise, and thus change practice48.  
Although equipoise is pointed to in the CRT literature as a moral requirement14, it is 
not obvious whether the traditional conception of clinical equipoise is easily applied to 
CRTs49. Clinical equipoise in typical RCTs is grounded in the fiduciary duties that 
physicians owe their patients; a physician is only justified in recommending enrolment in 
an RCT to her patient if clinical equipoise exists48,49. In many CRTs, the researcher-subject 
relationship is not analogous to the physician-patient relationship. So, it is not obvious 
whether clinical equipoise may be used as a moral justification for random cluster 
assignment49. 
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4) How should the risks and potential benefits of CRTs be evaluated? 
Neither the literature nor ethics guidelines offer substantive advice on how 
investigators and REBs should consider the harms and benefits in a CRT. REBs may be 
able to consider the harms and benefits of interventions in a CRT that are directly applied 
to individual subjects using the same criteria as those used in individually-randomized 
clinical trials13. The principle of beneficence requires that investigators maximize benefits 
to research subjects, while minimizing harms. Investigators and ethics committees are thus 
charged with ensuring that the risks posed to subjects in CRTs are reasonable in relation to 
the potential benefits.  
A widely accepted approach, called component analysis, provides a systematic 
framework for the assessment of harms and benefits in human subjects research13. 
Component analysis first divides study interventions into two categories. Therapeutic 
interventions are typically the interventions being evaluated in a clinical research study. 
They offer the prospect of direct benefit to subjects. In a clinical trial, therapeutic 
procedures must satisfy the conditions of clinical equipoise, must be consistent with 
competent care, and may only pose risks that are justified by the expected therapeutic 
benefit. Non-therapeutic interventions are those that are used to collect data, and thus 
solely serve a scientific purpose. The risks of non-therapeutic interventions must be 
minimized, consistent with sound scientific design, and must stand in reasonable relation to 
the knowledge that is expected to be gained from these interventions13. 
Component analysis may be applied to CRTs in which the study interventions are 
directed at individual subjects. It is not obvious whether component analysis can be applied 
as easily to CRTs that evaluate cluster-level interventions36. It remains an open question 
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whether public health interventions administered at the cluster level can be considered in 
the same way as therapeutic interventions that are administered to individual subjects. It is 
also unclear how to evaluate the harms and potential benefits of complex interventions that 
are designed to modify professional behaviour such as in healthcare knowledge translation 
or quality improvement studies36. 
 
5) How ought vulnerable groups be protected in CRTs? 
The principle of justice entails moral rules for subject selection, requiring that no 
individuals or groups be inappropriately excluded from research while also ensuring that 
vulnerable groups or individuals are not exploited as a population of convenience21. CRTs 
using vulnerable groups such as individuals in developing countries or populations with 
low socioeconomic status face similar justice issues to typical RCTs. CRTs must be 
responsive to the health needs of the population under study. In other words, the population 
under study must be selected because the use of that population is necessary to the 
scientific question of the trial, and the study itself must address the needs of that 
population27. Other questions of justice that have proven to be challenging for RCTs also 
apply to CRTs36. What ethical standards for subject protections ought to apply: local 
standards, or the standards of the study sponsor’s country? Should subjects in the control 
arm be offered the best proven control intervention, or thebest intervention that is locally 
available? What obligations do investigators and study sponsors have to subjects and host 
communities after a CRT is completed? 
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6) Who is a gatekeeper, and what are their responsibilities? 
There may be ethical, logistical or political reasons for seeking permission to enroll a 
group in a CRT. This permission is typically sought from an entity that has been described 
in various publications as a decision-maker30, guardian10, gatekeeper15,18, or cluster 
representation mechanism18. Requirements to seek permission from a cluster decision-
maker leads to several important questions. Who is empowered to speak on behalf of a 
community or group of individuals with respect to CRT enrolment? What is the source of 
their authority? What is the scope of their authorization for CRT participation: does it 
supplement or obviate the need for consent from individual cluster members? What out to 
be done if no legitimate cluster decision-maker can be identified? What criteria ought 
cluster decision-makers use to guide their decisions whether or not to enroll a cluster in a 
CRT? 
Many communities, whether geographic, cultural, religious or otherwise, have 
legitimate political representatives who are empowered to protect the collective interests of 
that community24. Examples of such individuals may include a mayor or tribal leader. The 
status of other groups that may be recruited as clusters in CRTs, including hospitals, 
schools, sports teams, workplaces, and many others, is less clear. Some of these groups 
may even have clear leaders, such as a hospital CEO or the coach of a sports team. The 
diversity of groups that may be involved in CRTs leads to difficulties defining the scope of 
a gatekeeper’s authority, and the criteria they ought to use when deciding whether or not 
the cluster they lead should participate in a CRT.  
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Summary 
Current research ethics guidance does not comprehensively address the numerous 
ethical challenges that arise from the CRT design. A systematic enumeration of these 
ethical questions and a plan to address each key ethical problem is necessary in order to 
provide investigators and research ethics committees with guidance as to how to conduct 
important research while simultaneously safeguarding the interests of research subjects.  
This dissertation will contribute to the systematic evaluation of ethics challenges in 
CRTs. This literature review enabled an enumeration of the key ethical questions stemming 
from the CRT design. This review also provided a summary of a robust conceptual 
framework for the ethics of human subjects research. This framework will be used to 
critically reflect on the findings of the empirical evaluation of ethics practices in CRTs 
described in the following two chapters. This framework will also form the basis of 
normative analysis of the questions “Who is a research subject?” and “When is consent 
required in CRTs?” in chapters five and six. 
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Glossary of terms 
Bias: The distortion of a measure of association between an exposure or intervention and 
an outcome due to some sort of systematic error. Subtypes include (but are not limited to) 
information bias, such as measurement error, or selection bias, which is a systematic 
problem with subject recruitment that influences study findings50.  
 
Clinical Equipoise: The ethical justification for random assignment in a clinical trial. 
Clinical equipoise exists if there is “state of honest, professional disagreement in the 
community of expert practitioners as to the preferred treatment.48” If clinical equipoise 
exists, then subjects are not disadvantaged by random assignment to one trial arm or 
another. 
 
Cluster: In a CRT, a cluster is a group of individuals with common features. The cluster 
may be the unit of randomization, unit of intervention, unit of analysis, unit of inference, or 
any combination of the above. 
 
Contamination: A source of bias that results from subjects in one trial arm having access to 
the interventions delivered in another trial arm.  
 
Knowledge Translation: Activities or processes that facilitate the transfer of high-quality 
evidence from research into effective changes in health policy and clinical practice51. May 
include such activities as practitioner education or processes of care such as electronic 
reminders of best practices. 
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Quality Improvement: Interventions that arelinked to assessment and that have thegoal of 
improving the process, outcome,and efficiency of complex systemsof health care52. These 
most often are intended to result in local improvements in quality of healthcare delivery, 
and are not necessarily generalizable to other settings.  
Randomization/Random Assignment: The random assignment of individual subjects (in an 
RCT) or clusters into different arms of a clinical trial. This ensures that the features of 
subjects that may influence the study’s findings are similarly distributed in each trial arm. 
 
Research: A systematic investigation designed to develop or contribute to generalizable 
knowledge34. 
 
Risk: The probability and magnitude of harm posed to a research subject by a research 
intervention 
 
Unit of Randomization: The entity that undergoes randomization to create trial arms. In a 
CRT, this may be the cluster itself (e.g. a community), or it may be an individual with an 
affiliation with a cluster that enables randomization of the cluster (e.g. a physician whose 
practice defines the cluster). 
 
Unit of Intervention: The entity that undergoes the experimental intervention. In a CRT, 
this may be the cluster itself (e.g. a community), or individuals within the cluster. 
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Unit of Analysis: The entity to which statistical inferences are imposed. Depending on the 
scientific question of a CRT, this may be the individual cluster member, the cluster as a 
group, or both. 
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Introduction 
Cluster Randomized Trials (CRTs) have become an important research tool in 
evaluating the effectiveness of interventions designed to improve the quality or 
efficiency of health care services.  CRTs may evaluate several kinds of healthcare 
interventions. They may evaluate the effect of a therapeutic intervention that is 
directed at individual subjects, and randomly assign subjects to trial arms in groups 
in order to avoid experimental contamination within groups1. Alternatively, some 
CRTs randomly assign healthcare professionals or organizations to trial arms in 
order to evaluate the effect of an intervention on the professional or healthcare 
organization. These trials may evaluate patient outcomes as well as professional or 
organization-level outcomes.  
The CRT design poses several unique challenges with respect to obtaining 
informed consent from study subjects. In studies with large clusters, such as 
communities, it may be logistically very difficult to obtain consent from all cluster 
members1,2. Some studies may include several types of subjects who receive 
different interventions in the same study. For example, in CRTs of educational 
interventions administered to health professionals, the professionals themselves are 
subjects and, in certain circumstances, their patients may be subjects as well3-5. In 
some studies, subject recruitment occurs after clusters have been randomly assigned 
to trial arms. Therefore, it is only possible to obtain consent for trial participation 
post-randomization. Some commentators have expressed concern that this may 
infringe on subjects’ autonomy rights1,2. Some methodologists have also expressed 
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concern that the information disclosed during the consent process may bias the 
findings of CRTs of behavioural interventions6,7. 
It has been postulated1-3 and observed empirically8 that consent practices in 
healthcare CRTs may vary depending on the kinds of interventions under study. 
Consent requirements for CRTs have been noted to vary between jurisdictions and 
ethics committees9,10, and over time10. Uncertainty over whether some CRTs 
constitute research or quality improvement (QI)11,12 may have also led to variability 
in consent practices in CRTs that evaluate healthcare QI interventions.  
This study has two objectives. 1) To estimate the frequency of reporting of 
informed consent from patients in healthcare CRTs; 2) To determine whether 
reporting of informed consent from patients in healthcare CRTs is associated with 
particular methodological features of a CRT or with secular features such as 
country of study conduct or the quality of journal in which a trial is published. 
Multivariable regression modelling was used to test for the presence of independent 
association between reporting of informed consent and these features of healthcare 
CRTs. 
Methods 
This study was conducted in the context of a larger project, funded by the 
Canadian Institutes of Health Research. This larger project is using multiple 
methods to examine ethical challenges posed by CRTs, with the ultimate goal of 
developing consensus-based international ethics guidelines for the conduct of 
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CRTs. One of the components of this project was to examine reporting of various 
ethical issues in published CRTs in health research. The search strategy described 
below was used to identify a sample of 300 published CRTs in health research. 
However, this thesis focuses solely on the reporting of obtaining informed consent 
from patients in CRTs that randomize health care providers or organizations.  
Sample 
A highly sensitive electronic search strategy (sensitivity 90.1%, precision 
18.4%)13 was implemented in Medline to identify reports of CRTs published 
between 2000 and 2008. This search strategy identified 27149 study reports that 
may have been cluster randomized trials. These were sorted in random order, and 
screened serially until a sample of 300 CRTs was reached. The following inclusion 
and exclusion criteria were applied to define the population of candidate CRTs for 
the larger study:  
Inclusion criteria 
(i) Random allocation by cluster; 
(ii) English language; 
(iii) Year of publication 2000 to 2008; 
(iv) Outcomes of interest pertain to individual or population health; 
(v) At least some outcomes observed on (or aggregated from) individuals 
within clusters. 
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Exclusion criteria 
(i) Quasi-randomized design; 
(ii) Further random or non-random allocation of individuals within clusters; 
(iii) Use of standardized patients only; 
(iv) Pilot or feasibility studies; 
(v) Trial protocols or methods papers; 
(vi) Obvious secondary analyses of trials with main results published 
elsewhere; 
(vii) Short communications, conference proceedings, letters to editor; 
(viii) Studies randomizing households, or dyads of different individuals (e.g., 
patient-caregiver, parent-child); 
The sample for this thesis is a subset of the sample of 300 CRT reports 
conducted in primary care and hospital settings. Therefore, an additional inclusion 
criterion was applied to identify this sub-sample:  
(i) CRTs in which the unit of randomization or unit of 
intervention was a healthcare provider, teams of healthcare providers or 
healthcare organization (e.g., primary care practice or group of practices, 
hospital or hospital wards, nursing home), or CRTs which were conducted 
in a healthcare organization. Two authors (MT and CB) determined whether 
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or not studies met this criterion. Disagreements were resolved with input 
from a third author (AM). 
It was estimated a priori that studies in primary and hospital care would 
comprise approximately half of the sample of 300 CRTs identified for the larger 
CIHR-funded study. A previous review of primary care CRTs published from 1997-
2000 demonstrated a frequency of patient consent reporting of 39%8. CRT 
investigators perceive that consent requirements have become more stringent in 
recent years10. Therefore, for the purposes of sample size calculations, we will 
postulate a frequency of consent reporting of 50% in our sample of CRTs. A sample 
size of 150 trials is sufficient to give a 95% two-sided confidence interval extending 
±  8% from an observed proportion of 50%. If, as Eldridge observed8, the 
frequency of consent reporting is less than 50%, this conservative sample size 
estimate will provide greater precision around a smaller proportion.  150 trials with 
a postulated prevalence of 50% for the reporting of patient consent will also be 
sufficient to allow a multivariable logistic regression model to include 
approximately seven predictor variables, according to a widely used rule of 
thumb14. 
Data Abstraction 
The 65-item abstraction form (Appendix A) includes items on the 
characteristics of the study design, study interventions, outcomes collected, consent 
procedures at the patient, health professional and cluster levels, and details of the 
ethics review process. Questions regarding the methodological features of the CRTs 
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were drafted and revised based on input from members of the study team with 
methodological expertise. Questions regarding ethical issues were drafted and 
revised based on input from study team members with research ethics expertise. 
The abstraction form was then pilot tested on a sample of 25 healthcare CRTs. This 
sample of 25 studies was also used for calibration of data abstraction by 4 
reviewers. Afterward, data was abstracted from each study report by a pair of 
reviewers, working independently. Disagreements were resolved by consensus.   
Statistical Analysis 
All analyses were performed using SAS, version 9.2 (SAS Institute, Cary, 
NC). Bivariable associations between the dependent and independent variable were 
evaluated using Pearson’s χ2, with Fisher’s exact test used if the expected 
frequency of events was small. Multivariable logistic regression modeling was used 
to generate adjusted odds ratios for the relationships between the dependent 
variable and each independent variable. 
Specification of Variables 
Dependent Variable 
Reporting of informed consent from individual patients. 
Whether or not investigators reported obtaining informed consent from 
patients was coded as a binary variable. The reference level, “no”, was recorded if 
the study explicitly stated that consent from individuals was not obtained, if the 
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study reported that a waiver of informed consent was used, or if the study did not 
report obtaining informed consent from individual patients. The variable was coded 
“yes” if articles explicitly state that consent was obtained from individual patients. 
The purpose of this dichotomization was to model actual consent practice. It was 
assumed that if informed consent from patients was not reported that it was not 
sought. 
Independent variables 
Twelve candidate independent variables relating to trial methodology were 
specified a priori by co-investigators on the CIHR project. Four authors (AM, AD, 
CW, MT) discussed the candidate independent variables, and came to a consensus 
that date of publication, country of study conduct, journal impact factor, unit of 
randomization, reporting of a study as quality improvement, type of experimental 
interventions, type of data collection interventions, and average cluster size would 
be included in the regression model.  
Five candidate variables which were initially put forward were not entered as 
candidate predictors: total sample size, trial type (individual- vs. cluster-level 
interventions), unit of randomization, unit of inference, and type of outcome 
observed. 
The trial sample size was considered less likely to be predictive of consent 
practices than average cluster size. Large individually-randomized RCTs obtain 
informed consent from all participants. However, obtaining informed consent may 
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be logistically more challenging in CRTs that randomize large clusters, such as 
communities15.  
The trial type (either cluster-cluster or individual-cluster, according to the 
typology proposed by Edwards et al.6 was considered likely to be correlated with 
the type of experimental intervention and type of data collection intervention 
variables.  
The unit of randomization was difficult to dichotomize into a conceptually 
meaningful binary variable with an easily interpretable odds ratio because of the 
heterogeneity of units of randomization (health care providers, institutions, 
communities, blocks of time).  
The unit of inference (patient-level vs. cluster-level) was considered likely to 
be correlated with the unit of randomization and the two variables describing trial 
interventions.  
The type of outcome observed (patient-level health outcomes vs. professional-
level outcomes, process measures or economic outcomes) was considered likely to 
be correlated with the data collection intervention variable. 
The seven variables chosen for the bivariable and multivariable regression 
analyses are specified as follows: 
Date of Publication 
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Date of publication was recorded as a binary variable comparing the periods 
of 2000-2004 and 2005-2008. This dichotomization point is approximately two 
years following the November 2002 publication of the UK Medical Research 
Council’s guidelines for the conduct of CRTs16, which also addresses the issue of 
informed consent. Studies whose consent practices may have been influenced by 
the promulgation of these guidelines would likely have been published in 2005 or 
later. We hypothesize that, because of the influence of the MRC guidelines and 
because of trends toward more restrictive research ethics review of CRTs observed 
by CRT researchers10, studies published in 2005 or later will be more likely to 
obtain informed consent from individual cluster members. 
Country of Study Conduct 
The variable country of study conduct grouped CRTs conducted in the United 
States and Canada as the alternate level, and CRTs conducted elsewhere as the 
reference level. We chose to dichotomize this variable in this way because research 
regulations in the US and Canada share many similarities, and evolved historically 
at different times and under different influences than ethics guidelines elsewhere. 
The practices of research ethics committees in the US and Canada are similar, but 
may differ from those elsewhere in the world. 
Journal Impact Factor 
We hypothesized that studies published in lower quality journals would be 
less likely to report obtaining patient consent. An empirical logit plot identified the 
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appearance of a discontinuity in the relationship between reporting of patient 
consent and journal impact factor occurring around the first quartile. It appeared 
that journals in the lower one quarter of impact factor were less likely to report 
obtaining patient consent, with journals in the upper three quartiles having a higher 
but roughly similar probability of reporting consent. Therefore, journal impact 
factor was dichotomized into a binary variable at the second quartile (2.219). The 
alternate value for the variable includes studies published in a journal with an 
impact factor less than 2.219. The reference value includes studies published in 
journals with an impact factor greater than or equal to 2.219. There were a small 
number of studies that had missing data for journal impact factor. The decision to 
dichotomize this variable allowed us to estimate a plausible value for impact factor 
either above or below the second quartile, thus avoiding their exclusion from the 
multivariable logistic regression analyses.  
Quality Improvement  
This variable will identify CRTs that are self-described as a trial of a 
healthcare quality improvement (QI) intervention. The reference level included 
CRTs that are not identified as QI, while the alternative level of the variable 
included reports of CRTs that specifically describe the study as an evaluation of a 
QI intervention. Informed consent from patients for healthcare QI activities is 
generally not required11,17. We hypothesized that studies that are identified as QI 
evaluations will be less likely to report informed consent from individual patients. 
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Type of Experimental Intervention 
Interventions targeted at individual patients, such as medical treatments, 
typically require informed consent and are distinct from interventions directed at 
the cluster-level which may have indirect effects on individual patients, such as 
educational interventions for health professionals or health system QI initiatives3. 
The reference level for this variable included studies which have only cluster-level 
experimental interventions and no patient-level experimental interventions. The 
alternate level included studies that have any patient-level experimental 
interventions. We hypothesized that studies that include patient-level experimental 
interventions will be more likely to report obtaining informed consent from 
patients. 
Type of Data Collection interventions 
The reference level for this variable included studies that do not employ any 
intervention upon or interaction with patients for data collection purposes, and use 
only routinely available data such as administrative or medical records. The 
alternate level included studies that do use direct interventions on patients, such as 
additional examinations or medical tests, or interactions such as surveys or 
interviews, for data collection purposes. The use of administrative data or private 
health information does not routinely require the use of informed consent18,19, 
although some jurisdictions and ethics committees have required consent for use of 
private health information20. We hypothesized that studies in which investigators 
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interact with or intervene upon patients for data collection purposes will be more 
likely to report obtaining informed consent from patients. 
Average Cluster Size 
It has been noted that obtaining informed consent from individual cluster 
members is logistically difficult in CRTs with large cluster sizes10,15. We therefore 
hypothesized that CRTs with larger cluster sizes would be less likely to report 
obtaining informed consent from patients. The average cluster size was calculated 
by dividing the number of individual patients included in each CRT at the time of 
baseline data collection by the number of clusters in the CRT at the time of baseline 
data collection. In cases in which the number of clusters at baseline was not 
reported, the number of clusters randomized was used.   Empirical logit plots with 
average cluster size divided into deciles confirmed that the odds of reporting 
consent tended to decrease as average cluster size increased. Since there remained a 
small number of trials for which cluster size could not be determined, a decision 
was made to dichotomize mean cluster size into a binary variable, split at the 
median. This decision allowed us to estimate a plausible value for mean cluster size 
either above or below the median value for most studies, thus avoiding their 
exclusion from the multivariable logistic regression analyses. The reference level 
includes studies with an average cluster size less than 29.5, while the alternate level 
includes studies with an average cluster size of 29.5 or greater. 
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Bivariable Analyses 
Bivariable associations between the dependent variable and each independent 
variable were examined with contingency tables. Relationships were tested for 
statistical significance using Pearson’s χ2 or Fisher’s exact test in the case of small 
expected frequencies. Odds ratios with 95% confidence intervals were generated for 
the unadjusted associations between the dependent variable and each of the 
independent variables.  
Logistic Regression Analysis 
The adjusted association between the dependent variable (reporting of 
individual informed consent) and the independent variables was examined using a 
multivariable logistic regression model. The aim of this analysis was to estimate the 
association between the dependent variable and all candidate independent variables, 
rather than to develop the most parsimonious model. We planned to estimate effect 
measures for each independent variable, which we hypothesized a priori based on 
conceptual and empirical work to be associated with consent practices. For this 
reason, all independent variables with no linear dependencies as revealed by 
multicollinearity diagnostics were entered into the model with no stepwise variable 
selection procedure. Multicollinearity was evaluated using the VIF and TOL 
options in SAS PROC REG. 
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Handling of Missing Data 
Missing data were observed for the variables Impact Factor and Average 
Cluster Size. Both of these variables were coded as binary variables, split at the 
median value. Values for missing data were estimated as follows. For studies with 
missing impact factor data (n=7), a value, either above or below the median value 
for this variable (3.052), was estimated. For studies with missing data on average 
cluster size (n=23), the full text of the article was examined for references to the 
number of subjects as well as for text that would allow estimation of the number of 
clusters. An estimate of the number of subjects and number of clusters was 
substituted so that a plausible value of average cluster size either below or above 
the median value for this variable (29.5) could be included in the dataset. We could 
estimate with reasonable certainty whether the average cluster size for most CRTs 
with missing data was either greater or lesser than the median value for this 
variable. Studies were excluded if no plausible value for number of subjects or 
number of clusters could be estimated (n=7), meaning that 16 studies had estimated 
data for the mean cluster size variable. Given that there were only seven remaining 
studies with missing data, the additional complexity of multiple imputation was not 
considered justified. A sensitivity analysis, to evaluate how estimation of missing 
data influenced the results of the analysis, was planned. A regression model was 
fitted using all independent variables, but eliminating studies with estimated data. 
Odds ratio estimates were compared to those generated by the model fit in the 
primary analysis that employed the dataset with estimated values. 
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Regression Model Diagnostics 
The calibration of the model was evaluated using the Hosmer-Lemeshow test 
using ten strata. Calibration refers to the ability of a model to match predicted and 
observed event rates across the spread of data. 
The discriminative power of the model was evaluated using the c-statistic, 
also known as the area under the ROC curve, which measures concordance between 
predicted and actual outcomes21-23. The c-statistic denotes the frequency with which 
the model can successfully discriminate between pairs of CRT reports, with one 
CRT reporting patient consent and one CRT that does not. A value of 0.5 indicates 
a discriminative value no better than chance, while a value of 1.0 indicates perfect 
discriminative power21-23. 
For logistic regression, there is no widely accepted analog to the coefficient of 
determination (R2), which is used in linear regression to quantify the proportion of 
variation explained by the regression model24-27. Several R2 analogs have been 
proposed in the literature. Two in particular make most conceptual and 
mathematical sense, and are used here. The first, R2O, is the squared Pearson 
correlation between the observed and predicted values of the dependent 
variable24,25. This approach is appealing because it is mathematically equivalent to 
the R2 used in linear regression. However, it is not a true measure of the proportion 
of variation explained, because R2 in linear regression and R2O in logistic regression 
are based on minimizing two different quantities24. The second, called R2L, is the 
proportional reduction in the value of the -2 log likelihood test between the null and 
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complete models. Although this is mathematically different from R2 and R2O, it has 
a more useful interpretation than R2O as the proportional reduction in prediction 
error between the null and complete models24. 
Secondary Analyses 
A prespecified secondary analysis was performed after dichotomizing country 
of study conduct as either a developing country  or as developed country (identified 
by the International Monetary Fund as an Emerging or Developing Economy28). 
The relationship between reporting of consent from individual subject and country 
of study conduct (developing vs. developed) was examined in a bivariable analysis, 
and using a logistic regression model including the other independent variables 
described above. 
Results 
The final sample of primary care and hospital-based CRTs, selected from a 
sample of 300 CRTs published 2000-2008, included 168 studies. Seven studies 
were excluded because of missing data for which plausible values could not be 
estimated. The analyses described below are based on a sample of 161 studies 
(Figure 1).  
Of the 161 studies included in the final sample, 86 (53.4%, 95% CI 45.7-
61.1%) reported obtaining informed consent from individual patients. 11 studies 
(6.8%) reported using a waiver of informed consent. 64 studies (39.8%) did not 
report obtaining informed consent from patients.  
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Bivariable Analyses (Table 1).  
No significant associations were observed between reporting of informed 
consent from patients and the country of study conduct. A significant bivariable 
association was observed between the reporting of informed consent from patients 
and the journal impact factor, the year of study publication, reporting of the study as 
QI, the use of patient-level experimental interventions, the use of patient-level data 
collection interventions, and average cluster size.  
Studies published in journals in the lower quartile of impact factor were less 
likely to report obtaining informed consent from patients. Studies published 2005-
2008 reported obtaining informed consent from individual cluster members more 
frequently than did studies published 2000-2004. CRTs reported as evaluating a QI 
intervention report obtaining informed consent from individual cluster members 
less frequently than non-QI CRTs. Studies evaluating patient-level experimental 
interventions reported obtaining informed consent from individual cluster members 
more frequently than did studies with only cluster-level experimental interventions. 
CRTs employing patient-level data collection interventions reported obtaining 
informed consent from individual cluster members more frequently than did studies 
that only used examination of medical or administrative data to evaluate outcomes. 
Studies with an average cluster size below the median value for this variable (29.5) 
reported obtaining informed consent from individual cluster members more 
frequently than did studies with a larger average cluster size. 
Multivariable Analyses 
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There was no statistical evidence of multicollinearity between the independent 
variables. Therefore, all candidate independent variables were included in the 
logistic regression analysis. Significant adjusted associations were observed 
between the dependent variable and journal impact factor, the year of publication, 
average cluster size, type of experimental interventions and type of data collection 
interventions (Table 2). These independent variables may be considered 
independent predictors of reporting of informed consent in healthcare CRTs. 
The country of study conduct (North America vs. others), and whether or not 
the study evaluated a QI intervention were not associated with reporting of 
informed consent from individual subjects after accounting for the other variables 
in the model. 
Regression Model Diagnostics 
The Hosmer-Lemeshow test indicates adequate goodness of fit for the 
multivariable model (C2 6.01, DF=8, p=0.645). Thus, the number of CRT reports 
that describe obtaining informed consent from individual cluster members is not 
significantly different than the number that would be predicted by the model. 
The model’s discriminative power is very good, indicated by a c-statistic 
value of 0.863.  
The pairwise correlation between the observed and predicted reporting of 
informed consent from individual cluster members is 0.616. R2O, the square of the 
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correlation, is 0.379. R2L, the relative reduction in predictive error between the null 
and complete model is 0.320. 
Effect of Missing Data (Table 3) 
Seven studies required estimation of data for the journal impact factor, while 
16 had required estimation of data for the average cluster size (2 studies had 
estimated data for both variables). A logistic regression model was fitted with all 
independent variables after excluding all studies with estimated data (n excluded= 
21, n included=140). The adjusted odds ratios were similar to the multivariable 
analysis that included all studies, although the adjusted odds ratio for journal impact 
factor was no longer statistically significant in this analysis.  
Secondary Analyses (Table 4) 
12 CRTs in the sample were performed in developing countries. Because of 
the relatively small number of studies performed in developing countries, Fisher’s 
Exact Test was used for the bivariable analysis, rather than Pearson’s χ2. A 
significant association between reporting of informed consent from individual 
cluster members and country of study conduct (developing vs. developed) was 
identified in a bivariable analysis. CRTs performed in developing countries 
reported obtaining informed consent from cluster members less frequently than in 
studies performed in developed countries (Unadjusted OR 0.21, 95% CI 0.06-0.79, 
p=0.012). 
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After adjusting for the other independent variables, the association between 
study conduct in developing vs. developed countries and reporting of individual 
informed consent remained statistically significant (Adjusted OR 0.20, 95% CI 
0.04-0.86, p=0.030). In this adjusted analysis, odds ratios for the other independent 
variable did not qualitatively change. However, the odds ratio for the Quality 
Improvement variable became statistically significant (Table 4), while the adjusted 
odds ratio for journal impact factor only approached statistical significance.  
Discussion 
Just over 60% of the CRT reports in this sample described the patient consent 
procedures used: 86 (53.4%) studies reported seeking patient consent, while 11 
(6.8%) reported using a waiver of consent. It is a source of concern that nearly 40% 
of studies did not report describe consent procedures. For these studies, it is 
unknown whether consent was sought, whether a waiver was used as provided in 
research ethics guidelines16,19,29-31, or whether consent was not sought for some 
other reason. CRT reporting guidelines32 do not explicitly require reporting of 
consent procedures, but this has been suggested in the CRT literature1, and is 
required in general research reporting guidelines33. Researchers’ omission of 
reporting of consent procedures is a source of concern, as no indication is given in 
these CRT reports whether subjects’ interests were adequately protected. 
This study has identified independent associations between reporting of 
informed consent from patients in healthcare CRTs and the journal impact factor, 
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the year of publication, average cluster size and the use of both patient-level 
experimental interventions and patient-level data collection interventions. These 
features have been previously noted in the CRT and bioethics literature as being 
likely to influence consent practices. This study provides empirical evidence to 
support these intuitions.  
All of the demonstrated associations between the reporting of informed 
consent and the independent variables fit our hypotheses. Investigators were more 
likely to report obtaining informed consent from patients if the CRT used patient-
level experimental interventions, if the study used patient-level data collection 
interventions, and if the study was published in 2005 or later. Investigators were 
less likely to report obtaining informed consent from patients if the average cluster 
size was large, if the CRT was described as evaluating a QI intervention, or if the 
study was published in a lower-quality journal. There is also evidence to suggest 
that patient consent is less likely to be reported in CRTs conducted in developing 
countries.  
The increased likelihood of reporting of informed consent in later years may 
be related to a number of factors. The UK Medical Research Council’s 
methodological guidelines for CRTs includes ethical guidelines that emphasize that 
individual informed consent should be obtained when possible16. These guidelines 
were published in 2002 and may have influenced investigators’ practices and ethics 
committees’ determinations in more recent years, both in the UK and in other 
countries. An ever-growing number of publications on the ethical challenges of 
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CRTs may have had similar influence. The association between reporting of patient 
consent and date of publication fits with researchers’ anecdotal observations that 
consent requirements have become more stringent in recent years10. Increasing 
awareness of reporting requirements for informed consent33 may have also 
contributed to increased reporting of patient consent in recent years.  
Studies with large cluster sizes were less likely to report obtaining informed 
consent from patients. In many cases, this is likely related to the logistical difficulty 
in obtaining consent from members of large clusters, such as all patients in a 
hospital system. The logistical effort required to obtain consent from all patients in 
some large CRTs would make some studies infeasible2,15. Current research ethics 
guidelines permit a waiver of consent for research posing only minimal risk that 
would otherwise not be feasible without the waiver19,29,30. Many healthcare CRTs 
meet these criteria and would be eligible for a waiver of informed consent3. This 
may account for the finding that studies with large cluster sizes were less likely to 
report patient consent. 
It has previously been observed that reporting of informed consent from 
patients was more likely in CRTs that include patient-level experimental 
interventions8. This study confirms that the use of patient-level experimental 
interventions is independently associated with the reporting of informed consent 
from individual patients.  
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Eldridge et al. conducted a review of 199 CRTs conducted in primary care 
settings. They developed a four-level typology of the kinds of experimental 
interventions used in these CRTs. 
• Individual-cluster interventions include such things as 
experimental treatments, information provided to patients, or the use 
of information on individual patients by health professionals to 
customize care. These interventions are targeted primarily at 
individual patients, and patients will ordinarily be able to choose 
whether or not to participate in the trial. The CRT design was 
typically chosen to avoid experimental contamination 
• External-cluster interventions refer to the use of additional 
staff in patient treatment that would not be available in routine care. 
These changes in cluster organization are intended to directly affect 
patient care, and patients will ordinarily be able to choose whether or 
not to participate in the trial. The CRT design is most often chosen in 
trials of external-cluster interventions for logistical reasons, in that it 
is easier to assign additional staff to a cluster such as a medical 
practice than it is to randomly assign patients from the same practice 
to either have or not have access to the additional staff. 
• Professional-cluster interventions are interventions that are 
directed at the health professionals, such as continuing professional 
development activities. They may have an indirect effect on the care 
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of individual patients, and patients are not able to avoid or opt out of 
the intervention. The CRT design is chosen to avoid contamination, 
as it is difficult for professionals to selectively apply new knowledge 
to different patients. 
• Cluster-Cluster interventions are targeted at the health 
professional, cluster organization or cluster population. The CRT 
design is chosen as the nature of the intervention is such that it can 
only be applied at the cluster level. Individual patients are not able to 
avoid or opt out of the intervention8. 
Eldridge et al. observed that 31% of trials that included cluster-cluster 
interventions (and possibly other interventions) reported obtaining patient consent. 
49% of trials with professional-cluster interventions but no cluster-cluster 
interventions reported obtaining patient consent. 80% of trials that contained no 
cluster-cluster or professional-cluster interventions (meaning that they had only 
external-cluster or individual-cluster interventions) reported obtaining patient 
consent8.  
Although our analytic approach was different from Eldridge et al., our 
findings are similar. Our definition of patient-level interventions included those that 
Eldridge et al. described as individual-cluster interventions (with the exception of 
the provision of individualized patient information to healthcare providers) and 
external-cluster interventions. Individual-cluster interventions are interventions 
directed at patients. External-cluster interventions represent innovative modes of 
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service delivery with unproven efficacy that can be likened to interventions directed 
at individual subjects3. We observed that studies that included patient-level 
interventions were more likely to report obtaining patient consent. Studies that 
included patient-level interventions may have also included cluster-level 
interventions. However, our analysis focused on whether or not a study included 
any patient-level interventions3,8,16,34. 
 We also identified an independent association between reporting patient 
consent and the use of patient-level interventions to collect data. We defined 
patient-level data collection interventions as any procedure administered to patients 
specifically to collect data, any interaction between researchers and patients to 
collect data, such as surveys or interviews, or the use of identifiable private 
information3,35. The use of de-identified or aggregate group data is not sufficient to 
make a patient a research subject3, and so is not included in our definition of 
patient-level data collection intervention. We observed a strong positive association 
between the use of patient-level data collection interventions and the reporting of 
informed consent.   
Quality improvement interventions are generally targeted at healthcare 
systems and practitioners, and rarely employ patient-level experimental 
interventions. Generally, informed consent from patients is not required for 
healthcare quality improvement activities11,17,36. This study demonstrates that this 
notion is reflected in current practice as the reporting of a CRT as QI is inversely 
associated with reporting of obtaining informed consent from individual patients, 
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when examined in a bivariable analysis. After adjusting for the other independent 
variables, the confidence interval crosses the null value, indicating a borderline 
association.  
Limitations 
The primary limitation of this study is that the dependent variable, reporting 
of informed consent from individual patients, may not reflect actual consent 
practices. It is conceivable that informed consent from patients was obtained, but 
not reported, for some studies. However, given that guidelines from the 
International Committee of Medical Journal Editors require reporting of informed 
consent procedures33, we believe that the reporting of informed consent is a 
reasonable surrogate for the actual practice of obtaining consent from patients. 
This review examines a sample of studies published between 2000 and 2008, 
and is likely representative of all published CRTs within that timeframe. However, 
quality improvement studies are frequently unreported in the literature11. Only 24 of 
the 161 studies in this sample of published CRTs are explicitly identified as being 
studies of quality improvement interventions, and therefore quality improvement 
studies may be under-represented in this sample and in the population from which 
they were drawn. One possibility for future work would be to repeat the analysis 
after including a sample of CRTs taken from the Cochrane Effective Practice and 
Organisation of Care Register of Studies37. However, studies in this database may 
not conform to standard clinical trial reporting guidelines32,33 and may be missing 
data with respect to other variables of interest. 
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The number of studies in this sample that were performed in developing 
countries was relatively small. For this reason, the confidence interval around the 
adjusted odds ratio for whether or not informed consent was reported in trials 
conducted in developing vs. developed countries is wide. In spite of the lack of 
precision of this estimate, the finding that CRTs performed in developing countries 
are less than 20% as likely to report obtaining informed consent compared to CRTs 
performed in developed countries is noteworthy. 
Some data were missing for the independent variables describing journal 
impact factor and mean cluster sizes. Given the dichotomous nature of the 
variables, plausible values for each missing data point were easily estimated. To 
evaluate the possible effect of this estimation method on the validity of our 
conclusions, a multivariable regression model was fitted using only data from 
studies with complete data. Excluding seven studies with estimated data for impact 
factor resulted in a loss of sufficient power to identify a statistically significant 
relationship between consent reporting and impact factor. However, no qualitative 
difference was observed for the estimated odds ratios for the other independent 
variables in the sensitivity analysis, indicating that are findings are largely robust in 
spite of the use of estimated data for two variables.  
Conclusions 
The methodological features that are independently associated with consent 
practices for individual patients in healthcare CRTs in this sample generally reflect 
the study features that have been identified in the cluster trial and bioethics 
79 
 
literature as likely having an influence on consent practices. Researchers’ 
perceptions of temporal trends toward increased requirement for patient consent in 
CRTs have been noted10, and are demonstrated empirically here. The notion that 
obtaining consent from individual cluster members may not be feasible in studies 
with large clusters2,15 appears to be reflected in current practice, according to this 
multivariable analysis. The importance of the type of interventions for consent 
practices has been discussed in the literature2,6,7,15 and observed empirically in a 
descriptive analysis8. The types of interventions evaluated in CRTs are here shown 
empirically to be independently associated with reporting of consent practices. 
This paper represents an empirical description of current practices with regard 
to obtaining informed consent from patients in healthcare CRTs. Whether or not 
current practices are satisfactory in respecting the interests of individual patients 
depends on the findings of further normative reflection. Conceptual work is 
required to determine under what circumstances patients in healthcare CRTs need 
be considered to be research subjects3,38, and then under what circumstances 
consent for CRT participation is required34,38. Only then can we reflect on the 
empirical findings to determine whether the current practices of researchers and 
ethics committees are acceptable. Consideration of these findings, informed by 
additional conceptual work that articulates a principled justification for consent 
requirements in CRTs, is essential for reinforcing good practices in trial conduct 
and ethics review, for remediation of errors in consent practices and ethics review, 
and for the development of regulatory guidance for CRTs. 
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Figure 1 
Selection of studies for systematic review data abstraction 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
27149 study reports identified by 
automated search strategy sorted 
with assignment of random 
number 
300 CRT reports meeting inclusion 
criteria from reports randomly 
selected by automated selection 
procedure  
168 CRTs conducted in primary care 
or hospital settings 
161 CRT reports in final sample  
138 CRTs conducted in public 
health or community health 
 
7 reports excluded because of 
missing data 
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Table 1. Bivariable associations between reporting of informed consent from cluster 
members and independent variables. N=161 
Independent Variable Reporting of 
Informed 
consent from 
cluster 
members 
 Odds ratio (95% 
CI) 
p 
 Yes No   
Journal Impact Factor 
(binary) 
    
2.2.19+* 73 (59.8%) 49(40.2%) 0.34 (0.16, 0.72) 0.004 
<2.219 13 (33.3 %) 26 (66.7%)   
Country of Study 
Conduct 
    
North America 35 (53.0%) 31(47.0%) 0.97 (0.52, 1.83) 0.935 
Other* 51 (53.7%) 44 (46.3%)   
Year of Publication     
2005-2008 57 (67.9%) 27 (32.1%) 3.49 (1.82, 6.69) <0.001 
2000-2004* 29 (37.78%) 48 (62.3%)   
Quality Improvement     
Yes 7 (29.2%) 17 (70.8%) 0.30 (0.12, 0.78) 0.010 
No* 79 (57.7%) 58 (42.3%)   
Patient-level data 
collection interventions 
    
Yes 75 (68.2%) 35(31.8%) 7.79 (3.58, 16.97) <0.001 
No* 11 (21.6%) 40 (78.4%)   
Patient-level 
experimental 
interventions 
    
Yes 54 (72.0%) 21 (28.0%) 4.34 (2.23, 8.46) <0.001 
No* 32 (37.2%) 54 (62.8%)   
Average cluster size     
29.5+ 28 (35.9%) 51 (64.1%) 0.23 (0.12, 0.44) <0.001 
<29.5* 58 (69.9%) 24 (30.1%)   
* indicates reference level of binary variable 
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Table 2. Adjusted odds ratios between obtaining informed consent from cluster members 
and independent variables. N=161. 
Independent Variable Adjusted Odds Ratio (95% CI) p 
Journal Impact Factor 
(2.219+* vs.<2.219) 
0.35 (0.13, 0.95) 0.040 
Country of Study Conduct 
(North America vs.Other*) 
0.85 (0.36, 2.04) 0.715 
Year of Publication 
(2005-2008 vs.2000-2004*) 
3.95 (1.74, 8.98) 0.001 
Quality Improvement 
(Yes vs.No*) 
0.33 (0.10, 1.05) 0.060 
Patient-level Data Collection 
Interventions (Yes vs.No*) 
4.95 (1.89, 12.97) <0.001 
Patient-level Experimental 
Interventions (Yes vs.No*) 
2.63 (1.12, 6.18) 0.027 
Mean Cluster Size (29.5+ 
vs.<29.5*) 
0.25 (0.11, 0.55) 0.001 
* indicates reference level of binary variable 
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Table 3. Adjusted odds ratios for obtaining informed consent from cluster members and 
independent variables, using only non-estimated data. N=140. 
Independent Variable Adjusted Odds Ratio (95% CI) p 
Journal Impact Factor 
(2.219+* vs.<2.219) 
0.40 (0.12, 1.38) 0.147 
Country of Study Conduct 
(North America vs.Other*) 
0.75 (0.27, 2.05) 0.573 
Year of Publication 
(2005-2008 vs.2000-2004*) 
5.19 (2.00, 13.42) <0.001 
Quality Improvement 
(Yes vs.No*) 
0.41 (0.12,1.43) 0.161 
Patient-level Data Collection 
Interventions (Yes vs.No*) 
6.13 (2.11, 17.79) <0.001 
Patient-level Experimental 
Interventions (Yes vs.No*) 
3.11 (1.18, 8.23) 0.022 
Mean Cluster Size (29.5+ vs.  
<29.5*) 
0.24 (0.10, 0.59) 0.002 
* indicates reference level of binary variable 
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Table 4. Adjusted odds ratios between obtaining informed consent from cluster members 
and independent variables, with country of study conduct comparing developed countries 
to developing countries. N=161. 
Independent Variable Adjusted Odds Ratio (95% CI) p 
Journal Impact Factor 
(2.219+* vs.<2.219) 
0.40 (0.15, 1.04) 0.059 
Country of Study Conduct 
(Developing vs. developed*) 
0.22 (0.05, 0.96)  0.043 
Year of Publication 
(2005-2008 vs.2000-2004*) 
3.98 (1.73, 9.12) 0.001 
Quality Improvement 
(Yes vs.No*) 
0.28 (0.09, 0.88) 0.030 
Patient-level Data Collection 
Interventions (Yes vs.No*) 
4.92(1.86, 13.03) 0.001 
Patient-level Experimental 
Interventions (Yes vs.No*) 
2.63 (1.10, 6.26) 0.029 
Mean Cluster Size (29.5+ 
vs.<29.5*) 
0.26 (0.12, 0.59) 0.001 
* indicates reference level of binary variable 
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Chapter 4 
 
 
 
Researchers’ Perceptions of Ethical Challenges of Cluster Randomized Trials: 
A Qualitative Analysis 
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Introduction 
Cluster randomization is a research design commonly used in public health, 
educational, social science and health services implementation research1. Cluster 
randomized trials (CRTs) are different from conventional randomized controlled 
clinical trials (RCTs). RCTs randomly assign individual research participants to 
different intervention arms and evaluate the comparative effectiveness of the study 
interventions using data collected from each participant. CRTs randomly assign 
groups of individuals to different intervention arms. The comparative effectiveness 
of the interventions in each arm is evaluated using data collected from individual 
cluster members, or from other sources such as administrative databases1. 
CRTs pose unique ethical challenges that stem from their methodological 
differences compared to conventional randomized trials. It can be difficult to identify 
precisely who is the research subject in a CRT, particularly in large community-
based public health CRTs and in CRTs evaluating educational interventions aimed at 
health professionals2-4. It is unclear under which circumstances, and from whom, 
informed consent is required in large community-based CRTs1,5,6. Some CRTs have 
employed “gatekeepers”, individuals who have made decisions regarding CRT 
participation on behalf of randomized clusters. There is little clear information as to 
how and when these individuals ought to be identified, and what is the scope of their 
authority7. There is no authoritative guidance as to how the risks and potential 
benefits in CRTs ought to be evaluated by research ethics committees5,7,8.  
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The objective of this study was to examine how CRT investigators, in practice, 
have addressed the ethical challenges in the CRTs they have conducted. A series of 
interviews was conducted with experienced CRT investigators.  A qualitative 
analysis was then performed: 1) To describe how experienced Cluster Randomized 
Trial (CRT) researchers have addressed ethical challenges arising from the CRT 
design. 2) To describe CRT researchers’ views on the ethics review process. 3) To 
document CRT researchers’ views on the need for comprehensive ethics guidelines 
for CRTs.   
Methods 
A qualitative approach was employed to capture rich data on informants’ 
experiences and insights9,10. A descriptive analysis approach was chosen11, with the 
goal of detailing the experiences and ideas of the informants. This descriptive 
approach is used to provide a comprehensive depiction of everyday events11. This is 
in contrast to the grounded theory type of analysis, which uses informants’ responses 
to develop theories that explain social phenomena, and phenomenology, which seeks 
to describe individuals’ lived experiences and perceptions in reaction to social 
phenomena 9,11. 
Sample Recruitment 
Based on the suggestions of the members of a multidisciplinary team 
assembled to study the ethical challenges associated with CRTs12, a purposive 
sample of potential informants was identified. To be considered eligible, potential 
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informants must have been the primary investigator on two or more cluster-
randomized trials or have published papers addressing the ethics of cluster-
randomized trials.  
 Initial contact with potential informants was made via e-mail by senior 
members of the study team (RB, AD, ME, JG, MZ). The email introduced the study 
design and purpose, and inquired about the potential informant’s willingness to 
participate. If the potential informant was willing to participate, the interviewer (AM, 
CB) arranged a time for the telephone interview A letter of information and a copy of 
the interview template was sent by email. At the time of the interview, informants 
were notified that the interview would be recorded and transcribed, but that no 
identifiable features would be reported. Verbal consent for participation was 
obtained, and the interview was conducted. 
The target sample size in qualitative research is achieved when data saturation 
occurs, that is when no new themes are identified with respect to a particular 
question of interest in successive interviews. This typically occurs after 12-20 
interviews. After analyzing 20 transcribed interviews, data saturation with respect to 
responses around the issue of informed consent in CRTs had been achieved. 
Final Sample 
Twenty-five potential informants were approached to participate in the study.  
Four individuals declined to participate. The interview from one informant was 
discarded as the recording was of insufficient quality for transcription and analysis. 
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The final sample included 20 experienced cluster trial researchers. There were ten 
European informants, six American informants, and four Canadian informants. All 
participants had been co-investigators on between two and twenty CRTs. 
Data Collection 
A semi-structured telephone interview guide was developed (Appendix A) and 
pilot tested on colleagues. The interview guide included questions about informants’ 
experience with CRTs, ethical issues in CRTs, ethical challenges encountered with 
particular CRTs and the ethics review process, and questions seeking input on ethics 
guidelines for cluster-randomized trials. Two trained interviewers conducted the 
interviews. The interview guide was modified in real-time by the interviewers to 
allow them to seek clarification from the informants or to probe important issues 
raised by the informants. The interview guide was also updated in an iterative 
fashion to explore issues that were raised by informants in previous interviews. All 
of the interviews were audiotaped, then transcribed verbatim. Transcripts were 
reviewed for accuracy by the interviewers. 
Data Analysis 
Each interview transcript was imported into qualitative data analysis software 
(NVivo 8, QSR Inc.). A directed content analysis approach was used, in that 
predetermined text analysis categories were used 13. The initial coding template for 
response categorization was developed by consensus of the investigators. Each 
transcript was reviewed independently by two of the researchers (AM and CB), and 
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responses assigned to the appropriate thematic coding categories. New categories 
were added in an iterative fashion by each researcher to his or her coding template in 
order to accommodate response themes that did not correspond to predetermined 
coding themes.  
After the initial coding, the researchers met and resolved disagreements in the 
emerging coding assignments by consensus. The coding template was then revised to 
include additional categories created in the first round of independent analysis, and to 
delete unused categories. This template revision also ensured fidelity in a second 
round of thematic coding, since both researchers were working from the same 
revised template. A second round of thematic coding was performed by the two 
researchers, using the new master coding template (Appendix B). Following this, the 
researchers met again to resolve discrepancies by consensus. 
Ethics Approval 
This study was approved by the Ottawa Hospital Research Ethics Board (File 
2007191-01H) and the University of Western Ontario Health Sciences Research 
Ethics Board (File 13755E). 
Results 
Informants were asked questions based on the main pre-identified themes of 
(1) ethical issues in the CRTs, (2) experiences with the ethics review process for 
CRTs, and (3) the need for, and input on, possible ethics guidelines for CRTs. 
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Ethical Issues in CRTs 
1. Informed consent 
Informants’ comments on the question of when informed consent is required 
from individual research participants varied widely. For many informants, whether or 
not informed consent was required in a particular CRT depended on the kind of 
intervention being evaluated. 
“The type of intervention that is being trialed is...of crucial importance. 
So, for example, whether...you are changing the way the entire service is 
delivered, or whether you are intervening at an individual level and you are just 
randomizing at a higher level for convenience.  So it is about which level...is 
the intervention being targeted at...” (Informant 11, Primary Care Researcher) 
The type of data collection procedures used in a CRT could also determine the 
need for consent from cluster members. Researchers almost universally obtained 
consent from cluster members if they interacted with these cluster members or 
intervened upon them to collect data.  
 “If we interact with the participant we get consent first.  If we are 
making observations in a public setting, we are not required to get 
consent...Those activities don’t require consent.” (Informant 3, Public Health 
Researcher) 
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Many informants related concerns over the effect of obtaining informed 
consent on the validity of a CRT’s findings. In particular, informants worried that 
disclosure of the nature of the interventions under study in CRTs of behavioural 
interventions may lead to bias if research participants modify their behaviour as a 
result of information disclosed during consent negotiations rather than as a result of 
the study interventions.  
“One of the things I am concerned about is bias. If you get really 
informed consent from people in trials it results in either bias or 
contamination.” (Informant 5, Statistician) 
Informants also shared a related concern with respect to studies of health 
services or quality improvement interventions in which the only intervention on 
individual patients is using health information for data collection. Informants 
expressed concern that requiring informed consent may make such CRTs logistically 
unfeasible. Several informants felt that these methodological challenges were 
sufficient to justify a waiver of informed consent for cluster members. 
“Wherever people propose that (requiring individual patient consent), it 
is the death of those kinds of studies.  It is the death of health services research.  
You can quote me on that.  If you require consent to use the data...to look at the 
performance of a system, it will be a complete disaster.” (Informant 1, Hospital 
Care/QI Researcher) 
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With respect to healthcare implementation research, informants had different 
perspectives on when, if ever, consent or permission from healthcare professionals is 
required. Investigators often asked permission, either from individual healthcare 
professionals or from a group practice, to enrol these professionals in their study.  
“Normally [permission would be obtained] at a general practice level. 
That would have been done at a partner level, so there would be a discussion 
within the practice and then agreement at a practice level.  There would have 
been consensual agreement between the partners, between the individual 
general practitioners that their practice would take part.” (Informant 11, 
Primary Care Researcher) 
Other informants proceeded with practice-based CRTs without securing the 
agreement of all healthcare professionals in the practice who might be affected by the 
intervention. 
 “For the ones targeted at practitioners, we had to install software in their 
electronic medical records systems and computers in their offices so that it 
would have been GPs in the practice who gave consent.  Within a practice, they 
didn’t all have to agree.” (Informant 2, Primary Care Researcher) 
Some informants argued that healthcare professionals have a professional 
obligation to participate in CRTs involving a knowledge translation or quality 
improvement intervention, which therefore overrides any requirement to obtain 
consent. 
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“I would argue that [there is a] professional responsibility to practitioners 
to take part in research that involves clinical knowledge.” (Informant 9, 
Primary Care Researcher) 
2. Role of the cluster gatekeeper or decision-maker 
Informants identified several ethical challenges related to the role of the 
gatekeeper, the individual who makes a decision with respect to CRT participation 
on behalf of a cluster. Informants noted challenges identifying the appropriate 
gatekeeper for certain kinds of groups, particularly municipalities. Opinions varied 
on whether municipal leaders had the appropriate authority to allow their community 
to participate in a CRT.  
“In some instances there really is no party to go to for permission when 
we are doing a community study for example and we are randomly assigning 
counties or cities.  There really isn’t anybody that gives permission for that 
kind of thing. Even in a city where there is a mayor, the mayor can’t give 
permission for a city to participate in something. At least that has always been 
my view.” (Informant 3, Public Health Researcher) 
Informants also recognized that some clusters, such as schools and hospitals, 
may have multiple gatekeepers because of the organizational structure of these 
institutions. 
“First off you have to have the district agree that you can even work in 
this district.  Then you have to get the principal to agree that they want to 
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participate in the project. And then we had... the president of the local parent 
leadership group.” (Informant 16, Public Health Researcher) 
In situations in which researchers had difficulty identifying the appropriate 
gatekeeper for community-based research, they typically sought the approval of 
some local advisory committee. 
“Our approach in virtually every instance was to organize a local 
community advisory board made up of community residents in the city if we 
were working with cities or in the county if we were working with counties.  
We would get their input on a variety of things though the basic design was 
set.” (Informant 3, Public Health Researcher) 
Another ethical challenge concerning gatekeepers related to the scope of the 
gatekeeper’s decision-making authority. Responses varied on whether the gatekeeper 
possessed sufficient authority to provide consent on behalf of all cluster members, or 
whether the gatekeeper was simply permitting access to individual cluster members 
who would subsequently provide consent for CRT participation.  
“I think the main issues for me still stem around the issue of consent.  
Who [gives] consent?  Whether consent needs to be achieved at every level of 
cluster or whether almost guardian consent is acceptable and that has been 
where the most discussion has happened really about in the ethical issues of 
cluster trials for me.” (Informant 11, Primary Care Researcher) 
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Some informants seemed comfortable accepting a gatekeeper’s consent on 
behalf of an entire cluster for studies that were evaluating cluster-level interventions, 
such as educational or quality improvement interventions targeted at health care 
systems or practitioners. 
“I would say most of them have been looking towards a cluster 
guardian...consent because most of the interventions I have been involved have 
been mainly around management interventions where the real intervention is at 
the level of either the practitioner, the health professional or the health care 
organization and this specific intervention hasn’t really been targeted at the 
lower level of the cluster, the patient level.” (Informant 11, Primary Care 
Researcher) 
Other informants expressed a different opinion. They felt it was important to 
obtain consent from individual patients in healthcare CRTs, regardless of whether 
consent for cluster enrolment was obtained from a gatekeeper. 
 “So there is a consent for the patient and a consent for in our case, the 
practice so there are 2 levels of consent if you like.  If there wasn’t patient 
consent involved, then obviously there would be very significant ethical issues 
but I have come to the view that if patients are given information and they 
consent, then that is fine.” (Informant 9, Primary Care Researcher) 
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3. Risks and potential benefits 
Our interview guide included items addressing the risks posed by CRT 
participation. Informants had few concerns regarding the risks posed to cluster 
members by CRTs. “Risks were none.  I think we came up with some for the ethics 
committee.” (Informant 14, Primary Care Researcher) 
The interventions under evaluation in CRTs were perceived as standard care 
with little or no incremental risk to cluster members. “None of the interventions that 
we have evaluated have put anyone at any kind of risk... there is certainly little risk 
involved” (Informant 3, Public Health Researcher) 
For healthcare CRTs that evaluated the effect of interventions on health 
professionals using patients’ health information, informants identified threats to 
privacy as the sole risk. “I think the core risk is loss of privacy.  That really is the 
only issue because we weren’t studying...a therapeutic intervention.” (Informant 8, 
Hospital Care/QI Researcher) 
Some informants voiced concern that members of clusters assigned to control 
groups may not benefit from an experimental intervention. “The dilemma and the 
tension again was this trial that is basically about the QI where the controlled 
practices got nothing.  They didn’t get anything but normal care.” (Informant 14, 
Primary Care Researcher) 
One commonly employed solution to address this dilemma was to offer 
the experimental intervention to the control clusters after the CRT had been 
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completed. “Sometimes we are so concerned about the control arm feeling that 
they don’t get anything that it might affect recruitment.  We offer them the 
intervention once the trial is over.” (Informant 14, Primary Care Researcher) 
An additional risk identified by one informant was that CRT enrolment may 
entail an increased clinical or administrative workload for participating medical 
practices. “The only risk I feel in doing a lot of research here is practices become 
overburdened by having to do research. (Informant 5, Statistician) 
Experiences with the ethics review process 
Many of the informants noted wide variability among research ethics 
committees, and across jurisdictions, in both the ethics review process and in ethics 
boards’ decisions. Informants noted that this variability has made it more difficult to 
do multicenter CRTs. “cluster...trials of hospitals randomise independent institutions, 
each of which has an [ethics committee]. Each [ethics committee], with its slightly 
different application procedures, forms and timelines has been a separate and trying 
process.” (Informant 7, Primary Care Researcher) 
Several informants commented that the ethics review process was easier in the 
past, and has become more cumbersome in recent years.  “...generally it hasn’t been 
too bad up until the last 5 years.  Beforehand we were quite comfortably able to get 
ethics approval ... but it is different now” (Informant 13, Primary Care Researcher) 
However, other informants commented that as ethics boards become familiar 
with the CRT design, the review process has gone more smoothly. “...Now CRTs are 
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widely accepted research methods, particularly in primary care studies, primary care 
settings.  Ethics committees are now actually quite comfortable with them. ” 
(Informant 14, Primary Care Researcher) 
Informants’ opinions varied on the effect of the ethics review process and 
regulatory requirements on the validity of a CRT. Half of the informants reported a 
positive impact of the ethics review process on the quality of their studies, while the 
other half reported negative effects. Perceived negative effects included threats to 
validity from consent processes, and diminished enrolment because of consent 
requirements.  
“As the participation rates drop...then the results are less generalizable 
and less helpful. There is no question that the higher hurdles for consent in 
school studies and certainly in clinic based studies have made it more difficult 
to do the work and to get high participation rates.” (Informant 3, Public Health 
Researcher) 
Perceived positive effects included requirements for greater methodological 
rigor and thoughtfulness in study design, and improved protections for research 
participants. 
 “I am a great believer that ethics committee do ask...searching 
questions...Just the process of thinking about the ethical implications of your 
design is something that we might not do if we didn’t have to go to ethics 
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committees...I think I would say for all my research, it is improved the quality 
of what we do.” (Informant 14, Public Health Researcher) 
Developing ethics guidelines for CRTs 
Informants were supportive of efforts to develop ethics guidelines for the 
conduct and review of CRTs. “I think there does still need to be a discussion 
document...on when is individual level consent an absolute requirement.” (Informant 
11, Primary Care Researcher) 
The most common suggestion for the content of ethics guidelines was to 
include education for research ethics committees on the ethical and methodological 
aspects of CRTs that make CRTs distinct from individually randomized trials. 
“I think that there are issues which make cluster trials different to the sort 
of trials that review boards normally see and that it would give me confidence 
as an investigator if I knew that they fully understood the difference.” 
(Informant 20, Hospital Care/QI Researcher) 
Discussion 
This study was designed to elicit the views of experienced CRT researchers on 
the key ethical issues involved in the conduct of CRTs, and to describe their 
experiences with the ethics review process for CRTs.  
Informants’ opinions on whether or not informed consent should be obtained 
from cluster members appeared to depend on the scientific question and experimental 
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interventions in particular CRT. Informants asserted that individual informed consent 
was necessary for CRTs in which cluster members were directly intervened upon. 
Informants in this sample frequently used waivers of informed consent for individual 
cluster members in large community-based CRTs, or in CRTs evaluating quality 
improvement or implementation strategies in healthcare or education.   
One reason often cited for avoiding obtaining informed consent from individual 
cluster members was a concern over consent practices possibly inducing some sort of 
bias that would threaten the validity of the CRT. This concern has been noted in the 
literature6,14. Further conceptual work appears necessary to clarify when, if ever, it 
may be permissible to waive requirements for informed consent from cluster 
members, and to identify the moral underpinning for such a waiver. Ethics 
guidelines, built on a robust conceptual foundation, should clearly lay out under what 
circumstances obtaining informed consent from individual cluster members is 
required, and under what circumstances the requirement for informed consent may be 
waived. 
Informants reported frequent challenges in identifying an appropriate 
gatekeeper who has legitimate authority to grant permission for a cluster such as a 
municipality or social group to be enrolled in a CRT. The gatekeeper for a 
professional group, such as a medical practice, hospital or school, may be more 
obvious. However it is unclear whether the agreement of all professionals (i.e. 
doctors, teachers) is required prior to the participation of a professional group in a 
CRT. Informants expressed concern over the scope of authority of the gatekeeper, 
105 
 
particularly with respect to whether permission from the gatekeeper was ever 
sufficient to obviate the need for informed consent from individual cluster members. 
Future conceptual work and guidelines for the ethical conduct of CRTs, should 
provide clear guidance on these issues. 
Many informants identified the problem of variability in ethics review between 
jurisdictions. They also described increasingly onerous oversight requirements 
imposed by ethics boards in recent years. This variability may be attributable to the 
fact that most jurisdictions do not have authoritative guidelines for the review of 
CRTs. Ethics boards are therefore required to use their own judgment in applying 
guidelines that do not address the unique ethical challenges posed by the CRT design, 
potentially resulting in idiosyncratic decisions. This indicates the need for 
comprehensive ethical guidelines that can direct the review of multi-jurisdictional 
CRTs. 
Several issues identified in the literature, and included in our interview guide, 
were not mentioned by informants. With respect to the assessment of harms and 
benefits of CRT participation, informants identified threats to privacy and risks of 
suboptimal treatment in control arms, as well as burdens to medical practices that 
participate in CRTs. Informants did not express concern about risks to individual 
research participants, especially in studies in which individual cluster members were 
not directly intervened upon. We suspect that this is because the interventions being 
evaluated in CRTs are often low-risk interventions designed to improve medical care 
or educational processes, and posed little ethical concern to investigators. However, 
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the view expressed by informants that CRT interventions pose no risk is misguided, 
as no experimental intervention in a trial can be considered to be free of risk15,16. 
Guidance on the ethical conduct of CRTs should educate investigators and research 
ethics committees on the identification of all important harms and benefits of CRT 
enrolment. Ethics guidance should also address how the analysis of risks and 
potential benefits for CRTs should be performed7,17. 
Limitations 
Our sample included experienced CRT researchers and individuals who have 
contributed to the literature on the ethics of CRTs. Their experiences may not 
necessarily be transferable to all CRT researchers. However, we are reassured that 
experienced researchers from a variety of locations, and in a variety of fields, voiced 
similar opinions on key ethical issues. Furthermore, the experience of the informants 
interviewed in this study lends weight to their views, and to our conclusions. 
Our informants worked mostly in developed countries, although some did 
perform CRTs in marginalized or underprivileged populations. This may be the 
reason that no informants voiced concerns about issues of distributive justice, such as 
fair participant selection, the reasonable distribution of burdens of CRT participation, 
and other issues encountered when conducting CRTs in developing countries. 
Conclusions 
Informants described challenges CRT investigators percieve with the ethics 
review process, expressed concern over when informed consent is required from 
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cluster members, and over the authority of cluster gatekeepers. Other important 
ethical challenges, such as the relationship between harms and benefits and issues of 
distributive justice appeared to be either less concerning to CRT researchers, or were 
under-appreciated. These views, offered by experienced CRT researchers, point to 
the need for further conceptual work on the ethics of CRTs, as well as the need for 
clear authoritative guidelines that address the unique ethical and methodological 
challenges of CRTs.  
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Introduction  
The CRT design is used in a diverse range of fields, including education, 
criminology, public health and health services research. Who ought to be considered a 
research subject in a CRT for the purposes of the regulation of research may be unclear. 
Are individual cluster members always research subjects? Does it matter whether cluster 
members directly receive an experimental intervention? Does it matter whether individual 
cluster members’ identifiable private information is used to generate outcome data? In 
some CRTs, individuals such as health professionals will be the ones randomly assigned to 
receive an experimental intervention. Are the health care professionals research subjects? 
Does it matter whether or not outcome data are collected from the professionals? Are 
patients necessarily research subjects if the intervention administered to the healthcare 
professional indirectly affects their care? 
The question of who constitutes a research subject in a CRT is important for two 
related reasons. First, the consequences of misidentifying research subjects in CRTs are 
significant for both subjects and investigators. If we fail to identify individuals who ought 
to be recognized as research subjects in a CRT, then we will fail to adequately protect their 
interests. If we are overly inclusive in identifying individuals as research subjects in a CRT, 
then investigators will be unnecessarily subjected to regulatory burdens that may hamper 
important research. Second, as a pragmatic concern for research ethics committees, 
research subjects must be appropriately identified before such issues as informed consent, 
assessment of benefits and harms, and the appropriateness of subject selection procedures 
may be considered. 
112 
 
 
 
This paper aims to develop a principled definition of “research subject” that 
investigators and research ethics committees can use in all types of human subjects 
research. This definition will be particularly helpful to CRT investigators and research 
ethics committees who review CRTs. We contend that the answer to the question “Who is a 
subject in a CRT?” may vary, depending on the specific study design, the population, and 
the interventions being evaluated.  
Examples: Challenges in identifying the research subject in 
CRTs 
CRTs are heterogeneous with respect to design, population, and interventions. The 
following four examples (a) illustrate the complexity of the question “Who is a research 
subject in CRTs?”, and (b) highlight the need for a principled definition of research subject 
that can be employed across the spectrum of CRTs. 
Example 1: The COMMIT Trial 
The COMMIT trial1,2 evaluated a multimodal community-level intervention aimed at 
reducing cigarette consumption, including a media and billboard campaign as well as 
targeted messaging toward smokers. Communities were randomly assigned to either the 
intervention or control arm. The effect of this complex intervention was evaluated using 
interviews with a random sample of smokers in each community, and also by comparing 
the amounts of tobacco purchased by people living in the intervention and control 
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communities. The study found that the intervention led to an improved quit rate for mild to 
moderate smokers, with no effect on the quit rate of heavy smokers.  
Who were the research subjects in this study? The survey respondents? Only 
residents of the communities who smoke? Every resident of participating municipalities?  
Example 2: A CRT of bed net distribution to reduce malaria prevalence 
A CRT that evaluated malaria prevention interventions3 randomly assigned 
Cambodian communities either to an intervention group in which bed nets were distributed 
to all residents in the intervention communities, or to a control group in which no bed nets 
were distributed. To evaluate local malaria prevalence, the population size was obtained 
from local census data and the number exposed to malaria was obtained from blood tests 
performed on a random sample of village residents. No identifying information on sampled 
individuals was retained. The study identified non-significant trends toward decreased 
malaria incidence and prevalence in the intervention communities.  
Who were the research subjects in this study? Only citizens of intervention 
communities who received bed nets? Citizens of control communities who provided blood 
samples? All citizens in intervention and control communities? 
Example 3: A CRT comparing interventions to improve primary care prescribing 
Naughton et al.4 compared the efficacy of two quality improvement interventions 
aimed at increasing prescribing by family physicians’ of antiplatelet and lipid lowering 
medications for patients with cardiovascular disease (CVD) or diabetes mellitus (DM). 
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Family physicians were randomly assigned to receive either a personalized summary of 
their prescribing practices for patients with CVD or DM via an academic detailing visit, or 
to receive a postal bulletin about optimal prescribing practices. The effect of the 
intervention on prescribing practices was evaluated by surveying physicians’ perception of 
the perceived effects of the intervention, as well as using objective data on prescribing 
practices from the national pharmacy insurance program database. The data on the patients 
and their prescriptions included the prescription type, age, gender, and a numeric identifier, 
but no name or address. Both interventions led to similar improvements in prescribing 
practices.  
In this study, there was no direct intervention on patients or any use of identifiable 
private information. Who were the research subjects in this study? All of the DM or CVD 
patients in participating practices? All patients in participating practices? The physicians 
receiving the interventions?5,6 
Example 4: A CRT comparing modes of educating patients prior to breast cancer surgery 
Goel et al.7 describe a CRT comparing the efficacy of two methods of informing 
breast cancer patients of their surgical treatment options. The intervention under study was 
directed at the patients, but administered by their surgeons. Surgeons were randomly 
assigned either to discuss treatment options with patients using a specially developed 
decision tool, or to use standard practice with the addition of extra printed information. The 
study compared the effect of the decision tool on patient anxiety and knowledge regarding 
115 
 
 
 
their options. No difference was observed in the study’s primary outcome between 
intervention and control groups.  
Who were the research subjects in this study? The patients? The surgeons?  
Methods 
The aim of this paper is to offer a principled definition of a research subject, and to 
apply this definition to CRTs, in order to assist investigators and research ethics 
committees. Currently available regulatory definitions of “research subject” are based on 
lists of procedures, i.e., an individual may only be classified as a research subject if he or 
she undergoes a procedure listed in regulations8-12. List-based criteria are not exhaustive, 
and may not be helpful in identifying subjects in novel research designs such as CRTs. 
Moreover, a principled definition of research subject may be used reflexively, to determine 
the adequacy of current and future research ethics regulations. 
Our analysis proceeds as follows. First, we review research ethics regulations and 
guiding documents for criteria that identify research subjects. Second, we search for a 
common theme on which we can build a definition of “research subject”. Third, we posit 
that a research subject is an individual whose interests are put at risk in the context of a 
research study. Fourth, we apply our definition of a research subject to CRTs and examine 
whether the effects of group-level environmental interventions are, by themselves, 
sufficient to make cluster members research subjects, and we consider the impact of 
random assignment on an individual’s status as a research subject. Fifth, we discuss how 
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our definition of research subject may be applied in a variety of CRT designs and contexts 
to identify research subjects who are entitled to regulatory protections. 
Who is a Research Subject? 
1. Regulatory definitions of  “research subject” 
The definition of  a research subject is a foundational problem in the ethics of human 
subjects research. However, there is very little regulatory guidance that helps to address 
this problem. Most international and national research ethics guidelines, including those of 
Canada and the UK,10,13-15 omit a definition of research subject. These documents were 
promulgated to guide the ethical conduct of research in which subjects are recruited 
individually, in which case it is usually clear from the outset who is the research subject. In 
addition, The UK Medical Research Council’s ethical guidelines for CRTs16 and CIOMS 
International Ethical Guidelines for Epidemiologic Studies17 fail to define a research 
subject. Perhaps more problematically, they appear to assume that cluster community 
members will necessarily be subjects, although they offer no meaningful rationale for this 
assumption16,17.  
One of the few national regulations to contain a definition of research subject is the 
United States Federal research regulations 45 CFR 468. These regulations, known as the 
Common Rule, govern all human subjects research conducted or funded by departments of 
the US federal government. The Common Rule is accompanied by a wealth of background 
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documents and commentary, and has been influential in other countries’ development of 
their own research ethics guidelines.  
The Common Rule offers the following criteria that identify a research subject. A 
research subject, according to the Common rule, is a “living individual about whom an 
investigator (whether professional or student) conducting research obtains 
(1) Data through intervention or interaction with the individual, or 
(2) Identifiable private information. 
Intervention includes both physical procedures by which data are gathered (for 
example, venipuncture) and manipulations of the subject or the subject's environment 
that are performed for research purposes. Interaction includes communication or 
interpersonal contact between investigator and subject. Private information includes 
information about behavior that occurs in a context in which an individual can 
reasonably expect that no observation or recording is taking place, and information 
which has been provided for specific purposes by an individual and which the 
individual can reasonably expect will not be made public (for example, a medical 
record). Private information must be individually identifiable (i.e. the identity of the 
subject is or may readily be ascertained by the investigator or associated with the 
information) in order for obtaining the information to constitute research involving 
human subjects8.” 
Most other regulations that contain definitions of research subjects are narrowly 
focused on one particular research design, namely clinical trials, and simply define research 
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subjects as those individuals receiving an experimental intervention in a clinical trial9,10,12. 
One exception is the Australian National Statement on Ethical Conduct in Human 
Research11. The Australian National Statement includes a list of six types of activities that 
make an individual a research subject, including: 
• taking part in surveys, interviews or focus groups; 
•  undergoing psychological, physiological or medical testing or treatment; 
•  being observed by researchers; 
•  researchers having access to their personal documents or other materials; 
• the collection and use of their body organs, tissues or fluids (e.g. skin, 
blood, urine, saliva, hair, bones, tumour and other biopsy specimens) or their 
exhaled breath; 
• access to their information (in individually identifiable, re-identifiable or 
non-identifiable form) as part of an existing published or unpublished source or 
database11. 
Four of these criteria describe different kinds of interventions upon, or interactions 
with, subjects, and are therefore reducible to the first item in the Common Rule criteria. 
The fourth and sixth item in the Australian National Statement criteria refer to the use of an 
individual’s information, including both identifiable private information and information 
with personal identifiers removed11.  
Because of its comprehensiveness, and because it is supported by a great deal of 
historical documentation, we will use the Common Rule criteria as a useful starting point 
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from which we can attempt to elucidate a principled definition of research subject. We will 
draw on other guidelines, such as the Australian National Statement, where applicable. 
In attempting to develop a definition of “research subject”, we will ask whether the 
components of the Common Rule criteria—obtaining data through intervention or 
interaction with an individual or the use of identifiable private information—have a 
common theme. If a common theme that unites the Common Rule criteria can be identified, 
this may be a foundation on which we can build a principled definition of research subject.  
2. Distinctive features of research subjects 
In attempting to identify a common theme between the criteria outlined in the 
Common Rule and other regulations, we will be guided by normative work on the 
distinction between a subject in clinical research and a patient in clinical practice. To do 
this, it is first necessary to distinguish between research and clinical practice.  In the 
Appendices to the Belmont Report, Robert Levine draws a distinction between research and 
ordinary medical practice based on the purpose of each activity18. Clinical practice, he 
argues, involves a health professional acting solely for the purpose of ameliorating the 
health of her patient. Research, on the other hand, is “…a systematic investigation, 
including research development, testing and evaluation, designed to develop or contribute 
to generalizable knowledge”8. Research may include interventions that offer benefit to 
research subjects, but these are not an essential component of an activity whose primary 
purpose is to benefit society in the form of expanded knowledge.  
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The insight that the intent of research is different from the intent of clinical practice 
leads to an important distinction between the physician-patient relationship and the 
investigator-subject relationship. Elucidating the difference in these two relationships helps 
us to identify the distinctive feature of research subjects.  
In clinical practice, the health professional and patient are in a fiduciary relationship. 
A fiduciary relationship is characterized by structural vulnerability, in which the 
beneficiary (in this case, the patient) entrusts the fiduciary (in this case, the health 
professional) with discretionary powers to act in the beneficiary’s interests19. Health 
professionals are empowered and obligated to act in patients’ health interests, and are also 
obligated to protect their privacy interests. Levine points out that in ordinary clinical 
practice, patients can be confident that their health professionals will act with patients’ 
interests in mind, as the sole purpose of clinical practice is to ameliorate the health of the 
patient18. 
The relationship between researchers and subjects is somewhat different. Levine18 
and Rothman20 note that clinician-investigators face a conflict of interests. On the one 
hand, they have an obligation to act in the best interests of their patient-subjects. On the 
other hand, clinician-researchers also have obligations to the study, such as ensuring 
compliance with experimental treatment protocols, that may conflict with their obligations 
to a patient’s welfare. As Rothman writes, “The bedrock principle of medical ethics—that 
the physician acted only to promote the well-being of the patient—did not hold in the 
laboratory…The doctor-patient relationship could no longer serve as the model for the 
investigator-subject relationship.” 20 Research regulations evolved specifically to safeguard 
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the interests of research subjects, as investigators’ conflict of interest prevents them from 
effectively acting in subjects’ interests20. 
Research subjects are vulnerable because a clinician-investigator’s obligation to 
protect subjects conflicts with his or her scientific obligations. As Levine puts it, the role of 
a research subject approximates that of a means to an end18. Both the Common Rule and 
Australian National Statement criteria specify ways in which a subject’s interests could be 
compromised for scientific purposes. When an investigator intervenes on a subject, either 
with an experimental intervention or in order to collect data, the subject’s welfare may be 
at risk. The same is true if an investigator interacts with a subject. By collecting personal 
information, the investigator may violate the subject’s privacy.  
3. A principled definition of “research subject”. 
As noted above, the Common Rule classifies research subjects as individuals whose 
interests may be compromised for scientific purposes. We therefore propose using this 
criterion as the basis for a novel definition of “research subject”: 
 A research subject is an individual whose interests may be compromised as a 
result of interventions in a research study. 
In this definition, “interests” refer generally to goods that an individual would 
ordinarily seek to protect. Research ethics regulations are primarily intended to protect 
subjects’ health, welfare and privacy interests. Interests, as far as this definition is 
concerned, may also include such things as economic interests.  
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We find historical support for this definition of a research subject in the 1974 US 
Department of Health, Education and Welfare (DHEW) regulations for human subjects 
research21. These regulations are the immediate predecessor of the Common Rule. Rather 
than define “research subject”, the DHEW regulations refer to “subjects at risk”.  A 
“subject at risk” is defined as:  
“any individual who may be exposed to the possibility of injury, including 
physical, psychological, or social injury as a consequence of participation as a subject 
in any research, development, or related activity which departs from the application 
of those established and accepted methods necessary to meet his needs, or which 
increases the ordinary risks of daily life, including the recognized risks inherent in a 
chosen occupation or field of service.21” 
4. Evaluating Current Regulations with a Principled Definition of “Research Subject” 
The principled definition of “research subject” that we have developed may be used 
to critically evaluate criteria in current regulations that identify research subjects. We can 
do this for the Common Rule, the Australian National Statement, as well as other research 
regulations.  Most regulations for clinical trials refer to subjects as individuals who receive 
experimental or control interventions in a clinical trial. This definition therefore identifies 
subjects as those who are intervened upon. These regulations are likely adequate for 
individually randomized clinical trials, but are not sufficiently exhaustive to be applied 
more broadly as they omit other ways in which individuals’ interests could be 
compromised9,10,12. 
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As previously noted, the Australian National Statement offers a six-item list of ways 
in which an individual could become a research subject. Four of these criteria (1, 2, 3 and 
5) identify ways in which researchers may intervene upon or interact with subjects. We can 
conclude, based on our principled definition of “research subject”, that these items are 
appropriate for inclusion on a list of criteria that identify a research subject. The fourth 
criterion includes “researchers having access to personal documents or materials” may 
compromise subjects’ privacy interests and merits inclusion11.  The sixth criterion defines 
any individual about whom a researcher obtains “information (in individually identifiable, 
re-identifiable or non-identifiable form) as part of an existing published or unpublished 
database or source”11 as a research subject. Yet, the use of non-identifiable information 
presents no risk to an individual’s privacy (or other) interests. Similarly the use of 
identifiable, publicly available information such as biographical materials or items of 
public record, presents no risk to an individual’s privacy (or other) interests. Our definition 
of research subject would thus lead us to conclude that this sixth item in the Australian 
National Statement is too broad for inclusion in a list of ways in which an individual could 
become a research subject.  
We can use our principled definition of research subject reflexively to examine 
whether all of the components of the Common Rule are germane to a definition of research 
subject. The Common Rule criteria include interventions on subjects or interactions with 
subjects, and the use of identifiable private information. These categories broadly describe 
means by which a research subjects’ interests could be compromised, and so merit 
inclusion in a definition of research subject. The Common Rule definition further defines 
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interventions as “physical procedures…and manipulations of the subject or the subject's 
environment”8. Physical procedures or manipulations of the subject necessarily involve 
some degree of risk, and therefore may compromise the subjects’ welfare interests. 
However, the reference to environmental manipulation is insufficiently explicit and 
requires further elucidation. 
The Importance of Environmental Manipulation 
According to the Common Rule, one way an investigator may intervene on research 
subjects is by manipulating their environment. With respect to healthcare CRTs, Mann and 
Reyes5 have interpreted this to mean that an intervention designed to alter a healthcare 
professional’s practice pattern represents a manipulation of the environment of all patients 
whose care may be influenced by a professional’s participation in a CRT. Thus, according 
to Mann and Reyes, every patient of a professional whose care may be influenced by a 
CRT intervention meets the regulatory definition of a research subject. This claim is 
understandable, given that much of the literature on the ethics of CRTs assumes that cluster 
members (in this case, patients) will necessarily be subjects16,22-25. If correct, their view has 
considerable implications for the conduct of CRTs. If, in CRTs targeted at health 
professionals or health systems, all patients are considered research subjects, the 
administrative burdens associated with protecting patients as research subjects would 
threaten the feasibility of many trials. We explore below whether the indirect effects of a 
research intervention at the group level (such as an educational intervention administered to 
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health professionals) implies that all individuals within the group (such as the patients of 
professionals participating in a CRT) must be considered research subjects. 
1. Can environmental manipulation make an individual a research subject? 
The CIOMS International Ethical Guidelines for Biomedical Research Involving 
Human Subjects14 includes in its definition of research any study that manipulates an 
individual’s social or physical environment, including field studies of pathogenic 
organisms or toxic chemicals. These guidelines, along with the CIOMS International 
Ethical Guidelines for Epidemiological Studies 17, address issues of informed consent in 
epidemiologic research and the analysis of harms and benefits for such research. Therefore, 
without actually defining “research subject” the CIOMS guidelines appear to acknowledge 
that individuals who may be affected by public health interventions that manipulate the 
environment such as water fluoridation or pesticide use are, in fact, research subjects 14,17.  
A broad interpretation of “environmental manipulation” is untenable, however, 
because it leads to absurd conclusions. It seems impossible that everyone whose 
environment is manipulated in the context of a research project must be considered a 
research subject. The term “environment” refers to “the surroundings or conditions in 
which a person, animal, or plant lives or operates” 26. Using this definition, “manipulations 
of the…subject’s environment” would imply that every person on Earth is a research 
subject in every research study. For example, studies in particle physics at the Large 
Hadron Collider (LHC) meet the Common Rule definition of research, in that they are 
systematic investigations designed to develop generalizable knowledge8. One concern 
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regarding the LHC project was that some experiments could create microscopic black holes 
that might be hazardous to the planet and all of its inhabitants27. If we were to employ a 
broad interpretation of “manipulations of the…subject's environment”, the Common Rule 
would require that particle acceleration experiments at the LHC be considered a 
manipulation of the environment for all human beings, meaning that everyone on Earth 
must be considered research subjects. This notion seems patently absurd. We therefore 
require a better understanding of what environmental manipulations are sufficient to make 
an individual a research subject. 
It is helpful to consider what the US National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research may have meant when they 
included “environmental manipulation” in their definition of a research subject. In a paper 
prepared for the National Commission in 1975 (included in the 1979 Appendix to the 
Belmont Report), Robert Levine defined research as “…manipulation, observation, or other 
study of a human being--or of anything related to that human being that might subsequently 
result in manipulation of that human being--done with the intent of developing new 
knowledge and which differs in any way from customary medical (or other professional) 
practice.”18 Specific reference to manipulation of an individual’s environment did not 
appear until the National Commission defined a research subject in their 1978 Report and 
Recommendations on Institutional Review Boards, and this language was incorporated into 
the Common Rule28. The Common Rule’s reference to manipulation of an individual’s 
environment took the place of Levine’s “anything related to that human being that might 
subsequently result in manipulation of that human being.” Exploring the reasons for this 
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change in regulatory language helps to clarify what kinds of environmental manipulation 
are sufficiently meaningful to consider an individual a research subject. 
Given the sorts of issues being discussed in the research ethics literature at the time, it 
seems likely that the National Commission was seeking to protect individuals who 
participated in studies evaluating the psychological effects of various environmental 
stimuli. Inclusion of environmental manipulation in the definition of research subject seems 
intended to capture research that deliberately manipulated subjects and placed their welfare 
at risk without direct intervention or physical contact from investigators.  
Examples of this type of research include studies examining the psychological and 
behavioural effects of habitation in simulated fallout shelters sponsored by the US Office 
of Civil and Defense Mobilization29, and studies evaluating the psychological effects of 
other environmental manipulations such as sensory deprivation30,31. Environmental 
manipulations in the Civil Defense studies includes such things as living in a confined 
space for prolonged periods, crowding, variable air quality, variable availability of potable 
water and exposure to variations in temperature. The individuals participating in these 
studies were subjected to physical or psychological discomfort resulting from the 
manipulation of their environment in the context of a research study. What these studies 
have in common, then, is that the study interventions placed the welfare of the subjects in 
jeopardy by manipulation of their environment rather than via direct intervention or 
physical touching by the investigators.  
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These practices support a narrower reading of the environmental manipulation clause. 
We suggest that environmental manipulation must have a direct impact on an individual in 
order to make him or her a research subject. In other words, the environmental 
manipulation must be designed to produce a direct effect on the individuals whose 
environment is being manipulated. We believe that this interpretation is consistent with the 
intent of the National Commission. We will therefore expand our definition of “research 
subject” to include any individual who is deliberately affected via manipulation of his/her 
environment by an investigator (Box 1). 
This conclusion is consistent with the language enshrined in the Final Report of the 
National Bioethics Advisory Commission. In their 2001 Report and Recommendations: 
Ethical and Policy Issues in Research Involving Human Participants, the Commission 
agrees that the term “subject” “…connotes the fact that the individual is ‘subjected’ to an 
action by the investigator.”32 The Commission specifically recommends that “…Research 
be considered to involve human participants when individuals 1) are exposed to 
manipulations, interventions, observations or other interactions with investigators or 2) are 
identifiable through research using biological materials, medical and or other records, or 
databases.”32 
2. Do indirect effects of CRT interventions on health professionals or health systems 
make patients research subjects? 
Mann and Reyes have construed a change in physicians’ practice patterns that result 
from educational or quality improvement interventions in a CRT to be a manipulation of 
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their patients’ environment, therefore requiring those patients to be considered research 
subjects5. We respectfully disagree. 
First, in order to turn an individual into a research subject, the environmental 
manipulation must be designed to produce a direct effect on that individual. This is not the 
case in CRTs that intervene on health professionals. The CRT design is chosen because the 
interventions under study are cluster-level interventions. The interventions being evaluated 
in these studies are intended to change health professionals’ behaviour by increasing 
professionals’ use of evidence-based strategies to improve care. Patients are not being 
directly manipulated by interventions administered to their health professionals. 
 Second, even if a change in a professional’s practice pattern did constitute a 
deliberate manipulation of patients via a manipulation of their environment (a claim that 
we do not grant), that manipulation does not jeopardize patients’ interests and is therefore 
not sufficient to warrant considering patients as research subjects. Examining the 
distinction between clinical research and clinical practice is again helpful with respect to 
this issue. Levine writes,  
“If a physician proceeds in his interaction with a patient to bring what he 
considers to be the best available technique and technology to bear on the 
problems of that patient with the intent of doing the most possible good for that 
patient, this may be considered the pure practice of medicine. By contrast, if a 
physician interacts with an individual with the intent of developing new 
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knowledge (not primarily for the benefit of that individual), this activity may be 
classified as research.”18  
When a health professional participates in a CRT, her patients may still fully entrust 
their welfare to her because she has no conflicting obligations to the trial itself. Physicians 
in this situation are subjects themselves, not investigators. Although the professional may 
have received an intervention aimed at improving practice, the professional is still expected 
to act in the best interests of her patients and in accordance with professional practice 
standards. As Henderson puts it, “In the studies in which an administrative intervention 
does not directly interpose between the physician and the patient, the patient’s treatment 
remains under the direction of the physician and is not removed by the process of 
randomization33.” Therefore, effects on practice patterns do not jeopardize the welfare 
interests of the patients of a health care provider participating in a CRT. Simply being a 
patient of a professional participating in a CRT of an educational, knowledge translation, or 
quality improvement intervention does not make one a research subject.  
Some studies evaluate patient-level effects as an outcome measure. The fact that a 
patient-level effect may be measurable is relevant to patients only insofar as their private 
health information may be used, or they may be asked to submit to surveys or additional 
examinations to evaluate the outcome of the CRT. Patients of professionals participating in 
a CRT of an educational or quality improvement intervention need be considered subjects 
only if they are directly intervened upon by or interact with investigators, or if their 
identifiable private information is used.  
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This conclusion does not necessarily hold for patients in CRTs evaluating alternative 
modes of health service delivery. These CRTs aim to evaluate the effect of different 
methods of providing care. This is different from CRTs of interventions directed at 
providers that aim to increase the use of evidence-based care while maintaining the 
fiduciary relationships that providers have to patients. Examples include CRTs evaluating 
the effect of employing specialist nurses in asthma management34 or the use of case 
managers for the reduction of inpatient length of stay on medical wards35. These CRTs are 
being conducted because the efficacy of the mode of delivery is uncertain. Randomization 
in clusters is undertaken for logistical reasons and to avoid experimental contamination. A 
trial evaluating the effect of an experimental mode of delivery is thus akin to a trial that 
evaluates an experimental treatment. Novel modes of healthcare delivery are therefore best 
thought of as direct patient-level interventions rather than environmental manipulations. In 
such studies, the patients would be research subjects because they are directly intervened 
upon.  
3. Implications for CRTs in fields other than healthcare 
In some CRTs, particularly in public health, the purpose of the experimental 
interventions is to deliberately manipulate individuals via their environment. For example, 
in the COMMIT study, billboards, and mass media ads (environmental manipulations) 
were intended to produce behavioural change in smokers living in intervention 
communities36. Another CRT evaluating interventions aimed at individuals via 
environmental manipulation is a CRT comparing rates of diarrheal illness in communities 
randomly assigned to water treatment with flocculant disinfectant or a control37. In these 
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studies, the purpose of the environmental manipulation is to intervene on individual 
residents. The residents of communities in such studies are therefore research subjects and 
entitled to regulatory protections. This does not necessarily mean that informed consent is 
required from all residents. Rather, many of these studies of environmental manipulations 
would meet regulatory criteria for a waiver of informed consent8,15,17. 
CRTs in education are roughly analogous to CRTs in healthcare: the teacher-student 
relationship has many of the characteristics of a fiduciary relationship19. If a CRT is used to 
evaluate the effect of a continuing education intervention for teachers, the indirect effect of 
the change in teachers’ performance on students will not require that students be 
considered research subjects. However, CRTs of experimental curricular programs may be 
more similar to CRTs evaluating novel methods of health service delivery, and may require 
treating students as research subjects. 
What is the importance of random intervention assignment? 
The importance of random intervention assignment has caused some concern in the 
literature on the ethics of CRTs. In CRTs, random group assignment is often performed 
before subjects are enrolled38. Indeed, in CRTs of large cluster-level public health 
interventions clusters may be randomly assigned to interventions that some cluster 
members may never receive, leading to the concern that the act of random assignment may 
make these individuals who are not affected by the intervention research subjects25. Some 
of the concern over randomization in CRT stems from how subjects are assigned in 
individually-randomized trials. In any randomized controlled trial, assignment to the 
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intervention or control arm (whether individually or in clusters), is determined by a 
mechanism that is beyond the control of the individual or group being randomized. For 
example, in healthcare clinical trials, treatment assignment is specified by the study 
protocol. Treatment is not determined by the clinician-patient dyad. Random assignment 
has been viewed by some as a research intervention39, which leads to the conclusion that 
randomization in and of itself makes an individual a research subject. 
We argue that random trial arm assignment is, in and of itself, not sufficient to make 
an individual a research subject. In any comparative study, regardless of the method of 
intervention assignment (random or non-random), assignment is out of the control of the 
individual or group being assigned. For this reason, the use of random intervention 
assignment is immaterial to the determination that an individual in a trial is a research 
subject. If some non-random method of intervention assignment were used in place of 
random assignment, the threats to subjects’ liberty and welfare interests would be 
unchanged. A research subject is an individual whose interests are threatened in the context 
of a research study. Whether intervention assignment is random or non-random is a moot 
point. 
Random assignment of clusters is, by itself, insufficient to make cluster members 
research subjects. The fact that, in many CRTs, group assignment is determined before 
subject enrolment should be acknowledged in consent discussions with individuals who are 
identified as research subjects according to a principled definition. 
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Implications for Cluster-Randomized Trials 
To summarize our conclusions, we suggest that the following four criteria may be 
used to define research subjects: 
1. An individual who is directly intervened upon by an investigator for 
research purposes; 
2. An individual who is deliberately intervened upon via manipulation 
of his/her environment by an investigator for research purposes; 
3. An individual with whom an investigator interacts for the purpose of 
collecting data; 
4. An individual about whom an investigator obtains identifiable 
private information for the purpose of collecting data. 
A detailed discussion of these criteria and their implications for CRTs follows. 
A research subject is an individual whose interests may be compromised as a result of 
interventions in a research study including: 
 
1. An individual who is directly intervened upon by an investigator for research 
purposes 
Individuals are research subjects if, in the context of a research study, they are the 
recipients of an experimental intervention (active or control) or if they undergo an 
intervention to collect data, such as an additional examination.  
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If an intervention is targeted at individual cluster members but random assignment is 
done at the cluster level (typically to avoid treatment contamination or for logistical 
reasons) then the individuals receiving the intervention should be considered research 
subjects. In healthcare, this would include CRTs evaluating therapeutic or health promotion 
modalities aimed at individual patients, as well as CRTs evaluating new modes of health 
service delivery. An example of the former includes a CRT evaluating the effect of 
individualized exercise prescriptions for patients, randomized by physician practice40. An 
example of the latter includes a CRT evaluating the effectiveness of asthma management 
using specialist nurses34. In these studies, the individuals themselves are being 
manipulated, and should therefore be considered research subjects.  
In healthcare CRTs, the intervention under study is often not administered to patients, 
but rather to healthcare professionals, and the outcomes are evaluated using patient data. It 
may be reasonably asked whether the health professionals who receive an educational 
intervention in a CRT are research subjects or collaborators. Collaborators are individuals 
who contribute to the design of, or participate in the conduct of, a research study. 
Collaborators are not recipients of experimental interventions. In healthcare CRTs, the 
health professionals are receiving an experimental educational or quality improvement 
intervention. When they are directly intervened upon in this way, health professionals 
participating in a CRT meet the definition of a research subject5,6,41. 
Some healthcare CRTs evaluate complex interventions that may include 
combinations of health professional education, novel modes of health service delivery and 
patient-level interventions. An example is a CRT evaluating a primary care program aimed 
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at reducing obesity42. In this trial, primary care providers in the intervention arm received 
an educational intervention on motivational techniques and physical activity for obese 
patients. Patients in the intervention arm were screened for obesity, and obese patients were 
counseled by the physician and referred to local sports foundations to receive 
individualized exercise counseling.  In determining whether or not patients need be 
considered research subjects for these CRTs, an ethics committee needs to examine each 
intervention in such a CRT to determine whether a particular intervention is directed at 
patients, or whether data collection includes interaction between researchers and patients or 
the use of identifiable private information. Interventions on health professionals mean that 
the health professionals will be research subjects. Patients will not necessarily be research 
subjects because of interventions on health professionals. But, patients will be research 
subjects if there are patient-level interventions (either therapeutic interventions or direct 
interventions to collect data) or novel modes of health service delivery are used, if 
researchers interact with patients, or if the study uses patients’ identifiable private 
information to evaluate outcomes. 
 
2. An individual who is deliberately intervened upon via manipulation of his/her 
environment by an investigator for research purposes 
Individuals who are intervened upon via manipulation of their environment are 
research subjects. This includes individuals who will be affected by CRTs of public health 
interventions, whether the unit of randomization is a municipality, a neighborhood, a 
family, or some other group whose environment may be manipulated. Because these 
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individuals are research subjects, they are entitled to regulatory protections, including the 
determination by a research ethics committee that the risks to their interests do not 
outweigh the potential benefits offered by the CRT. Many of these studies would meet 
regulatory criteria for a waiver of informed consent because the interventions in these 
studies pose only minimal risk and would likely be unfeasible without a waiver of consent. 
 We concluded above that the indirect effects that a CRT may have on an individual 
are not sufficient to warrant considering that individual to be a research subject. In 
healthcare CRTs, patients may be indirectly affected by educational or quality 
improvement interventions that are directed at healthcare professionals or institutions. The 
physicians under study continue to have an obligation to act in patients’ best interests, and 
have no competing obligations to the study itself. The physician-patient relationship is 
preserved. If there are no patient-level interventions, if the researcher has no interaction 
with individual patients, and there is no use of identifiable private information for research 
purposes, patients are not research subjects.  
 
3. An individual with whom an investigator interacts for the purpose of collecting data 
Any individual from whom an investigator, in the context of a research study, obtains 
data through any kind of interaction should be considered a research subject. Interaction 
includes any kind of communication or interpersonal contact between investigator and 
subject, for example interviews, focus groups, or questionnaires. Such modes of interaction 
may be employed in CRTs when collecting data reported by individual cluster members. 
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Any data collection through interaction means that the respondents are entitled to 
protections as research subjects8,11. 
 
4. An individual from whom an investigator obtains identifiable private information 
for the purpose of collecting data. 
Obtaining identifiable private information about individuals within a cluster will 
make these individuals research subjects, and therefore make them entitled to protections. 
Conversely, there is no risk to an individual’s privacy if the researchers are only collecting 
anonymized or aggregate group-level information43. Individuals whose data have been 
anonymized before transfer to the investigators, or whose administrative or health-related 
information is used to generate aggregate measures for a cluster are not research subjects 
unless they are manipulated in some other way.  
Practical Applications for Ethics Review of CRTs 
We will now apply our new definition to the issues raised earlier in ‘Examples: 
Challenges in identifying the research subject in CRTs”:  
Example 1: The COMMIT Trial 
The COMMIT trial1,2 evaluated a multimodal community-level intervention, 
including a media and billboard campaign and targeted messaging toward smokers, aimed 
at reducing cigarette consumption. These interventions did not directly manipulate 
139 
 
 
 
individuals, but did intervene on individuals via environmental manipulation. Therefore, 
individuals in the participating communities are research subjects.  
 
Example 2: A CRT of bed net distribution to reduce malaria prevalence  
The distribution of bed nets constitutes a direct intervention on individuals. 
Therefore, all residents of the intervention communities who received a bed net are 
research subjects. Individuals contributing blood samples, whether from intervention or 
control communities, were also directly intervened upon and are research subjects. In this 
study, no private identifiable information was collected. Therefore, citizens of control 
communities who did not contribute blood samples, were not recipients of an intervention, 
were not intervened upon via manipulation of their environment, did not interact with 
researchers, did not contribute identifiable personal information, and were not research 
subjects. 
Example 3: A CRT comparing interventions to improve primary care prescribing 
The physicians in this study were recipients of an experimental intervention, and are 
research subjects. The patients received no intervention from study personnel, had no 
interaction with the study personnel, and contributed no identifiable private information. 
Therefore, the patients of physicians participating in this particular study are not research 
subjects.  
Example 4: A CRT comparing modes of educating patients prior to breast cancer surgery 
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In this study, the patients were recipients of an experimental intervention in that they 
received one of two candidate modes of education about their surgical options. They 
responded to questionnaires to generate outcome data, and contributed identifiable medical 
information. For all of these reasons, they are research subjects. The surgeons delivering 
the experimental decision tool underwent training, while those in the control group had 
their practices modified by using additional printed information. These educational 
interventions and changes in practice are research interventions, meaning that the surgeons 
participating in both arms of the study are also research subjects.  
Conclusions and Future Work 
We have defined a research subject as an individual whose interests may be 
compromised as a result of interventions in a research study, and have specified four ways 
in which research subjects’ interests may be compromised (Box 1). Research subjects are 
those individuals who are intervened upon by researchers, either by direct interventions or 
by deliberate manipulations of their environment, those who interact with researchers to 
provide data, or those whose identifiable private information is used to generate data.  
In articulating a principled definition of a research subject, with specifications that 
help to identify research subjects, this paper represents an essential first step in addressing 
additional questions on how to protect research subjects in CRTs. The specifications that 
help define the research subject may be used by investigators and research ethics 
committees to help ensure that research subjects in CRTs receive necessary protections and 
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that important research is not hindered by incorrect application of research ethics 
guidelines and regulations. 
Subsequent papers will rely on this novel definition of research subject and analyze 
the implications of this innovation on such issues as:  informed consent; harm-benefit 
analysis; subject selection and protection of vulnerable subjects; and the role and authority 
of cluster gatekeepers in CRTs.   
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Box 1. Definition of a Research Subject 
 
 
A research subject is an individual whose interests may be 
compromised as a result of interventions in a research study 
including: 
1. An individual who is directly intervened upon by an 
investigator 
2. An individual who is deliberately intervened upon via 
manipulation of his/her environment by an investigator 
3. An individual with whom an investigator interacts for the 
purpose of collecting data 
4. An individual about whom an investigator obtains 
identifiable private information for the purpose of collecting 
data. 
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Introduction 
The question of when it is necessary to seek informed consent from subjects in 
cluster randomized trials (CRTs) has stirred substantial discussion in the CRT literature. 
In an article published in the British Medical Journal entitled “Ethical Issues in the 
Design and Conduct of Cluster Randomized Controlled Trials”, Edwards et al. describe 
the difficulties  associated with obtaining informed consent in CRTs1. The authors suggest 
that the requirement to seek informed consent is inextricably linked to the type of 
interventions being evaluated. Their analysis relies on a distinction between two types of 
CRTs: individual-cluster trials and cluster-cluster trials.  
In individual-cluster trials, experimental interventions are directed at individual 
cluster members but subjects are randomized in clusters in order to avoid experimental 
contamination1. In these studies, it is generally possible to seek subjects’ informed 
consent, just as in an individually-randomized trial.  
Cluster-cluster studies, on the other hand, evaluate experimental interventions that 
target entire clusters1. In these studies it may not be possible for cluster members to avoid 
the experimental interventions, thus making individual refusal of the study interventions 
meaningless.1,2 In addition, when dealing with large clusters, it may be logistically 
impossible to seek consent from all cluster members1,3.  
The relationship between trial type (individual-cluster or cluster-cluster) and the 
feasibility of obtaining informed consent lies at the heart of the United Kingdom Medical 
Research Council (MRC) document Cluster Randomized Trials: Methodological and 
Ethical Considerations4. The authors of this document conclude that , if seeking consent 
from individual subjects is feasible, then investigators are obligated to do so. If, on the 
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other hand, seeking consent from individual subjects is not feasible, authorization to 
enroll a cluster in the study must be sought from a cluster representation mechanism—an 
entity or an individual charged with making decisions in the interest of the entire cluster. 
Thus, according to both Edwards et al., and the authors of the MRC guidelines, whether 
or not consent is required from individual subjects in CRTs depends on the feasibility of 
doing so. 
The association Edwards and colleagues identify between the type of interventions 
being evaluated and the feasibility of seeking informed consent from individual cluster 
members seems intuitively correct. Moreover, their conclusions are reflected in actual 
practice, in that investigators routinely seek consent in CRTs evaluating individual-level 
interventions, but not in CRTs evaluating cluster-level interventions5-7. Unfortunately, the 
conclusion that the need to seek consent depends solely on the feasibility of doing so fails 
to follow the general principles guiding human subjects research. If consent cannot be 
obtained, then other conditions must be satisfied in order to safeguard subjects’ interests.  
When must investigators obtain informed consent from human subjects in CRTs? 
This paper seeks to answer this question by examining the challenges related to obtaining 
informed consent in CRTs through the lens of research ethics. We first examine the 
ethical principles and moral theories that underpin consent requirements in order to 
develop a conceptual framework that lays out the fundamental purpose of informed 
consent requirements. Using this framework, we address the key questions related to 
informed consent in CRTs, namely: 1) How may CRTs proceed if seeking informed 
consent is not feasible? 2) Is it permissible to seek informed consent after randomization 
of clusters? 3) What information must be disclosed to potential subjects? 4) May opt-out, 
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or passive consent strategies be used instead of seeking informed consent? 5) Do 
professionals have an obligation to participate in CRTs? 
 
Prior work: Who is a research subject? 
Clearly identifying who is a research subject in a CRT—and who is not—helps to 
address some of the concerns outlined in the CRT literature regarding the feasibility of 
seeking consent in cluster-cluster trials1-3,7-9. In the preceding article in this series, entitled 
“Who is the Research Subject in Healthcare Cluster Randomized Trials?” we developed a 
principled definition of “research subject”10. We argued that a research subject is an 
individual whose interests may be compromised in the context of a research study. This 
includes any individual: 1) who is directly intervened upon by an investigator; 2) who is 
deliberately intervened upon via manipulation of his/her environment by an investigator; 
3) with whom an investigator interacts for the purpose of collecting data; 4) about whom 
an investigator obtains identifiable private information for the purpose of collecting 
data10. As a general rule, informed consent for CRT participation must be sought from 
research subjects. Conversely, seeking consent from cluster members who are not 
research subjects is not required. 
The implication of using a principled definition of “research subject” are illustrated 
using the example of patients managed by primary care physicians in the NEXUS trial 11. 
In this CRT, 247 primary care practices were randomly assigned to receive interventions 
designed to increase general practitioners’ compliance with radiography guidelines for 
patients with nontraumatic back and knee pain. The comparative efficacy of the 
interventions was evaluated by examining the change in number of lumbar spine and knee 
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radiographs ordered per thousand patients per year for two years. These data were 
obtained by abstracting data from patient records from a random sample of primary care 
practices in each trial arm11.  
The primary care physicians who received the experimental interventions were 
research subjects, according to the definition of “research subject” outlined above. 
Consent issues for professionals who are intervened upon in CRTs are discussed further 
below. 
The patients of physicians participating in the NEXUS study were not intervened 
upon, either directly or via manipulation of their environment, nor did investigators 
interact with them10,12. Investigators obtained identifiable private information from the 
medical records of a sample of patients. Patients whose private information was used 
were research subjects. Whether or not consent was necessary for this sample of patients 
is discussed below. Patients whose medical records were not used were not research 
subjects. Their consent was not required10,12. 
The remainder of this paper will address consent requirements for research subjects 
in CRTs. As a general rule, research subjects in a CRT must provide informed consent for 
trial participation. As will be discussed below, exceptions to informed consent 
requirements may apply to CRTs in clearly defined circumstances. 
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Moral Foundations of the Requirement for Informed Consent 
for Research Participation 
Informed consent for research participation is a central ethical safeguard for 
research subjects13-15. This section outlines the moral foundations of informed consent 
requirements and examines how they apply to CRTs.  
In the Belmont Report the National Commission for the Protection of Human 
Subjects in Biomedical and Behavioral Research identified three basic ethical principles 
for research involving human subjects: respect for persons, beneficence, and justice. 
Consent requirements for research participation stem from the principle of respect for 
persons14, which requires: 1) that the wishes of autonomous individuals be respected, and 
2) that individuals with diminished autonomy be protected14.  
Autonomous individuals may be understood as those who are capable of self-
government and are able to make responsible choices for themselves. Autonomous 
choices are those that are intentional, substantially informed, and substantially free of 
coercing influences16,17.   
The principle of respect for persons may be viewed as deriving from deontological 
moral theory, which defines right action as the satisfaction of moral duties16-19. Kantian 
deontological theory posits that autonomous individuals have intrinsic moral worth in 
virtue of their capacity for rational decision-making about their ends. Respect for the 
intrinsic moral worth of others entails respect for their autonomous choices. The famous 
Kantian dictum exhorts us to always treat others as ends in themselves rather than merely 
as the means to an end17,18,20,21.  
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The requirement to obtain informed consent for research participation is consistent 
with the kinds of duties owed by investigators to autonomous individuals. According to 
Freedman, consent requirements arise,  
“…from the right which each of us possesses to be treated as a person, and in the 
duty which all of us have, to have respect for persons, to treat a person as such, and 
not as an object. For this entails that our capacities for personhood ought to be 
recognized by all─these capacities including the capacity for rational decision and 
for action consequent upon rational decision. 19”  
Research necessarily involves “using” subjects as a means of acquiring scientific 
knowledge. Why would an individual choose to become a research subject, thereby 
jeopardizing her privacy or welfare  for the sake of science? We suggest that the rational 
research subject would only agree to such constraints if she agreed with the goals of the 
study. In consenting to study participation, the research subject adopts the scientific ends 
of the study as his or her own. Granting one’s consent to participate would, therefore, 
signal that the research participant is treated as an end in and of herself and not merely a 
means of and was fulfilling the researchers’ objectives. 
Another way of getting at the essence of informed consent may be by contrasting 
two operational definitions thereof, namely, autonomous authorization and effective 
consent. Autonomous authorization is a moral concept according to which a person 
chooses to adopt the goals of research as his or her own and thereby consents to study 
participation17. The individual must be informed, competent and free from coercion.   
Effective consent, by contrast, is a legal concept, relating to a legally or 
institutionally circumscribed definition of the conditions for valid decision-making17. 
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Autonomous authorization and effective consent are often functionally synonymous. 
However, this is not always the case. For example, a teenager may have the rational 
capacity to make an autonomous authorization but not to provide effective consent if 
proscribed from doing so on account of his or her age17.  
We can therefore understand autonomous authorization to research participation 
practically as the subject’s agreement to the interventions that are part of the research 
protocol, and conceptually as the subject’s embracing of the goals of the research study19. 
Ideally, legal or policy criteria for effective consent should be derived from the necessary 
conditions for autonomous authorization. If the purpose of informed consent regulations 
is to enable autonomous decision-making i.e., to allow subjects to choose whether or not 
to adopt the ends of the study as their own, then research ethics regulations and guidelines 
must be evaluated on the extent to which they accomplish this purpose 17.  
Research ethics guidelines lay out the criteria for effective consent for research 
participation, and thus fulfil the end of enabling autonomous authorization. Informed 
consent guidelines require that potential subjects have the capacity to decide whether or 
not to participate in the research study at hand; that their decision be free of coercion; that 
they be adequately informed of the details of the study’s purpose and interventions; and 
that they understand the information given to them15,22-24.  
Disclosure requirements almost universally include the following: an explanation of 
the purpose of the study; a description of the study interventions; a description of the risks 
and potential benefits to subjects from research participation; a description of alternatives 
available to potential subjects should they choose not to participate; a description of 
confidentiality protections; a statement assuring potential subjects that participation is 
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voluntary, that they may withdraw at any time, and that their quality of care will not be 
affected should they choose not to participate or to withdraw; and information on whom 
they may contact with questions15,22-24. If these disclosure requirements are met, then 
potential subjects will be able to decide whether or not to embrace the study’s ends as 
their own.  
In the remainder of this article, we address the ethical challenges associated with 
obtaining informed consent in CRTs will be addressed using the following ethical 
framework:  
1) Consent requirements stem from the basic ethical principle of respect for 
persons, which requires that the choices of autonomous individuals be 
respected.  
2) The principle of respect for persons may be rooted in deontological moral 
theory, which posits that autonomous individuals have an intrinsic worth 
and are entitled to respect.  
3) Autonomous individuals shall not be used solely as means to an end. They 
must also be treated as ends in themselves.  
4) The purpose of seeking informed consent is to enable potential subjects to 
embrace the ends of the research study as their own. 
 
Addressing consent challenges in CRTs 
Prior to considering specific issues related to seeking consent in CRTs, it is 
important to be clear about what consent is for. In individually randomized clinical trials, 
consent is obtained prior to randomization and includes consent for random assignment, 
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for the experimental interventions in either study arm, and for the interventions used to 
collect data. In CRTs, all of these may be disaggregated: consent for random assignment, 
experimental interventions, and for the interventions used to collect data may be sought 
separately. This disaggregation may be necessary because of the intrinsic features of the 
CRT design. It may not be possible to seek consent for random assignment if individual 
cluster members are not identifiable at the time of cluster randomization. In individual-
cluster trials, seeking consent for the experimental interventions may be feasible, 
independent of whether or not it is possible to seek consent for random assignment. In 
cluster-cluster trials, it may or may not be feasible to seek consent for the experimental 
interventions. Furthermore, if the interventions are unavoidable, refusal would be 
meaningless. Even if it is not possible to seek consent for randomization or for 
experimental interventions, it may be possible—and necessary—to seek consent for data 
collection procedures such as physical examinations, interviews and the use of 
identifiable private information.  
Specific questions relating to seeking consent in CRTs are addressed in detail 
below. 
1) How may CRTs proceed if seeking consent is not feasible? 
Edwards et al.1, Hutton2, and Donner and Klar3 have noted that, in certain 
circumstances, seeking informed consent from cluster members in a CRT may not be 
feasible. There are two reasons for this. Firstly, that clusters may be large enough that the 
logistical difficulties associated with seeking consent from all cluster members would 
make the study infeasible3. Secondly, some cluster-level interventions may be 
unavoidable, effectively rendering individual refusal meaningless1,2.  
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A CRT conducted in India randomly assigned nine geographical sectors in Punjab 
either to an insecticide spraying program to reduce malaria transmission, or to no 
intervention25. The effect of the spraying program on malaria incidence was evaluated by 
collecting blood samples from residents reporting a fever and also through cross-sectional 
surveys in which blood samples were collected from schoolchildren in participating 
communities. The spraying program intervened on residents via environmental 
manipulation; therefore all residents of sectors in the intervention arm were research 
subjects10,22.  
In this case, it would have been exceedingly difficult to seek informed consent from 
all individuals in intervention sectors. Moreover, even if it were possible to obtain 
consent, the environmental intervention was unavoidable. What would have been the 
point of obtaining informed consent? This begs the question: how may such a CRT be 
performed if seeking subject consent for the experimental intervention is impossible?  
Such a trial may qualify for a waiver of informed consent as provided for in many 
national and international research ethics guidelines15,22,26. The moral justification for a 
waiver of informed consent lies in the relationship between the basic principles of respect 
for persons and beneficence14,16,17. When a conflict between basic principles occurs, we 
must weigh the relative importance of the competing moral demands of each 
principle27,28. The principle of respect for persons entails the moral requirement to seek 
informed consent from potential subjects. Beneficence requires that investigators 
minimize harms while maximizing benefits, and that risks to subjects must be offset by 
either benefit to the subjects themselves, or to society14. We may argue that beneficence 
entails a requirement to pursue valid research for the betterment of society. Because 
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neither principle supersedes the other, a moral justification for a waiver of informed 
consent lies in prioritizing the competing demands of each.  
Seeking informed consent from subjects allows them to exercise their autonomy in 
adopting the ends of the study as their own, and allows them to safeguard their own 
interests. If subjects’ interests can be safeguarded in another way, then there may be cases 
in which the demands of beneficence—producing valid research to benefit society—may 
reasonably outweigh the demands of respect for persons—to seek informed consent from 
subjects. A waiver of consent is only permissible if the risks to subjects’ interests, and the 
consequences of setting aside their autonomy rights, are minor, and if the social benefits 
that may accrue from the research cannot be otherwise obtained. 
This is not a utilitarian argument. A utilitarian might conclude that societal benefit 
necessitates overriding the autonomous wishes of a small number of research subjects 
even when consent could be obtained, and where subjects’ interests at stake are 
significant. Rather, this is a principled moral foundation for guidelines permitting a 
waiver of consent in narrowly-specified circumstances.  
Numerous examples exist22-24,29,30, but the oldest regulation outlining the 
requirements for an alteration or waiver of informed consent is found in the US Common 
Rule (45 CFR 46.116d), first published in 198122. The Common Rule requires that 
following conditions all be met in order for an alteration or waiver of consent 
requirements to be approved by an ethics committee:  
(i) The research involves no more than minimal risk to the subjects; 
(ii) The waiver or alteration will not adversely affect the rights and welfare of the 
subjects; 
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(iii) The research could not practicably be carried out without the waiver or 
alteration; and 
(iv) Whenever appropriate, the subjects will be provided with additional pertinent 
information after participation31. 
The majority of national and international guidelines for waivers of consent are based on 
the protections outlined above, and are substantively similar in both language and 
application22-24,29,30. A detailed discussion of each of these requirements follows. 
 
1.1) The research involves no more than minimal risk to the subjects 
According to the rules and regulations governing human subjects research drafted 
by the US Department of Health and Human Services, minimal risk means that “the 
probability and magnitude of harm or discomfort anticipated in the research are not 
greater in and of themselves than those ordinarily encountered in daily life or during the 
performance of routine physical or psychological examinations or tests.32” In other words, 
the risks to subjects from interventions in a CRT must be similar to the risks posed by 
interventions in routine healthcare, public health or educational practice. Minimal risk 
interventions for data collection include, but are not limited to, interviews, surveys, 
physical examinations, and collection of data from patients’ medical records32.   
Many CRTs would meet this minimal risk criterion. In healthcare CRT, for 
example, the interventions being evaluated are generally variations on routine care and do 
not pose any additional risk. Data collection is often accomplished using subjects’ 
medical records, or by using physical examinations or interviews. Thus, the data-
collection interventions in healthcare CRTs often pose only minimal risk.  
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In the malaria prevention CRT described above25, geographical districts were 
randomly assigned either to a pesticide spraying program or to a control. The 
implementation of a pesticide spraying program is consistent with the kinds of measures 
that a public health department would ordinarily undertake, so the pesticide spraying is 
consistent with the risks of daily life for residents of intervention communities. Therefore, 
the experimental intervention poses only minimal risk to subjects. If it can be successfully 
argued that seeking consent from individual residents for spraying is not feasible, a 
waiver of consent for the pesticide spraying intervention is reasonable.  
 
 1.2) The waiver or alteration will not adversely affect the rights and welfare of the 
subjects  
The meaning of the second requirement, that the waiver or alteration must not 
adversely affect the rights and welfare of subjects, is not elaborated on in the text of the 
Common Rule. So what, exactly, does it mean? The National Bioethics Advisory 
Commission has suggested that safeguarding subjects’ rights means ensuring that 
investigators and ethics committees adhere to other federal or state statutes that might 
offer more stringent privacy protections than the Common Rule33. This interpretation 
seems redundant, in that any other regulations with more stringent privacy protections 
will override the Common Rule.  
It seems counterintuitive that a requirement to preserve the rights and welfare of 
subjects is included in regulations permitting a waiver of consent, which outline precisely 
when the autonomy rights of research subjects may be set aside. It is, perhaps, more 
helpful to consider this second requirement as a complement to the first requirement that 
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risks be minimal. Both of these requirements are aimed at ensuring that subjects’ interests 
(be they welfare interests, financial interests, economic interests or other) are not 
unreasonably jeopardized in the context of a research study that uses a waiver of consent. 
 
1.3) The research could not practicably be carried out without the waiver or alteration 
CRT investigators have suggested that some studies may not be feasible without a 
waiver of consent for a variety of reasons. These generally relate either to the feasibility 
of obtaining consent from individual subjects1,2,8, or to the potential for biased responses 
because of information disclosed during the consent process1,2,5,9. Each of these reasons 
for seeking a waiver of informed consent will be examined separately. 
 
1.3.1) Seeking consent may not be feasible 
In CRTs of cluster-level interventions, it may be impossible for cluster members to 
avoid the intervention1,2. Informed refusal is effectively meaningless if the intervention is 
unavoidable. Some CRTs may randomize clusters that are so large as to make obtaining 
consent from all subjects logistically impossible1,2,8. 
The preamble to the Common Rule explicitly states that large scale public health 
studies in which it is impossible to obtain consent from all individuals who may be 
affected by the study intervention may be eligible for a waiver31. It is reasonable to extend 
this conclusion to CRTs in other fields of inquiry.  
A waiver of consent may be used in studies that do not involve an interaction with 
or intervention on subjects, but that do use identifiable private information to collect 
outcome data 33. This practice has been justified because the logistical effort required to 
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obtain consent from subjects for the use of their private information is prohibitively 
difficult21. This applies particularly to healthcare CRTs that intervene on health 
professionals and only use patient information to generate effect measures for the 
interventions under study. In such studies, it would not be necessary to seek the consent 
of the patients whose private information is used to generate data. In the NEXUS study 
cited above, for example, consent was not sought for abstracting identifiable private 
information from the medical records of patients to evaluate the effect of experimental 
interventions administered to those patients’ primary care physicians11.  
No sharp demarcation exists to determine when seeking consent is practicable or 
impracticable. This determination, rather, is within the discretionary authority of a 
research ethics committee. An ethics committee may consider a number of factors in 
making this determination, including the size of the population, as well as the cost and 
logistical feasibility of seeking consent from all subjects34. If a waiver is desired, CRT 
investigators must convince the research ethics committee that seeking consent from 
subjects is not feasible. The ethics committee, in turn, is charged with making the 
qualitative determination as to whether the risks to subjects are minimal and  the societal 
benefit that may be gained by performing the research without obtaining informed 
consent outweighs the autonomy interests of individual subjects.  
The malaria-prevention pesticide study cited above25 would likely satisfy the 
criterion that the study could not practicably be carried out without the waiver. The 
spraying intervention could not be avoided by residents of intervention clusters. The 
clusters are also sufficiently large that seeking informed consent from individual residents 
for the spraying intervention would be so logistically difficult as to make seeking 
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informed consent infeasible. Therefore, because seeking consent is infeasible and because 
the spraying intervention poses only minimal risk, the pesticide spraying study would 
likely be eligible for a waiver of informed consent for the spraying intervention under 
current research ethics guidelines15,22,26. 
 
1.3.2) Potential for bias because of information provided to subjects during consent 
negotiations 
It has been suggested that the potential for bias in CRTs as a result of information 
disclosed in the consent process may be sufficient to justify a waiver of consent1,9,35,36. 
CRTs often evaluate interventions aimed at modifying the behaviors of cluster members. 
Knowledge of the purpose and nature of interventions offered to the other arms of a trial 
may bias the outcome of the study. For example, a CRT may evaluate an intervention to 
improve physician uptake of clinical practice guidelines. If members of the control group 
know the details and purpose of the intervention, they may choose to familiarize 
themselves with the guidelines, thus biasing the estimate of the intervention’s effect35. 
Some commentators have suggested that the potential biasing effect of the consent 
process for such trials may justify modifying or waiving consent requirements, because 
undertaking an experiment that is scientifically invalid is unethical1,9,35,36.  
There is no specific regulatory guidance that provides criteria for determining when 
concerns for study validity might outweigh obligations to seek subjects’ informed 
consent34. Concern for bias is one justification for the use of a waiver4,34. Investigators 
concerned that information disclosed during the consent process might bias study findings 
may apply for a waiver of consent. An application to the research ethics committee for a 
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waiver must demonstrate that the CRT meets regulatory criteria for a waiver. Specifically, 
investigators should provide convincing evidence that disclosure would so bias the study 
findings as to make the study impracticable. Investigators must also demonstrate that the 
interventions under study pose only minimal risks to subjects. This approach fits with the 
moral justification for a waiver of consent: that the societal benefit of research knowledge 
may not be obtained otherwise and the risks to subjects’ interests, and that the 
consequences of setting aside their autonomy rights, must be minor.   
 
  1.4) Whenever appropriate, the subjects will be provided with additional pertinent 
information 
Respecting the research subject as a person, not simply as a means to an end, 
requires that the nature and purpose of the research be disclosed. Providing subjects with 
information about the study when a waiver of consent is used is therefore important in 
ensuring that subjects are respected as persons19. Yet, how does this requirement apply to 
CRTs that use a waiver of consent? If obtaining consent from subjects in large CRTs is 
logistically impossible, it is likely that providing subjects with additional information is 
equally impossible. Providing additional information to subjects through the media or 
signs in healthcare institutions that a study is being conducted, and that they are entitled 
to seek more information from study investigators may be one way of satisfying this 
requirement.  
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Waivers of consent in CRTs with cluster-level and individual-level interventions 
It is important to note that a waiver of consent may apply to some, but not all, 
interventions in a CRT. Some studies evaluating cluster-level interventions evaluate 
outcomes by collecting data from a smaller sample of each cluster. For example, in the 
pesticide-spraying example CRT cited above, malaria incidence was ascertained by 
screening residents and obtaining blood samples of individuals with fevers and from a 
cross-section of school children25.  
Because each individual who undergoes additional examinations, interviews, or 
tests to generate data is identifiable and accessible, it is feasible to seek consent for data-
collection interventions. In this case, a waiver of consent would only apply to the 
pesticide-spraying intervention. 
Informed consent for data-collection procedures should be sought when doing so is 
feasible, even if these interventions pose only minimal risk. One example of a data-
collection intervention that may be eligible for a waiver is the review of a large number of 
medical records, as was done for research subjects in the NEXUS study cited above11. 
 
2) May informed consent be sought after randomization of clusters? 
As random assignment of clusters is often done before the intervention is 
administered, it may be impossible to obtain consent until after randomization has been 
completed35. Hutton notes, “Scientific and logistical constraints associated with [CRTs] 
imply that consent cannot necessarily be requested before an intervention is assigned to a 
person…In some cases it is logically impossible to obtain consent for the intervention 
prior to randomization of clusters. 2”  
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An example of such a study is a CRT conducted in Nepal that evaluated the 
comparative efficacy of three different strategies for umbilical stump cleansing on 
neonatal mortality and incidence of omphalitis (infection of the umbilical stump)37. The 
units of randomization were geographical sectors of rural Nepal. Mothers were randomly 
assigned in geographical clusters to use either dry cord care (the standard technique, used 
in the control arm), to washing the stump with soap and water, or to use a disinfectant 
solution for stump cleansing. The stump care techniques were performed on the infants by 
health workers who visited new mothers on a predetermined schedule. Neonatal mortality 
and incident cases of omphalitis were recorded by the visiting health workers. Each 
mother gave informed consent for study participation during a prenatal health visit37. 
Enrolling subjects prior to randomization of clusters was not possible because mothers 
had not yet become pregnant at the time of cluster randomization.  
Some commentators have expressed concern that seeking subjects’ consent for CRT 
participation after cluster randomization may not respect subjects’ autonomy rights2,8. 
Based on our understanding of the purpose of seeking informed consent, this concern 
appears unjustified. 
The purpose of seeking informed consent is to enable subjects to autonomously 
embrace the ends of the study as their own. This purpose is still achieved if consent for 
CRT participation may only be sought after random assignment of clusters, and if 
subjects are approached for consent at the earliest possible opportunity. If potential 
subjects are informed that group assignment has already been determined, then they may 
freely choose whether or not to participate in the CRT. The fact that group assignment has 
already been determined does not limit potential subjects’ autonomy or their ability to 
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embrace the study’s objectives as their own. Potential subjects may freely choose whether 
or not to participate in the CRT. Thus, it is permissible to seek informed consent for CRT 
participation after randomization has been done.  
In the Nepalese CRT cited above, it was impossible to seek informed consent prior 
to randomization of clusters. However, mothers were free to decide whether or not to 
participate in the study. The purpose of seeking informed consent─enabling potential 
subjects to make autonomous choices to adopt the scientific purpose of the study as an 
end of their own─was still achieved in this trial, even though consent was sought after 
random assignment of clusters.  
 
3) What information must be disclosed to subjects? 
Potential research subjects must be given sufficient information to allow them to 
decide whether or not to participate in a study19. As outlined above, guidelines for 
disclosure during consent processes generally include a statement of the study’s purpose, 
a description of the nature, risks and potential benefits of the interventions involved, and 
the potential subjects’ options should they choose not to participate 15,22-24.   
If subjects are enrolled after randomization of clusters has taken place because 
seeking consent prior to randomization is impossible, they must still be informed of: the 
purpose of the study, detailed information about the trial arm to which they have been 
assigned, and information about their options should they choose not to participate in the 
trial. 
Information about the purpose of the study is essential to a potential subjects’ 
decision as to whether or not they can embrace the study’s scientific ends as their 
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own17,18,20,21. Therefore, the purpose of the study must be described in sufficient detail so 
as to allow potential subjects to decide whether or not the study’s ends are consistent with 
their values.  
Potential subjects must be provided with a detailed description of the interventions 
administered in the trial arm to which their cluster has been randomly assigned.  
However, detailed information about other arms in a CRT is not necessary. The choice 
facing the potential subject is whether to participate in the CRT, in the arm to which their 
cluster has been assigned, or not to participate in the CRT. Detailed information about the 
interventions offered in other arms of the trial (i.e. interventions that the subject would 
not receive) is immaterial to the potential subject’s decision whether or not to participate.  
In the Nepalese umbilical stump care study cited above37, a consent form provided 
to mothers whose clusters were assigned to the chlorhexidine arm, for example, would 
include the following details:  
“The purpose of this study is to determine whether any of three different 
techniques for cleaning your infant’s umbilical stump is more effective in 
preventing stump infection or death. Health workers in participating communities 
were randomly assigned to use one of three different stump cleaning techniques. 
The health workers from your community who visit you after the birth of your 
baby will be using a mild disinfectant solution to cleanse your baby’s umbilical 
stump. Specifically, on the 1st, 2nd, 3rd, 4th, 6th, 8th, 10th, 12th, 14th, 21st and 28th day 
after your baby’s birth, you will be visited by a health worker who will cleanse 
your baby’s umbilical stump using the mild disinfectant solution. They will also 
examine the umbilical stump for infection and examine your baby for signs of 
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more serious infection. On day 1 and 14, they will also ask you questions about 
factors that may affect your baby’s risk of infection”  
One fortuitous effect of the use of tailored disclosure between different arms of a 
CRT is that the potential for bias may be mitigated. Commentators have expressed 
concern that, if subjects assigned to the control arm were informed about the content of a 
behavioural intervention in the experimental arm during the consent process, they may 
modify their behaviour in such a way that their response to the control interventions may 
spuriously approximate the response of individuals in the intervention arm1,9,35,36.  
For example, in the umbilical stump care study37, if mothers assigned to the dry 
stump care arm surreptitiously used soap and water because they were informed of this 
technique during the consent process, the study’s findings may be biased toward a null 
effect of the intervention. But, if consent is sought after randomization of clusters, it is not 
necessary to provide subjects in one arm of a CRT with information about the 
interventions in other arms. Thus, the potential for bias is minimized. 
 
4) May passive consent be used in CRTs? 
In some large CRTs of cluster-level interventions36,38-40, investigators have used a 
“passive consent” approach to subject recruitment. In the passive consent approach, 
investigators take steps to inform potential subjects that a research study is being 
conducted, and may even provide information about the study itself. If investigators 
receive no indication from a potential subject that he/she objects to being enrolled in the 
study, then that subject is presumed to have agreed to participate. This technique is 
commonly used in CRTs in education. Information about the purpose and interventions in 
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a study are sent home with students. If the students do not return a document, signed by 
their parent or guardian, that they decline participation, then they are presumed to agree to 
study enrolment38.  
In health services research, passive consent is used somewhat differently. In many 
studies conducted in healthcare settings, notices are posted in patient areas that research is 
being conducted, although detailed information about the study is not provided. The 
notices indicate that, if the patients do not wish to participate in the research study, then 
they may contact the investigators in order to opt out36,39,40. It may be impossible for 
subjects to opt out of some cluster-level interventions, although it may be feasible for 
subjects to opt out of data collection1,7.  
A passive consent model is best thought of as an alteration of consent processes that 
are permitted under various waiver of consent guidelines22,23,26. When used as described 
above in healthcare CRTs, an opt-out model satisfies none of the elements of informed 
consent. Subjects cannot be assumed to have embraced the study’s scientific ends as their 
own. There is no assessment of subjects’ decision-making capacity. There is no assurance 
that potential subjects are making decisions freely. The notices posted typically do not 
offer sufficient information for potential subjects to make a responsible choice whether or 
not to participate. There is no assurance that potential subjects understand the information 
provided in the notice. Indeed, there is no assurance that all potential subjects have even 
seen the notice. 
When passive consent is used in school-based studies, the information sent home 
with students often contains sufficient information to enable a capable parent or guardian 
to decide whether or not to allow their child to participate in the CRT38. However, there is 
 171 
no assurance that each child will give the information to their parent. There is no 
assurance that the parent or guardian understands the information. Nor is there any 
assurance that the parent or guardian is capable of deciding whether or not to permit their 
child to participate in the CRT38. 
The use of a passive consent model is subject to the same regulatory demands as the 
use of a waiver of consent. An investigator must convincingly argue that the research is 
not feasible without the alteration of typical consent practices. The interventions in a 
study using a passive consent model must pose only minimal risk. Because passive 
consent models are subject to the same regulatory requirements as a waiver of consent, 
passive consent approaches are not any more protective of subjects’ autonomy and 
welfare interests than a waiver.  
Although passive consent models do not offer any additional protection beyond that 
offered under waiver of consent guidelines, the use of passive consent may be justified on 
pragmatic grounds. For example, in school-based CRTs, passive consent may be required 
by school administrators or parent groups38. A hospital-based CRT evaluating a quality 
improvement intervention for diabetes care used a passive consent model because 
“clinicians and the laboratories owned by community hospitals were worried about public 
concern as patients discovered they were enrolled without consent into a research 
project.39” CRT investigators may choose to use a passive consent strategy for similar 
pragmatic reasons.  
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5)   Are professionals obligated to participate in CRTs of interventions designed to 
improve their practice? 
 
In CRTs evaluating an educational intervention on professionals, such as teachers or 
health care workers, the professionals are the recipients of an experimental 
intervention2,10,41,42 and are, therefore, research subjects10,41,42. In order to reasonably bear 
the burdens of research participation, they must be able to embrace the study’s ends as 
their own. Therefore, informed consent must generally be obtained10,41,42. However, there 
may be circumstances in which seeking consent from professionals is logistically 
difficult. In such cases, CRTs may meet regulatory criteria for a waiver of consent.  
The NEXUS study cited above evaluated the comparative efficacy of educational 
reminder messages or audit and feedback on adherence to clinical practice guidelines for 
lumbar spine and knee radiography11. Two-hundred-and-forty-seven clusters of primary 
care practices were randomly assigned to receive either reminder messages, audit and 
feedback, both interventions, or simply a mailed copy of the practice guidelines. The 
study investigators argued that seeking consent from all physicians in each of those 247 
primary care practices was so impracticable as to make the study unfeasible, and that the 
interventions were sufficiently similar to routine activities that they posed only minimal 
risk35. Similar large-scale studies of interventions designed to improve professional 
practice may meet regulatory criteria for a waiver of consent  for health 
professionals15,22,23,26 
Some investigators have argued that professionals may have obligations to 
participate in CRTs that would override their right to autonomously choose whether or 
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not to participate2,5,35. This suggestion is based on two claims. First, that professional 
obligations to engage in continuing professional development entail an obligation to 
participate in CRTs5,35. As Hutton claims: “In some cases, the experimental units, that is, 
professionals, might have a duty to enrol as part of their continuing professional 
development.2” Second CRTs may offer direct or indirect benefits to patients, thereby 
obligating health professionals to participate5,35. According to Hutton and colleagues, 
“…If a health care professional chooses not to participate in a study, they are in effect 
denying their patients the potential benefits of participation.35” Both of these claims may 
be refuted. 
Health professionals are required to engage in continuing professional development 
as a matter of professional obligation and as a condition of licensure in many 
jurisdictions43. Physicians, in particular, have a great deal of latitude in determining the 
means by which the continuing education is completed. Acceptable options may include 
self study, conference attendance, preparation for teaching, and formal educational 
programs leading to a degree or diploma44. This wide discretion in choosing professional 
development activities undermines any claim that health professionals have an obligation 
to participate in CRTs. Participation in a CRT of an educational intervention may be one 
among many acceptable options for engaging in continuing education. Given the 
numerous ways in which a health professional may meet their continuing professional 
development obligations, there is no basis on which an obligation to participate in CRTs 
of educational interventions can be derived from continuing professional development 
obligations.  
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The fact that an educational or quality improvement intervention is being evaluated 
in a CRT means that its efficacy is unproven45,46. If there were certainty as to the efficacy 
of an educational or quality improvement intervention, a CRT would be unethical45, and 
professionals would be able to access that effective intervention through ordinary means. 
The uncertainty about the efficacy of an educational or quality improvement intervention 
undercuts any argument that professionals ought to participate in CRTs for the good of 
those that they serve. 
In addition, control groups in CRTs may receive either no intervention or some 
other intervention that approximates routine practice. This further undermines arguments 
that professionals ought to enroll in CRTs because of their obligation to act in the interest 
of those whom they serve. 
It is therefore possible to make three conclusions about professionals who are 
research subjects in CRTs: 1) neither fiduciary obligations nor professional obligations to 
engage in continuing education require health professionals to participate in CRTs; 2) 
when it is possible to seek consent from professionals for participation in a CRT, their 
consent should be sought; 3) some CRTs, in which  it is not feasible to seek consent from 
all professional subjects, and in which the interventions under study pose only minimal 
risk, may be eligible for a waiver of consent.  
 
Summary 
Numerous commentators1-3,7,9,35 have identified the difficulties associated with 
obtaining informed consent for participation in CRTs. This paper has addressed these 
challenges by appealing to basic ethical principles, and to the moral theories that underpin 
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these principles. Consent requirements stem from the principle of respect for persons, 
which requires that the choices of autonomous individuals be respected. Seeking 
informed consent empowers research subjects to choose to adopt the study ends as their 
own, authorizing interventions that serve a scientific purpose. This conceptual framework 
leads to specific conclusions about key ethical issues that arise because of the unique 
methodological features of CRTs. These may be formulated as a set of guidelines for 
investigators and research ethics committees to identify when consent must be obtained 
from participants in CRTs: 
 
1. As a general rule, consent must be obtained from all subjects in CRTs. 
This includes cluster members, as well as individuals who may be the recipients of 
interventions designed to produce a cluster-level effect such as health professionals or 
teachers. However, many CRTs may meet the regulatory criteria for a waiver of informed 
consent. 
2. If random cluster assignment occurs prior to subject enrolment, subjects 
must be informed of the purpose of the study, the nature of the interventions to which 
they will be exposed in the arm of the study to which they have been assigned, and their 
options should they choose not to participate.  
3. There is no obligation to inform potential subjects of interventions that are 
exclusive to other study arms and inaccessible by other means. Potential subjects must be 
informed of the details of the trial arm to which their cluster has been randomized, and of 
other options should they choose not to participate. 
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4. Passive consent strategies are not a sufficient substitute for obtaining 
informed consent, nor do they offer any advantage to subjects beyond the additional 
protections that are required for a waiver of consent. However, a passive consent strategy 
may be chosen for pragmatic reasons, provided that regulatory criteria for a waiver of 
consent are met. 
5. Large CRTs that intervene on professionals may be eligible for a waiver of 
consent from those professionals, provided that seeking consent from all of the 
professionals is impracticable and that the interventions pose only minimal risk. However, 
CRT participation cannot be construed as a professional obligation. If seeking consent 
from professionals who are research subjects is feasible, then such consent must be 
obtained. 
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Summary and Discussion 
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Summary of Findings 
 
This dissertation has two principal objectives. The first objective is to empirically 
describe current practices in addressing ethical challenges in healthcare CRTs, with an 
emphasis on informed consent. The second objective is to answer two normative questions: 
1) Who is the research subject in CRTs? and 2) When is informed consent required from 
subjects in a CRT? 
Empirical Work:  
Chapter Three  
The empirical evaluation of current research ethics practices began by identifying 
features of CRTs that are associated with the reporting of obtaining informed consent from 
patients in a large sample of published CRTs. A sample of 161 CRTs performed in 
healthcare settings were identified from a random sample of CRTs published between 
2000-2008. Both bivariable and multivariable regression analyses were used to examine the 
relationship between reporting of patient consent and such features as: the date of 
publication; country of study conduct; journal impact factor; average cluster size; use of 
patient-level experimental interventions and patient-level data collection interventions; and 
reporting of the study as quality improvement research.  
In our sample of healthcare CRTs, reporting of informed consent from patients was 
independently associated with the use of experimental interventions directed at patients, 
with the use of patient-level data collection interventions, with smaller cluster sizes, and 
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with publication in recent years. Lack of reporting of informed consent from patients was 
independently associated with publication in lower impact journals, and with study conduct 
in developing countries.  
It is not unreasonable to infer that reporting of patient consent reflects actual 
consent practices. Therefore, investigators are more likely to seek patient consent in CRTs 
that use patient-level interventions and in studies with small cluster sizes. These findings 
are in keeping with published commentaries on the ethics of CRTs which speculate that it 
may not be possible to seek informed consent in studies evaluating cluster-level 
interventions1-5 or in studies with large cluster sizes1,5.  
Consent practices were only described in 60% of CRT reports: consent was 
obtained in 53%, while consent requirements were waived in another 7% of studies. 40% 
of study reports do not mention consent practices, in spite of the requirement to document 
in study reporting guidelines6. It may be that a waiver of consent was used in a large 
proportion of studies that did not report their consent practices. However, this should have 
been documented. The fact that consent procedures were not described is a significant 
failure of these reports and the journals that published them. 
Chapter Four 
A purposive sample of twenty experienced CRT investigators was interviewed with 
the goal of describing how experienced researchers have addressed ethical challenges in 
practice. Informants participated in a semi-structured interview, which included questions 
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on ethical challenges encountered in practice, experiences with the ethics review process, 
and the need for comprehensive international ethics guidelines for CRTs.  
The scope of ethical concerns identified by informants paralleled the scope of 
ethical concerns identified in the CRT literature. Informants’ responses focused largely on 
consent issues and the role of cluster decision-makers. The analysis of the interviews 
suggested that, as in the CRT literature, important ethical challenges such as the analysis of 
harms and benefits of CRTs and justice issues are less important to, or unappreciated by, 
experienced CRT investigators.  
With respect to informed consent practices, the findings of this study were similar 
to those of the quantitative analysis in the previous chapter. Informants confirmed that 
whether consent was sought from individual cluster members in practice depended on the 
kinds of intervention under study. Informed consent is sought more often in CRTs of 
individual-level experimental interventions than in CRTs of cluster-level interventions.  
Informants also offered testimony that ethics review procedures and consent 
requirements have become more stringent in recent years. This qualitative finding agrees 
with the quantitative finding that investigators reported seeking patient consent more 
frequently in studies published 2005-2008 compared to studies published 2000-2004.  
Informants had differing views of the impact that the ethics review process has had 
on their work. Some informants felt that the questions asked by research ethics committees 
had a positive effect on CRT protocols. Others felt that requirements imposed by research 
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ethics committees, such as the need to seek subjects’ consent, had a negative impact on 
study validity.  
Informants cited variability in research ethics review as an important impediment to 
the conduct of multicentre CRTs. They also felt that comprehensive international ethics 
guidelines would be useful in educating research ethics committees about the unique 
methodological features of CRTs and the ethical issues stemming therefrom. One important 
purpose for international ethics guidelines for CRTs would be to encourage uniformity in 
research ethics review. 
Normative Work: 
 Chapter Five  
Prior to being able to address issues relating to consent, the analysis of risks and 
potential benefits, and equitable subject selection, it is essential to be clear about who is the 
research subject in a CRT. Research subjects in CRTs must be correctly identified to 
ensure that subjects are adequately protected and that research is not hampered by the 
inappropriate application of research ethics regulations in situations in which cluster 
members are not research subjects. 
The question of who is a research subject was answered by identifying the features 
common to different regulatory definitions of “research subject”, and evaluating these 
features in the light of conceptual work describing the distinction between a patient and a 
research subject in a clinical trial. We define a “research subject” as an individual whose 
interests are put at risk in the context of a research study. This may occur if the individual 
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is directly intervened upon, is intervened upon via manipulation of his/her environment, 
interacts with the research team, or contributes identifiable private information. 
This definition of “research subject” has important implications for the ethics of 
CRTs. First, individuals who receive interventions intended to produce a cluster-level 
effect are research subjects. This includes health professionals and teachers who receive 
educational or quality improvement interventions that are being evaluated in the CRT. It is 
important to recognize that these individuals have interests that may be compromised in the 
context of a CRT, and that they merit protection as research subjects. This is a separable 
issue from whether or not consent is required from these subjects—a question considered 
in chapter six. 
Second, some cluster members may not fulfil the definition of “research subject”. 
Cluster members who are not intervened upon, either directly or via manipulation of their 
environment, who do not interact with investigators, and who do not contribute identifiable 
private information are not research subjects. This includes patients whose health 
professionals are intervened upon in a CRT of an educational or quality improvement 
intervention. They are not intervened upon directly, nor does any indirect effect of the CRT 
intervention on their care constitute an environmental manipulation. If they do not interact 
with researchers or contribute identifiable private information, then they are not research 
subjects. It follows that, if they are not research subjects, their consent for research is not 
required. 
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Chapter Six 
Working with this definition of “research subject”, we then addressed the question 
of when consent is required in CRTs.  We did so by relying on a conceptual framework 
grounded in the basic ethical principles and a moral theory that supports these principles. 
This framework outlines the purpose of seeking informed consent and may be summarized 
as follows: consent requirements stem from the basic ethical principle of respect for 
persons, which requires that the choices of autonomous individuals be respected. The 
principle of respect for persons may be viewed as being rooted in deontological moral 
theory, which posits that autonomous individuals have an intrinsic worth and are entitled to 
respect. Autonomous individuals must not be used solely as means to an end; they must be 
treated as ends in themselves. The purpose of seeking informed consent is to enable 
potential subjects to embrace the ends of the research study as their own. 
As a general rule, informed consent must be obtained from all research subjects in a 
CRT. If it is not possible to obtain informed consent from subjects prior to randomization 
of clusters, then seeking informed consent after randomization is permissible. Potential 
subjects may choose to participate in the CRT—or not—knowing the trial arm to which 
their cluster has been assigned. That cluster randomization has taken place before cluster 
enrolment does not diminish a potential subject’s ability to freely choose whether or not to 
embrace the study’s ends as their own. Nor does it treat a subject solely as means to an end, 
provided that informed consent is sought at the earliest opportunity—and before any 
research interventions are performed on that subject.  
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If subjects are enrolled after clusters have been assigned to different trial arms, then 
they need only be provided with information material to their choice whether or not to 
participate in the CRT, namely the purpose of the study; the nature, risks and potential 
benefits of interventions that they would undergo in the arm to which their cluster has been 
assigned; and their options should they choose not to participate.  
In studies of cluster-level interventions that are impossible to avoid, the use of a 
waiver of consent for the study interventions may be permissible, although consent for 
some data collection procedures may still be required. A waiver of consent may be used for 
CRTs of minimally risky interventions if seeking informed consent from all subjects would 
make the study unfeasible. This may be the case in very large clusters, or if the only 
individual-level intervention is the use of identifiable private information that is collected 
from administrative sources such as medical records. If data collection interventions such 
as physical examinations, interviews or specimen collections are performed on cluster 
members, then informed consent should be sought for these interventions. 
Professionals cannot be required to participate in a CRT as a consequence of 
professional obligations. However, circumstances may exist in which a CRT that examines 
interventions on professionals may meet regulatory criteria for a waiver of informed 
consent: specifically, if seeking consent is not feasible; if the interventions pose only 
minimal risk; if rights and welfare are not adversely affected; and (if appropriate) subjects 
are debriefed after the study is completed. 
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Discussion 
Reflections on the relationship between empirical and normative work 
In recent years, there has been a growing academic movement which suggests that 
answering some research questions requires a methodology that combines both empirical 
work and ethical analysis7. McMillan and Hope offer a cyclical model for the interaction 
between empirical and normative work. It is not simply that empirical work generates 
questions for ethical reflection, or that an ethical analysis led to an empirical question. 
Rather, some problems require both empirical and normative work. The findings of 
empirical work may stimulate ethical reflection, which may, in turn, drive policy change, 
the effects of which can be evaluated empirically7.  
Tan and Hope provide an example of how this model is applied to questions around 
informed decision-making in patients with anorexia nervosa8. Tan and Hope sought to 
determine whether traditional conceptions of decision-making capacity were adequate to 
guide decisions about when it is appropriate to impose treatment against the wishes of 
anorexic patients. They began with a qualitative interview study to gain a detailed 
appreciation of the rationale for choices that anorexic patients make about whether or not to 
comply with treatment. The data indicated that patients refuse treatment based on values 
that are related to the disorder itself, such as the sense of control that anorexic behaviour 
gives to patients. These data conflicted with the traditional conception of lack of decision-
making capacity, which assumes that incapable patients make decisions based on false 
beliefs or faulty reasoning. Therefore, the data prompted further conceptual work that 
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sought to determine whether or not values closely related to a mental disorder may justify 
refusal of treatment in the way that other kinds of values justify an informed refusal. Tan 
and Hope offer that the conclusions of this conceptual work would drive the 
implementation of policy with regard to the imposition of treatment for anorexic patients8. 
This dissertation fits this cyclical model as proposed by McMillan and Hope7: both 
empirical analysis and normative work is essential in order to comprehensively address 
important ethical problems in CRTs. The empirical work identified the ethical problems 
posing the most important challenges to CRT investigators, and described how ethical 
problems in CRTs are addressed in practice. These findings stimulated reflection on 
specific ethical questions, namely “Who is the research subject in CRTs?” and “When is 
consent required in CRTs?” The conclusions of the normative work enabled critical 
reflection on the empirical data. This included identification and discussion of deficiencies 
in ethics practices, and the use of a conceptual framework for the ethics of human subjects 
research to identify important ethical issues that were not reported by CRT investigators. 
The conclusions of the normative work, and critical reflection on current practice, will 
guide the development of comprehensive guidelines for the ethical conduct of CRTs 
Empirical work identifying normative questions 
The interviews done in chapter four documented CRT researchers’ views on the 
ethical problems in CRTs, and asked detailed questions about how these issues were 
addressed in practice. The principal ethical challenges noted by study informants were 
related to seeking informed consent from cluster members in CRTs. Namely, they 
identified issues of feasibility of seeking consent, potential for bias as a result of disclosure 
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of study details to subjects, and whether or not consent was required from professionals 
who were intervened upon. Prior to being able to address investigators’ concerns over 
consent issues, normative work was required to clearly identify who is the research subject 
in a CRT. Therefore, the key question of who is a research subject in a CRT was examined 
in chapter five.  
The question of who is a research subject was addressed by appealing to scholarly 
work that supports this conceptual framework for research ethics. This scholarly work 
distinguished clinical research from medical practice, and subjects from patients. These 
distinctions illuminated our analysis of current regulatory definitions of “research subject”, 
enabling the development of a definition of research subject that is applicable to the entire 
range of human subjects research. This work has important implications for CRTs. First, in 
CRTs in which individual cluster members are not intervened upon, do not interact with 
investigators and do not contribute identifiable private information, these individual cluster 
members are not research subjects, and therefore, their consent is not required. Second,  
individuals, such as professionals, who receive an experimental intervention intended to 
produce a cluster-level effect, are research subjects and, as a result, their consent may be 
required.  
The normative work in chapter six was directly stimulated by the findings of the 
empirical work in chapters three and four. In addressing the question “When is informed 
consent required in CRTs?” the relationship between the types of interventions under study 
and the need to seek informed consent was examined, as well as issues of post-
192 
 
 
 
randomization consent, potential from bias resulting from disclosure of study interventions, 
and the need for consent from professionals who are intervened upon in a CRT. 
We drew on the principle of respect for persons, and on a moral theory on which 
this principle is based, to address challenges related to seeking informed consent from 
subjects in CRTs. Consent requirements stem from the principle of respect for persons. 
This principle, which may be viewed as being rooted in deontological theory, is based on 
the unconditional worth of autonomous individuals, and demands that the wishes of 
autonomous individuals be respected. By adequately informing subjects during the consent 
process, and by allowing subjects to make free choices, subjects are able to freely adopt the 
scientific ends of the CRT as their own, effectively authorizing interventions that may put 
their welfare at risk. When it is not possible to seek subject consent prior to random cluster 
assignment, seeking consent at the earliest opportunity post-randomization is sufficiently 
respectful of subjects’ autonomy, provided that they are informed of the study’s purpose 
and the interventions that they would be subjected to should they choose to participate. If 
obtaining consent is not feasible, or if the study intervention cannot be avoided, then 
waiving consent is permitted, provided that risks to subjects are minimal. 
Reflecting on empirical work based on findings of normative work 
The conclusions of the normative work in this dissertation make it possible to 
critically reflect on the empirical findings.  
Studies with small cluster sizes and that used patient-level interventions were more 
likely to report seeking patient consent. This fits with the opinions of informants in chapter 
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three, who related that they only sought consent when feasible to do so. The normative 
work in this dissertation leads us to conclude that whether consent may be waived for study 
interventions is related to more than just the feasibility of seeking consent. Waiving 
consent requirements is only permissible when seeking consent is not feasible and when 
threats to subjects’ welfare interests are minor, i.e. when interventions for which the waiver 
of consent is sought pose only minimal risk. Thus, we can conclude that researchers and 
investigators require clear guidelines outlining the necessary conditions for use of a waiver 
of consent.  
Consent issues in CRTs represent a paradigmatic example of how both empirical 
work and normative work can be used in concert to address key challenges in the ethics of 
human subjects research. Empirical work identified concern among researchers about 
consent requirements and a practice of waiving consent that may or may not be sufficiently 
respectful of subjects’ interests. Normative work laid out a moral justification for a waiver 
of consent, and criteria establishing when a waiver of consent is permissible. These 
conclusions enabled reflection on current practice, and identified how current practice must 
be improved. The conclusions of the normative work can also guide the development of 
policy to ensure that subjects’ interests are adequately protected while ensuring that 
methodologically valid CRTs may be carried out. 
This dissertation applied both empirical findings and normative work in reaching 
other conclusions about how ethical issues in CRTs ought to be addressed. In Chapter four, 
experienced CRT researchers rarely mentioned issues relating to the analysis of risks and 
potential benefits, fair subject selection, and the use of vulnerable populations. However, 
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these issues are critically important in the conceptual framework based on the Belmont 
Report principles. Thus, the use of a conceptual framework is important in identifying 
areas that require further education for investigators and research ethics committees, and 
clear guidelines addressing these issues, to ensure optimal protection of subjects in CRTs. 
 
Implications for Current Practice 
The findings of the empirical work and the conclusions of the normative work in 
this dissertation lead to conclusions about how current practice in CRTs should change. 
1. Investigators and ethics committees must recognize that individuals who 
are intervened upon in order to produce a cluster-level effect (such as 
professionals) are research subjects. Their consent is required (unless 
criteria for a waiver are met), the risks and potential benefits to these 
individuals must be considered, and rules for fair subject selection should 
apply to these individuals. 
2. Investigators and ethics committees should use a principled definition of 
“research subject” determine whether or not individual cluster members 
are research subjects. Cluster members who are not research subject need 
not be approached for consent. Cluster members who are research 
subjects should be approached for consent unless criteria for a waiver are 
met. 
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3. With respect to seeking consent, investigators and ethics committees 
should consider randomization, experimental interventions and 
interventions used to collect data separately. Consent for random cluster 
assignment may be waived if subjects are not identifiable prior to cluster 
randomization or if clusters are sufficiently large so as to make seeking 
consent for cluster randomization infeasible. A waiver of consent may be 
sought for experimental interventions if seeking consent is not feasible 
and if the interventions pose only minimal risk. If seeking consent is 
feasible or if interventions pose more than minimal risk, then consent for 
experimental interventions should be sought prior to randomization of 
clusters (when feasible) or at the earliest possible opportunity after 
randomization of clusters. The same requirements apply to data collection 
interventions: consent may be waived if the seeking consent is infeasible 
and the interventions pose only minimal risk. Otherwise consent for data 
collection interventions must be sought from each subject.  
 
Implications for Ethics Guidelines for CRTs 
The empirical and normative work in this dissertation is intended to inform the 
development of international consensus guidelines for the ethical conduct of CRTs9. Ethics 
guidelines for CRTs should be comprehensive, addressing all of the ethical challenges 
posed by the CRT design.  
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Guidelines should address the concerns of CRT investigators and ethics 
committees, and protect the rights and welfare of research subjects. In order to optimally 
protect research subjects, guidelines should be comprehensive in scope. The use of a 
conceptual framework, based on the Belmont Principles, facilitates the identification of 
ethical challenges that have not been identified by CRT investigators or addressed in 
literature. In particular, challenges related to the analysis of harms and benefits, and the just 
selection of research subjects have not been addressed, and require further work in order to 
inform the development of ethics guidelines for CRTs.  
Given the findings in this dissertation, international ethics guidelines for CRTs 
should include the following:  
1. A statement of basic ethical principles: respect for persons, beneficence and 
justice. These will be derived from the principles articulated in the Belmont 
Report. 
2. A definition of “research subject”. A research subject is an individual whose 
interests may be compromised as a result of interventions in a research study 
including: 
a. An individual who is directly intervened upon by an investigator 
b. An individual who is deliberately intervened upon via manipulation of 
his/her environment by an investigator 
c. An individual with whom an investigator interacts for the purpose of 
collecting data 
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d. An individual about whom an investigator obtains identifiable private 
information for the purpose of collecting data. 
3. A detailed statement of consent requirements. Generally, consent for CRT 
participation must be obtained from all individuals meeting the definition of 
“research subject” in a CRT.  
a. If subject enrolment is done prior to randomization of clusters, 
information to be disclosed to potential subjects must include the 
purpose of the study; detailed information about the nature, risks, and 
potential benefits of the experimental interventions in each study arm; 
detailed information about the nature and risks of any interventions done 
solely to collect data; and information about the potential subjects’ 
options should they choose not to participate. 
b. If it is not feasible to seek consent for participation prior to 
randomization of clusters, seeking a potential subjects’ consent for CRT 
participation in the arm to which their cluster has been assigned is 
permissible. This consent refers to the experimental interventions in the 
arm to which the potential subjects’ cluster has been assigned, as well as 
any interventions used to collect data.  
c. If subject enrolment is done after randomization of clusters, information 
to be disclosed to potential subjects must include the purpose of the 
study; detailed information about the nature, risks, and potential benefits 
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of the experimental interventions in the study arm to which that potential 
subject’s cluster has been assigned; detailed information about the 
nature and risks of any interventions done solely to collect data; and 
information about the potential subjects’ options should they choose not 
to participate. 
d. A waiver of consent for experimental interventions is permissible if: 
i. The interventions pose only minimal risk; 
ii. The study could not reasonably be conducted without the use of 
a waiver of consent for the experimental interventions. 
e. A waiver of consent for data collection is permissible if:  
i. The interventions pose only minimal risk; 
ii. The study could not reasonably be conducted without the use of 
a waiver of consent for the experimental interventions. 
f. Passive consent strategies are subject to the same restrictions as the use 
of a waiver of consent. 
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Implications for other fields of inquiry 
The findings in this dissertation have implications for CRTs in fields other than 
healthcare, as well as for nonrandomized studies that examine interventions that are 
administered in clusters.  
In chapter five, a principled definition of “research subject” was developed. 
Although this definition was developed by appealing to examples in healthcare research, it 
is intended to be applicable to all fields of human subjects research, including CRTs in 
other fields. A research subject is an individual whose interests may be compromised in the 
context of a research study, either by being intervened upon (either directly or by 
environmental manipulation), by interacting with investigators, or if their identifiable 
private information is used. 
CRTs are widely used in public health, education and a variety of other domains of 
research. In public health research, research subjects include includes individuals residing 
or visiting communities participating in a CRT of a public health intervention that cannot 
be avoided, such as a CRT evaluating water decontamination strategies. In education 
research, students of a school or school district participating in a CRT of a novel curricular 
innovation would be considered subjects. These research subjects merit regulatory 
protections in order to safeguard their interests, including being asked to provide informed 
consent to study participation (unless criteria for a waiver of consent are met), and the 
careful review of risks and potential benefits by a research ethics committee. 
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Our conclusions may also be extended to nonrandomized trials. Consider, for 
example, a nonrandomized study in which intensive care units in Michigan were assigned 
to employ either educational and safety interventions intended to reduce catheter-associated 
bloodstream infections, or to no intervention10. The healthcare providers were intervened 
upon by investigators and are therefore research subjects. The patients were not intervened 
on, interacted with, nor were they deliberately manipulated via environmental 
manipulation. No identifiable private information was used to ascertain the relative 
effectiveness of the educational and safety interventions: only administrative data on 
infection rates was used. Therefore, the patients in this study are not research subjects, and 
consent was not required.  
Our work on the issue of informed consent in CRTs is also applicable to other fields 
of inquiry. Our conclusions regarding the timing of consent, disclosure requirements and 
the use of a waiver of consent is applicable to nonrandomized studies in other fields that 
employ CRTs, such as public health and education. If group assignment is determined 
before subject enrolment, and consent could not have been obtained at that time, then 
seeking consent after group assignment is permissible. Potential subjects must be informed 
of the study’s purpose, the nature, risks and potential benefits of the interventions that they 
will undergo and their alternatives should they choose not to participate.  
The application of waivers of informed consent is the same for nonrandomized 
studies as for CRTs. Investigators must argue that he research is not feasible without the 
waiver, and the study must meet the other regulatory criteria for a waiver 11. Similarly, opt-
out consent practices offer no protection to subjects beyond those outlined in waiver of 
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consent regulations. Investigators may choose to employ an opt-out strategy for pragmatic 
reasons, but requirements for a waiver of consent must be met before such a strategy is 
used. 
 
Future Work 
Future work will examine how risks and potential benefits to subject CRTs ought to 
be evaluated by research ethics committees12. The definition of “research subject” 
developed in this dissertation leads to the conclusion that CRTs often include different 
types of subjects. Subjects may include individual cluster members (who are either 
intervened upon or contribute identifiable private information), as well as subjects who are 
intervened upon in order to produce a cluster-level effect, such as teachers or health 
professionals. The analysis of risks and potential benefits in a single CRT will likely be 
different for each different type of subject. Furthermore interventions directed at one type 
of subject may have consequences for another. For instance, interventions directed at health 
professionals may present both risks and potential benefits for their patients. Conversely, 
interventions directed at patients may have consequences for their treating professionals, in 
that they may either contribute to or alleviate professional workload burdens. How ought 
these indirect risks and potential benefits be considered by a research ethics committees? 
Questions associated with the evaluation of risks and potential benefits in CRTs will 
be the focus of additional papers from the CIHR-funded working group referenced in 
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chapters one and two9,12. The conclusions of this work will inform the development of 
comprehensive international guidelines for the ethical conduct of CRTs. 
The work done in this dissertation will also serve as the basis for my own future 
work. In particular, the conclusions of this work will be applied to work on the ethics of 
knowledge translation and quality improvement research, and the methodology involving 
the joint application of empirical and conceptual work will be used in addressing epistemic 
questions in clinical trials. 
The CRT design is often used in large knowledge translation (KT) or quality 
improvement (QI) studies. KT is an activity aimed at increasing the uptake of high quality 
scientific evidence in medical practice and healthcare policy13. QI is an activity intended to 
improve outcomes or the efficiency of processes in health care systems14. KT and QI 
interventions are administered to health care systems or health care professionals. If 
successful, they lead to improvements in patient outcomes. KT and QI research evaluates 
the efficacy of these interventions. Research in these fields poses many of the same ethical 
questions as do CRTs: Who is the research subject? When is consent required? How ought 
a research ethics committee evaluate the risks and benefits of the interventions being 
studies? What does it mean to be fair in the selection of research subjects and research 
populations in KT and QI research? The conclusions of the work in this dissertation are 
likely to be very relevant to KT and QI research. Both empirical work, in order to evaluate 
current ethics practices in KT and QI research, and normative work will be required to 
comprehensively address the range of ethical questions posed by research in these fields. 
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Thus, future work will involve the application of both the methodology of this dissertation, 
and its conclusions, to ethical questions raised by KT and QI research. 
Epistemic questions raised by clinical trials in medicine can also be addressed by an 
approach combining both empirical and normative work. One particular challenge 
amenable to this approach is the question, “When should a clinical trial be stopped in the 
face of mounting evidence of the superior efficacy of one experimental treatment?”15  
Answering this question is important, in order to ensure that research subjects are not 
assigned to a treatment that is known to be inferior. In addressing this question, the work of 
Benjamin Freedman is useful starting point. Freedman writes that a clinical trial should be 
designed such that, at its completion, its findings will resolve a state of disagreement in the 
clinical community as to the preferred treatment16. In other words, the findings of a clinical 
trial should be sufficiently convincing as to broadly influence clinical practice. In reality, 
the results of a single trial rarely change practice13 (hence the need for knowledge 
translation interventions), it is an empirical question as to how much evidence is sufficient 
to be convincing to expert clinicians to stimulate a change in practice. This empirical 
information may help to set an evidentiary standard that researchers should hope to meet 
with the design of a clinical trial. The question of when to stop a trial early will then be 
reduced to “when will accumulating clinical trial data be sufficient to meet this standard?” 
Answering this question involves both empirical work on the effect of stopping early on the 
accuracy and precision of estimates of effect15, and normative work that addresses the 
ethical implications of enrolling subjects in clinical trials in the face of mounting evidence 
of the superiority of one trial arm. By combining the findings of both normative and 
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empirical work on this issue, robust guidelines for early stopping of clinical trials may be 
formulated. I propose to address this challenge in future work. 
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Appendix A. Data abstraction form for published CRTs used in chapter two.
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1. Study ID (this is the Medline UID number – also the pdf file name)  
2. Reviewer name  
3. Publication year  
4. Journal name  
 
General Study Characteristics 
 
5. Country of study recruitment (for identification of developing nations, use World Economic outlook 
database April 2008 edition at http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/groups.htm#oem): 
1 Canada 
2 USA 
3 UK or Ireland 
4 Australia  
5 Other developed country /countries (specify) (e.g., Canada and USA)  
6 Other developing country/countries (specify)  
 
6. Country of first author (attempt to identify online if not reported): 
1 Same as country of study recruitment (or one country of study recruitment) 
2 Other (specify)   
 
7. Study funding source reported? 
1 Yes 
2 No 
 
8. If Q7=Yes, specify funding source: (If unclear, confirm online or with author; NA if Q7=No) 
 Yes No NA 
a) Industry  1 2 3 
b) Government agency, international development agency, university  1 2 3 
c) Foundation, special interest group (e.g., Bill and Melinda Gates Foundation, 
Alzheimer’s society, charitable/non-profit organization) 
1 2 3 
 
9. Type of clusters (units of randomization): 
1 Primary care practices (intact practices – includes multiple health professionals in at least some practices) 
2 Individual primary care physicians (individual GPs) 
3 Other individual health professionals (specify) 
(e.g., dentists, surgeons, nurses, midwives) 
 
4 Hospitals 
5 Nursing Homes 
6 Primary care clinics 
7 Units of time (specify setting) (e.g., primary care clinics, nursing homes)  
8 Households/ families 
9 Residential areas (specify) (e.g., villages, 
neighbourhoods, parishes, hamlets, balozi, household clusters) 
 
10 Public health clinics 
11 Schools 
12 Classrooms 
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13 Worksites 
14 Churches 
15 Other (specify) (e.g., teams of health professionals)  
Study Design 
 
Note: In order to complete data abstraction, a single primary outcome must be 
identified for each trial. Use the following hierarchy: First primary outcome stated by 
authors; if no primary outcomes specified, use outcome in sample size calculation; if 
sample size calculation not reported or reported for a sub-study only, use first outcome 
listed under ‘Objectives’; if still unclear, refer trial to arbitration before proceeding.). 
Note: Data abstraction pertains to main study component (the patient population on 
which the primary outcome evaluation is carried out), i.e., disregard sub-studies within 
the main trial, e.g., if a smaller group of patients are enrolled for more intensive follow-
up. 
 
10. Were primary outcome measure(s) identified by authors? (Authors clearly distinguished 
between main (or primary) and secondary outcomes measures?) (Note: Not acceptable if authors merely stated 
primary objectives without operationalizing in terms of specific variables.) 
1 Yes (specify number)  
2 No 
 
11. For quality control purposes, state the single primary outcome data abstraction will 
be based on:  
 
 
 
12. Trial design at cluster-level: 
1 Parallel trial (clusters independently randomized to different treatments with or without pre-test) 
2 Factorial trial (specify factors and levels) (e.g., 2x2)  
3 Cross-over trial 
4 Other (specify) (e.g., latin squares, split-plot, stepped wedge)  
 
13. Method of random allocation: 
1 Completely randomized design (unrestricted randomization) 
2 Stratified design  
3 Pair-matched design 
4 Other (specify) (e.g., minimization algorithm)  
 
14. a) Data collection schedule for primary outcome:  
1 Posttest only design (primary outcome measure observed post-intervention only) 
2 Pretest-posttest design (primary outcome measure observed both pre- and post-intervention) 
 
b) Specify number of discrete observation time points or indicate 99=“continuous 
surveillance” (Note: Post-test only design with continuous surveillance would typically correspond with a 
cohort design in Q15 (and patient attrition is possible in Q28), whereas post-test only design with one discrete 
observation time point only would correspond with a cross-sectional design (and no patient attrition possible in 
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Q28). (E.g., patients enrolled at baseline and followed for 30 days to observe hospitalization = continuous 
surveillance.)  
 
 
15. Trial design at patient-level (primary outcome): 
1 Nested cross-sectional design (each patient measured only once or different patients measured each time point) 
2 Nested cohort design (same patients measured at different time points or in continuous 
surveillance) (NOTE: Patient-level attrition is possible in a cohort design but NOT in a cross-sectional design) 
3 Primary outcome evaluated on both cross-sectional and cohort components 
Characteristics of Outcomes and Interventions  
 
16. Type(s) of experimental interventions (all components of intervention): 
 Yes No 
a) Educational/ quality improvement interventions targeted at health professionals 
(e.g., distribution of educational materials, outreach visits, audit and feedback) 
1 2 
b) Quality improvement interventions targeted at organization of health care or 
health services delivery (e.g., financial, shifting of professional roles, multi-disciplinary teams, 
integration of services, changes in setting or equipment, home visits by nurses) 
1 2 
c) Patient health promotion or educational intervention (e.g., promotion of breastfeeding, 
smoking cessation intervention, decision aid, disease screening promotion) 
1 2 
d) Direct patient therapeutic intervention (e.g., experimental intervention includes specific drug to 
be prescribed to all patients, vaccines/vitamin supplements, insecticide spraying, surgery, testing of new clinical 
pathway – distinguish from indirect changes to patient therapies as a result of guideline adherence)  
1 2 
e) Other (specify)  
 
17. Type of intervention administered in control arm (Note: disregard activities administered in all 
clusters prior to randomization e.g., to ensure similar levels of knowledge before starting the intervention): 
1 Not reported 
2 No active intervention (i.e., usual care) 
3 Scaled down version of active intervention (includes some basic elements of 
active intervention) (e.g., one educational visit, printed guidelines only) 
4 Placebo or sham intervention (e.g., vitamin placebos, education on unrelated medical conditions) 
5 Other active intervention (head to head comparison)  
6 Other (specify) 
 
18. Typology of trial interventions (options are hierarchical and based on ability to opt 
out): (For more detailed explanation and notes, see notes document or Eldridge ea, 2005, Clinical Trials v2)  
1 Cluster-cluster (Targeted at cluster organization, health professional, or cluster population - 
individuals cannot opt out of the intervention) (e.g., information on patient population fed back to health 
professional, change in organization; changes to electronic medical records/ software system; mass media campaign, water 
fluoridation, insecticide spraying, posters, changes to physical environment) (Primary reason for clustered design is 
intervention cannot be carried out any other way) 
2 Professional-cluster (Targeted primarily at health professional – individuals can decline to 
have their data used, but intervention is still likely to have an effect on them) (e.g., physician 
education intervention to improve detection of dementia) (Primary reason for clustered design is to avoid contamination) 
3 External-cluster (Additional staff) (Targeted at cluster organization - individuals can opt 
out by declining to see the additional staff) (e.g., specialist nurses) (Primary reason for clustered design is 
logistical and/or financial) 
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4 Individual-cluster (Targeted primarily at individuals but may be delivered by health 
professional – individuals can opt out in the same way as they would in an individually 
randomized trial)  (e.g., vaccines, vitamin supplements, patient decision aid administered by physician, intervention to 
promote breastfeeding delivered by midwives, clinical pathway to treat pneumonia in nursing home residents) (Primary 
reason for clustered design is to avoid contamination and increase individual compliance) 
 
19. Type(s) of data collection interventions for primary and secondary outcomes: 
 Yes No 
a) Medical record review or use of routinely collected data  1 2 
b) Patient specimen collection or physical examination not required for normal 
patient care  
1 2 
c) Interviewer-administered patient questionnaires (telephone/face-to-face) (Disregard if 
applied to follow-up non-respondents to the initial postal survey only) 
1 2 
d) Self-administered patient questionnaires (postal, e-mail, internet) 1 2 
e) Health professional survey questionnaires or interviews 1 2 
f) Other (specify if none of the above)  
g) Specify which one of a) to f) above applies to the primary outcome   
 
20. Primary and secondary outcomes observed: 
 Yes No 
a) Patient outcomes (clinical or non-clinical outcomes e.g., morbidity, mortality, depression/anxiety scores, 
patient satisfaction, quality of life. Note: Length of hospital stay could be either a patient outcome (as an indicator 
of degree of illness) or a process measure (as an indicator of physician adherence to guidelines).  
1 2 
b) Process measures (“process measures” refers to actual medical care such as diagnoses, treatment, 
referral and prescribing, e.g., hospitalization, number of guideline-adherent prescriptions, number of healthcare 
visits, % visits where guidelines were followed) 
1 2 
c) Other health professional outcomes (e.g., satisfaction, quality of care, behavioural intentions) 1 2 
d) Economic outcomes (even if reported in separate publication) 1 2 
e) Other (specify)  
f) Specify which one of a) to e) above applies to the primary outcome  
 
Cluster and Patient Flow 
 
21. Were patients recruited to the study (including recruitment for data collection 
purposes only)? (Refers to main study component- disregard substudy involving smaller group of patients) 
1 Yes 
2 No 
 
22. Number of study arms (we need to know if there were multiple intervention or control arms so that patient 
numbers can be divided up appropriately when assessing imbalances): 
a) Intervention arms  
b) Control arms  
 
NOTE: In Q23 to 28, combine across arms if multiple intervention or control arms; If 
head-to-head comparison, choose the reference intervention as control arm. If reference 
intervention not clear, refer trial to arbitration.  
If not reported or unclear, indicate as missing = -1. 
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23. Number of clusters randomized: 
a) Total  
b) Intervention arm  
c) Control arm   
 
24. Number of randomized clusters included in baseline data collection (assess post-
randomization withdrawals) (Note: randomized clusters not identifying any eligible patients at baseline 
are considered as withdrawals): 
a) Total  
b) Intervention arm  
c) Control arm   
 
214 
 
25. Number of clusters (from those in Q24) that were lost to follow-up (Note: clusters not 
identifying any eligible patients at follow-up are considered lost to follow-up ):  
a) Total  
b) Intervention arm  
c) Control arm   
 
26. Number of patients providing data at baseline: (As reported in flow diagram or in table 
describing baseline characteristics of clusters and patients. Will be used to assess average cluster size.) 
a) Total  
b) Intervention arm  
c) Control arm   
 
27. Number of eligible patients invited but excluded from baseline data collection (e.g., 
refusal/ non-response): (Note: If there was no patient recruitment (Q21=2), report as 0; if patients recruited 
prior to randomization (Q32=2), record b) and c) as NA=-9; if not reported, record as missing = -1.) (Will be used 
to assess risk of selection bias).  
a) Total  
b) Intervention arm  
c) Control arm   
 
28. Number of patients (from those in Q26) that were lost to follow-up at final 
observation time (or time that was used to assess primary outcome): (Note: Report as 0 if 
cross-sectional design (Q15=1); disregard in-migration / patients added to clusters after baseline data collection): 
a) Total  
b) Intervention arm  
c) Control arm  
 
Methodological Quality Indicators  
 
29. Sample size / power calculations presented? 
1 Not presented or presented for substudy or outcome regarded as secondary only 
2 Patient-level accounting for ICC (“Sample size was based on a significant effect size of 0.5, incorporated an 
ICC of 0.05 and was based on enrollment of 4 patients per physician”; “Based on a mean (SD) number of admission days 
per resident enrolled, within cluster variance of 2 days and between-cluster variance of 3 days and 10 residents per nursing 
home”. Usually will involve stating at least the average cluster size and the ICC/ design effect/ overdispersion 
factor/within-and between-cluster variance or stated that accounting for clustering without reporting value of ICC.) 
3 Cluster-level (Should be clear that cluster-level summary data are used for calculation e.g., “sample size was based 
on the hospital as the unit of analysis…assuming a rate of episiotomy of 42% at baseline, with a standard deviation of 
15%, we need 18 hospitals to identify a decrease in episiotomy rate.” Use of standard deviation in the case of proportions 
indicates that binary data was summarized at cluster-level and treated as continuous data for the purpose of sample size 
calculation.) 
4 Patient-level without accounting for ICC (usually difficult to tell whether at patient- or cluster-level unless 
specifically stated) 
5 Unclear whether at patient- or cluster-level or whether accounted for clustering (e.g., “sample 
size was calculated to give a power of 80% of detecting a difference of 1 SD at 5% significance in mean diagnosis 
concordance score”; “sample size of 500 participants would result in 80% power to detect a difference of 10 points 
between groups”) 
6 Other (specify) (e.g., based on intermediate level of clustering)  
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30. If there was no patient recruitment (Q21=No), assess risk of patient selection 
(“identification”) bias: (Optional: use explain field to clarify your choice): (We want to 
avoid option 6 as far as possible) 
1 NA (Q21=Yes) 
2 Not possible (patient identification was completed prior to randomization) 
3 Unlikely (patient identification post-randomization but: done by person blinded to group allocation, computerized 
process without regard to group allocation, or researcher/independent person without knowledge of clinical characteristics 
of patients; OR eligibility criteria such that unlikely to be subverted by knowledge of random assignment (e.g., all women 
delivering in hospitals within specified time period were included)) 
4 Possible (e.g., unblinded individuals with knowledge of clinical characteristics of patients identified participants 
prospectively after randomization) 
5 NA (patient identification is aim of intervention, e.g., intervention to improve detection of dementia in primary care) 
6 Unclear (explain) (e.g., not clear who identified patients)  
 
31. If patients were recruited to the study (Q21=Yes), who approached patients? 
1 NA (Q21=No) 
2 Health professional usually involved in patient’s care or regular program staff  
3 Member of research team or someone not usually involved in patient care or service delivery 
4 Mail questionnaire (specify sent by …) (e.g., researcher, GP)   
5 Not reported or unclear 
6 Other (specify)  
 
32. If there was patient recruitment (Q21=Yes), assess risk of patient selection 
(“recruitment”) bias: (Optional: use explain field to clarify your choice): (We want to 
avoid option 5 as far as possible) 
1 NA (Q21=No) 
2 Not possible (patients were identified and recruited prior to randomization and same patients followed over time) 
3 Unlikely (identification and recruitment post-randomization but: done by person blinded to group allocation, or invitation 
by mail questionnaire most likely with identical information to patients in different arms) 
4 Possible (e.g., identification or recruitment by unblinded individuals with knowledge of clinical characteristics of patients, 
or possibly different information to patients in different arms) 
5 Unclear (explain) (e.g., not clear who recruited patients)  
 
33. Concealment of allocation (secure allocation) (Note: EPOC distinguishes between sequence 
generation and allocation concealment – however, our eligibility criteria likely will exclude trials subject to bias as 
a result of sequence generation): 
1 Done (Unit of allocation was institution or professional and randomization was performed on all units at the start of the 
study –this will be the case for most cluster trials; or unit of allocation was by household, patient or episode of care and there 
was some form of centralized randomization scheme, on on-site computer system or sealed opaque envelopes.) 
2 Not done (open list of random numbers/ coin flip was used or security could have been compromised, or allocation was 
altered by investigators, professionals or patients) 
3 Not clear (unit of allocation was by household, patient or episode of care and method of concealment not described) 
 
34. ITEM DELETED  
 
35. Protection against contamination: (EPOC) 
1 Done (e.g., allocation by community, institution or practice and unlikely that control arm received the intervention) 
2 Not done (likely that control arm received intervention, e.g., cross-over trials or patients within the same cluster allocated 
to control and intervention arm) 
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3 Unclear (e.g., professionals allocated within an institution and communication among professionals may have occurred) 
36. Analysis for primary outcome: 
1 At patient-level accounting for ICC (e.g., using mixed-effects logistic regression, GEE taking account of 
clustering by physician, Chi-square statistic adjusted for clustering, random effect for physician, hierarchical modeling, multi-
level modeling, alternating logistic regression) 
2 At cluster-level (clearly stated that analysis at cluster-level, e.g., “analyses performed using patient-level variables 
aggregated at the provider-level”, analysis was based on hospital rates, t-test weighted by inverse variance etc.) 
3 At patient-level not accounting for ICC (more difficult to distinguish, e.g., multivariable regression analysis of 
patient-level data with no mention of clustering, or standard 2-sample test on patient-level data without mention clustering or 
stated that since ICCs were low, clustering was ignored in presentation of results)  
4 Unclear whether at patient-level or cluster-level or whether accounted for clustering  
5 Other (specify) (e.g., based on intermediate level of clustering, both individual-level 
and cluster-level analyses used for primary outcome analysis) 
 
 
37. Primary outcome reported as statistically significant?  
1 Yes 
2 No 
 
38. Type of test for primary outcome evaluation in Q37: (purpose of item is to distinguish between 
trials where a significant result is desirable versus not desirable, e.g., equivalence study, intervention is 
harmful/not safe)  
1 Effectiveness/Efficacy 
2 Safety/Tolerability (e.g., safety of iron supplementation in malaria-prone settings) 
3 Equivalence/Non-inferiority 
4 Other (specify) (e.g., descriptive study only)  
 
39. ICC or design effect estimates reported for any outcomes recorded at patient-level? 
(not referring to ICC used for sample size calculation): 
1 Yes 
2 No 
 
40. Blinding of health professionals: (use the following hierarchy to identify relevant HPs: a) HPs 
targeted by intervention, b) individual HPs that were the units of randomization, c) if HPs were not the units of 
randomization, the HPs in each cluster involved in administering interventions to patients, d) regular HPs involved 
in patient care.  
1 Yes (stated explicitly that health professionals were blinded/ not informed of their 
allocation status) 
2 No (stated explicitly that health professionals could not be blinded to allocation status, or 
that they were informed of their allocation status or obvious) (e.g., the same specialist nurses/surgeons 
administered both treatment and control)  
3 Not reported or reported but unclear (e.g., reported as “double blind trial” without specifically identifying who 
was blinded, or “participants” were blinded but unclear whether referred to patients or health professional participants) 
 
41. If Q40=1 or 2, capture verbatim the relevant statements including what information 
was given to different arms  (e.g., “physicians were not informed of their study group assignment”, 
“allocation was revealed to surgeons after random assignment”) or state “Obvious” and reason.  
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42. Blinding of patients: 
1 Yes (stated explicitly that patients were blinded/ not informed of their allocation status OR 
obvious) (e.g., there was no patient recruitment and patients were clearly unaware of the trial) 
2 No (stated explicitly that patients could not be blinded to allocation status or that patients 
were informed of their physician’s allocation status)  
3 Not reported or reported but unclear (e.g., patient decision aid and not reported whether patients knew 
whether they have received the experimental or control intervention; or trial reported as “blinded” without specifically 
identifying who was blinded)  
 
43. If Q42=1 or 2, capture verbatim any relevant statements including what information 
was given to different arms (e.g., “patients in intervention and control arms received identical 
information about the trial”) or state “Obvious” and reason. 
 
 
 
44. Blinding of primary outcome assessment: 
1 Yes (stated explicitly that primary outcomes were assessed blindly or obvious) (e.g., based on 
computer algorithm applied to electronic records without regard to random allocation or based on identical postal 
questionnaires in both groups) 
2 No (stated explicitly that outcome assessors / interviewers / data abstractors were not 
blinded to allocation status or obvious) (e.g., GPs aware of allocation status assessed primary outcomes)  
3 Not reported or reported by unclear 
 
45. If Q44=1 or 2, capture verbatim the relevant statements or state “Obvious” and 
reason: 
 
 
 
46. Capture verbatim any other statements regarding blinding where it is unclear who the 
blinding refers to (e.g., “participants were not informed of their study group assignment”, “double-blind 
trial”) 
 
 
 
47. Relevance of blinding for primary outcome measure assessment: 
1 Primary outcome measure is objective (unlikely to be influenced by knowledge of allocation status; e.g., 
length of hospital stay, mortality, blood pressure) OR patient identification is aim of intervention (e.g., 
intervention to improve detection of dementia in primary care)  
2 Primary outcome measure is subjective (vulnerable to bias from knowledge of allocation status, e.g., patient 
self-report of health status, depression scales, quality of life measures, subjective diagnoses) 
3 Not clear  
 
Ethical Quality Indicators 
 
48. Study reported as “Quality Improvement” / QI anywhere in text? 
1 Yes 
2 No 
218 
 
 
49. Stated whether requirements of Declaration of Helsinki followed? 
1 Yes 
2 No 
 
50. REB review reported? 
1 Stated REB approval and identified committees (e.g., “The Ottawa Hospital REB”) 
2 Stated REB approval – did not identify committees (e.g., “local research ethics committees of each 
study site” and the study sites themselves are not identified) 
3 Stated REB exempt (specify reason)  
4 Not reported  
 
51. Number of ethics committees involved (indicate as missing if not reported)  
 
52. Data and Safety Monitoring Board in place? 
1 Yes 
2 No 
3 Not reported 
 
53. Was a gatekeeper identified (separate from the REB) that allowed access to each 
cluster? 
1 Yes (specify) (e.g., hospital administrators, lead physicians, nursing home 
management, “responsible authorities”, government initiated program) 
 
2 No (e.g., “practices agreeing to participate were randomized…”, or cluster is individual health professional) 
 
54. Was gatekeeper consent reported? (should be explicitly reported as “consent”) 
1 Yes (e.g., “hospital administrators provided consent to randomization”) 
2 No 
 
55. Capture verbatim any statements about any form of gatekeeper agreement to 
participate, including what consent was for (e.g., participation, review of medical records)  
 
 
 
56. Reporting of any health professional consent procedures (requires specific reference 
to “consent”): 
1 Reported informed consent was provided including method (e.g., “physicians provided written/ verbal 
consent”) 
2 Reported informed consent was provided but no details on method (e.g. “consenting GPs were 
randomized”) 
3 Reported waiver of informed consent 
(specify reason) (e.g., to avoid Hawthorne type effect) 
 
4 Not reported (e.g., “physicians agreeing to participate were randomized”, “participating physicians were 
randomized”, nursing homes were enrolled in the trial and no report of consent from nurses administering interventions)  
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57. Capture verbatim any statements about any form of health professional agreement to 
participate, including what “consent” was for (e.g., participation, review of medical records) and 
use of opt-in versus opt-out procedures:  
 
 
 
 
58. Reporting of patient consent procedures (Note: refers to main study component): 
1 Reported informed consent was provided including method (e.g., written, verbal) 
2 Reported informed consent was provided but no details on method 
3 Reported waiver of patient consent (specify reason) 
(e.g., routine outcome data, no personal identifiers collected) 
 
4 Not reported (e.g., “patients agreeing to participate…”, implied by return of survey questionnaire but not reported, or 
there was no patient recruitment and waiver of informed consent not reported) 
59. Capture verbatim any statements about patient “consent”/agreement to participate, 
including what consent was for (e.g., participation, review of medical records), and use of opt-in 
versus opt-out procedures:  
 
 
 
60. Capture verbatim any statements about attempts to protect patient confidentiality or 
privacy (e.g., “anonymized data were collected”, “no personal identifiers were transmitted”) 
 
 
 
 
61. Incentives offered? Specify as nr = “not reported” or verbatim (e.g., CME credits, $1000 for 
computers): 
a) Gatekeeper  
b) Health professionals  
c) Patients  
 
62. Capture verbatim any author comments on REB review process or impact of 
informed consent procedures on study: (e.g., impact on study 
duration/costs/feasibility/recruitment/scientific validity/ differential process and outcome among centres):  
 
 
 
 
63. Capture verbatim any other statements relating to ethical issues (e.g., “patients who declined 
to participate were offered the successful treatment after completion of the trial”; “individuals in control clusters 
were not prevented from seeking active treatment”) 
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64. Any other general reviewer comments about ethical or methodological issues? (e.g., 
trial was stopped early for harm, stopping rules were in place, adverse events reported) 
 
 
 
 
65. Do authors reference a separate publication which may provide further details on 
items required in this data abstraction form?  
1 Yes 
2 No 
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Appendix B. REB approval from the University of Ottawa and UWO
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Appendix C. Interview guide used for key informant interviews in chapter four 
225 
Key Informant Interview 
 
1. What types of cluster randomized trials have you been involved with?  
[Prompt: We are interested in the type of research that you have done, i.e., primary, secondary or 
tertiary care, public health, and the types of interventions and outcomes you were looking at] 
 
2. What was your involvement in these trials? 
[Prompt: Clinical investigator, social scientist, statistician, epidemiologist…?] 
 
3. Approximately how many cluster randomized trials have you been involved with? 
ethical issues 
 
4. Have you come across any ethical issues in the cluster randomized trials you have 
been involved with? What were these issues and why did they arise? 
 
5. How did you try to resolve these issues? Were the solutions satisfactory?  
 
 
6. Tell me about your experiences with obtaining ethics approval for the cluster 
randomized trials you have been involved with. 
 
7. Has the ethics review process had any impact (positive or negative) on the quality of 
your trials? 
 
8. Can you identify a particular trial which presented the most challenging or interesting 
ethical issues? Tell me more about this trial. 
[Prompt: Nature of the intervention, outcomes of interest, types of clusters, ethical issues…] 
 
9. Has this trial been published? Where? 
particular trial. 
 
 
10. What were the main reasons for using cluster randomization?  
[Prompt: To avoid contamination, cluster-level intervention, ethics, feasibility…?] 
 
11. Now we are interested in the clusters that were selected for recruitment to the trial. 
How were they identified or selected? Who consented on behalf of each cluster and 
how were the decision-makers identified?  
 
12. Did the decision-makers receive any incentives or benefits from their participation? 
 
13. Were there any ethical concerns with the role of the decision-maker in this trial?  
 
14. Did you experience any difficulties in recruiting clusters to the trial? 
[Prompt: What reasons given for refusing to participate?] 
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15. Now we are interested in the individuals that participated in the trial. How were they 
identified or selected?  
[Prompt: e.g., through random sampling, had to satisfy eligibility criteria…] 
 
16. Did the individuals consent prior to being randomized? If not, why not?  
 
17. Did the individuals consent to receiving the intervention? If not, why was consent not 
sought? 
 
18. What information was given to individuals about the trial and the interventions 
involved? 
[Prompt: where individuals aware of the trial?] 
 
19. How were the outcomes assessed? 
[Prompt: telephone survey, in-person interview, secondary data sources…] 
 
20. Did all individuals providing data for analysis consent to data collection? If not, why 
was consent not obtained? 
 
21. Did you experience any difficulties in recruiting individuals to the trial? 
[Prompt: What reasons given for refusing to participate?] 
 
22. Describe any potential risks or benefits to individuals, and clusters or communities in 
this trial. 
 
23. What opportunities existed for individuals to withdraw from the trial?  
 
24. Did individuals have access to the intervention outside the trial? 
 
25. Did individuals in the control group have access to the intervention during or after the 
trial? 
 
 
 
26. Do you have any other comments about ethical issues, the ethics review process, or 
ethics guidelines for cluster randomized trials?  
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Appendix D. Final coding template for descriptive qualitative analysis in chapter 
four 
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Consent from Individuals 
 Active vs. passive consent 
 Awareness of trial 
 Completion of questionnaire as consent 
 Consent from individuals with limited capacity 
 Consent process as source of bias 
 Consent to data collection 
 Consent to receive intervention 
 Implied consent for data collection within consent for care 
 Incentives to individuals 
 Individual consent superseding need for cluster or community consent 
 Individual (informant’s) perception of need for consent 
 Information provided to individuals 
 Opting out of data collection 
 Opting out of intervention 
 Subject coercion 
 Timing of individual consent re: randomization, Zelen design 
 Waiver of consent from individuals/need for consent from individuals 
 
 
Consent from Gatekeeper 
 Alternatives to individual gatekeepers (e.g. advisory boards) 
 Gatekeeper authority 
 Gatekeeper consent overriding individual consent 
 Identification of appropriate gatekeeper 
 Incentives to gatekeepers 
 Information provided to gatekeepers 
 Multiple levels of gatekeepers 
 
 
Consent from Cluster Participants (e.g. physicians, teachers) 
 Cluster level drop-outs 
 Coercion of cluster participants 
 Compensation for time or activity 
 Democratic consent of cluster or practice 
 Influence of opinion leader 
 Incentives to clusters (financial, infrastructure) 
 Need for consent from cluster participants 
 Professional obligation for research participation 
 Reasons for refusal 
 
 
Risks and Potential Benefits 
 Equipoise between intervention arms 
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 Intervention as standard or nonstandard care 
 Obligations to research subjects 
 Overburdening of some clusters 
 Perception of no risk to individuals or clusters 
 Risks to professional reputation 
 Tradeoff of benefits to society vs. risks to individuals 
 Uncertainty about intervention safety or efficacy 
 
 
Privacy 
 Access to patient data 
 Breaking of privacy protections during trial 
 Obstacles from healthcare bureaucracy 
 Privacy protections for individual data 
 
 
Conflicts of Interest 
 
 
Methodological Concerns 
 Contamination 
 Selection of clusters 
 Fairness 
 Selection criteria 
 Practicality of consent 
 Stopping rules 
 
 
Ethics Board Review Process 
 Access to intervention for control groups 
 Access to intervention for non-study individuals 
 Change in regulations or review over time 
 Difference in regulation or review between jurisdictions 
 Duration of ethics review process 
 Importance of type of intervention for ethics review 
 Need to educate ethics boards about cluster trials 
 Negative impact of review process 
 No impact of review process 
 Positive impact of review process 
 
 
Ethics Guideline Recommendations 
 Conflicts of interest with professional obligations 
 Distinction between health services research, KT, and QI 
 Education about cluster design 
230 
 Need for ethics approval 
 Reporting standards 
 Requirements for valid design and analysis 
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